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Cancer arises when a group of cells within the body start growing in an abnormal 
manner destroying tissues and organs. Pancreatic neuroendocrine tumours (PNETs) 
are a type of cancer that occurs due to abnormal growth of hormone-producing cells 
in the pancreas. Insulinoma (INS) is the most commonly diagnosed PNET in humans 
and dogs. They mainly cause problems by secreting an excessive amount of insulin, 
the hormone that regulates sugar levels in the blood. An increased production of 
insulin can cause persistent low sugar levels in the blood that can be life-threatening 
if not properly treated. 
INS are usually restricted to the pancreas and can be easily treated with surgery. 
Occasionally, INS may spread and develop secondary tumours beyond the pancreas, 
most often affecting the liver. These INS are known as malignant. In dogs, INS is 
more common and it is often malignant. Human and dog malignant INS share many 
features, thus, INS that naturally occurs in dogs can represent a valuable model for 
studying the natural progression of human malignant INS.  
This project aimed to investigate a small group of cancer cells, called cancer stem 
cells (CSCs), considered responsible for promoting tumour growth. By 
characterising these cells the aim was to identify potential ways to target them. It is 
known that CSCs hijack biological pathways that are normally involved in cell 
growth and repair and use them to defend themselves against commonly used cancer 
therapy allowing them to resist treatment and continue to grow. Here, human and 
canine INS CSCs were isolated and studied to identify biological signalling 
pathways linked to the development of drug resistance. To understand the relevance 
of these mechanisms for patient treatment, we determined the active genes in canine 
INS samples to reveal a set of biological signalling pathways involved in the 
progression and spread of the disease. Results of this study showed that the Notch 
pathway is involved in the early stage of INS carcinogenesis and in promoting the 
growth of INS cancer cells. Interestingly, the Notch pathway has previously shown 
to have a key role in pancreatic development and as well in the spread of PNETs. 
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Using specific inhibitors, evidence was provided that inhibition of Notch signalling 
could reduce the growth of INS CSCs, and made them more susceptible to 
commonly used chemotherapy. In conclusion, these findings provided evidence that 
the Notch pathway might be an interesting drug target for improving, in the future, 




Pancreatic neuroendocrine tumours (PNETs) are the most common neuroendocrine 
tumours diagnosed in humans and dogs.  Due to the highly heterogeneous nature of 
these tumours, definitive data are still lacking over the molecular mechanisms 
involved in their cancerous behaviour.  
This study focused on insulinoma (INS), as it is the most commonly diagnosed 
PNET in human and veterinary oncology. INS is an insulin-producing tumour that 
causes a hypoglycaemic syndrome related to the excessive insulin production. In 
humans, it is often a small benign neoplasm readily curable by surgical resection 
whereas, in dogs, INS is often malignant. Despite current treatment modalities, 
malignant canine and human INS have a poor prognosis as patients tend to develop 
metastases in liver and lymph nodes that do not respond to current therapies. From a 
comparative oncology perspective, the close resemblance 
 of canine and human malignant INS makes canine INS an interesting study model 
for human INS.  
Cancer stem cells (CSCs) are critical for the engraftment and chemoresistance of 
many tumours. Although CSCs have been isolated from a range of solid tumours, a 
comprehensive characterisation of INS CSCs has not yet been reported. In this study, 
it was confirmed that INS CSCs can be enriched and are potential targets for novel 
INS therapies. Highly invasive and tumourigenic human and canine INS CSCs were 
successfully isolated and exhibited greater resistance to chemotherapy, which may 
play a significant role in the poor prognosis of this disease. To date, the mechanisms 
by which tumours spread and the clinical causes of chemoresistance remain only 
partially understood. Here, RNA-sequencing analysis was performed over a small set 
of canine INS tumour samples in order to identify mechanisms involved in INS 
carcinogenesis through different stages of the disease. Preliminary data showed that 
distinct gene profiles characterised early and late stage of canine INS. Interestingly, 
differential gene expression and gene pathways analysis, highlighted that sets of 
genes involved in pancreatic embryogenesis and insulin secretion were 
overexpressed in canine primary INS lesions compared with normal pancreas. The 
 XXVIII 
Notch pathway is fundamental in pancreatic embryogenesis and it has been 
previously associated with carcinogenesis of neuroendocrine tumours and with the 
CSC phenotype. Protein analysis showed that the Notch pathway is activated in both 
human and canine INS CSCs, particularly when treated with chemotherapy, 
indicating that the Notch pathway may be involved in chemoresistance. Additionally, 
it was demonstrated that inhibition of the Notch pathway decreased INS CSCs' 
survival and chemoresistance, both in vitro and in vivo. These findings provide 








Pancreatic neuroendocrine tumours (PNETs) comprise a heterogeneous group of 
endocrine tumours arising in the pancreas. They are among the most common 
neuroendocrine tumours (NETs) and are becoming increasingly important both 
clinically and from a research standpoint (Ehehalt et al., 2009; Ito et al., 2012; Ro et 
al., 2013; Reid et al., 2014).  
In humans, PNETs comprise 1.3% to 2.8% of new pancreatic malignancies each year 
(Zhang et al., 2013; Yu, 2016). According to various Asian and European population 
studies, they are uncommon neoplasms with an incidence lower than 1 per 100,000 
persons per year (Halfdanarson et al., 2008; Ehehalt et al., 2009; Vandamme et al., 
2015). Generally, PNETs have a more indolent clinical course than do pancreatic 
ductal adenocarcinomas, which arise from the exocrine pancreas and comprise the 
majority of pancreatic cancer diagnoses (Lubeseder-martellato et al., 2016). 
Remarkably, up to 40% of all PNETs are incidentally diagnosed, highlighting the 
number of clinically asymptomatic cases (Okabayashi et al., 2013; Zhang et al., 
2013). In fact, the incidence is frequently higher in autopsy studies, ranging from 
0.8% to 10% suggesting that these tumours frequently go unnoticed (Ehehalt et al., 
2009; Ito et al., 2012; Ro et al., 2013). The incidence of PNETs in veterinary 
oncology is unknown. However, they are still considered rare neoplasms (Finotello 
et al., 2014).   
Insulinomas (INS) are the most commonly diagnosed PNETs in human and canine 
patients (Buishand et al., 2010; Okabayashi et al., 2013). INS are insulin-producing 
tumours that can arise from beta-cells of the pancreas (Trifonidou et al., 1998; 
Jonkers et al., 2007; Polton et al., 2007; Goutal et al., 2012). Clinical signs of INS 
are usually related to the excessive production of insulin. The incidence of INS in 
humans is reported to be four cases per million of the population per year, and the 
peak age-specific incidence rate occurs in the fifth decade of life with a slight female 
predilection (Callacondo et al., 2013). The incidence of canine INS seems higher 
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compared to humans. In fact, data collected at the Department of Clinical Sciences of 
Companion Animals of Utrecht University, have recorded at least 10 cases of canine 
INS each year, on a total population of 2 million dogs in the Netherlands (Buishand, 
unpublished data). 
The principles of management of INS include the diagnosis and control of the 
functional hormonal syndrome and the potentially malignant tumour (Polton et al., 
2007; De Herder et al., 2011). The treatment of choice for localised benign tumours 
is surgical resection (Bailey and Page, 2007; Vaidakis et al., 2010; Wouters et al., 
2011). However, for malignant INS that require adjuvant therapy following surgery, 
the medical treatment options are rarely curative (Corroller et al., 2008; Goutal et al., 
2012; Baudin et al., 2014).  
In dogs, previous reports in the literature describe average life expectancies for 
malignant INS of approximately one year for patients undergoing surgery and 6,5 
months for medical management (Tobine et al., 1999; Polton et al., 2007; Goutal et 
al., 2012). In humans, patients diagnosed with malignant INS have a survival rate 
within 30-60% at 5 years from diagnosis (Borson-Chazot et al., 2013; Rossi et al., 
2014; Giuroiu and Reidy-Lagunes, 2015). Whereas, for patients treated with 
chemotherapy after surgery the survival time rise to 71% at five years (Corroller et 
al., 2008). 
Malignant INS can be hard to diagnose as they require diagnostic tools and treatment 
approaches different from those commonly used in human and veterinary oncology 
(Anlauf et al., 2009; Goutal et al., 2012). Therefore, molecular markers that predict 
INS behaviour and new treatment strategies are required to improve clinical 
decision-making in human and canine patients diagnosed with malignant INS. From 
a comparative oncology perspective, which aims to utilise spontaneous tumours in 
pet animals as natural models for the study of human cancer biology and therapy 
(Gordon et al., 2009), the similarities of canine INS to human malignant INS, makes 
canine INS an interesting study model for human malignant INS.  
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1.2  Comparative anatomy of Canine and Human Pancreas 
 
Before describing the biological and clinical aspects of human and canine PNETs 
and specifically of INS, the main anatomical and histological features of the pancreas 
in these two different species will be briefly outlined here. 
The pancreas is a glandular lobulated organ. The embryonic pancreas in vertebrates 
develops from the endoderm as evaginations of the primitive gut. A dorsal and 
ventral protrusion grow, branch and then fuse to form the definitive pancreas 
(Edlund, 2002; Gittes, 2009; Tsuchitani et al., 2016).  
 
The pancreas is a composite gland that contains both exocrine and endocrine 
components. The precursor cells are called amphicrine cells, and they are 
developmentally plastic as they may differentiate into either endocrine or exocrine 
cells (Ordonez, 2001). The exocrine part constitutes the majority of the pancreas 
volume whereas the endocrine part constitutes just about 2% of it (Edlund, 2002; 
Tsuchitani et al., 2016). The exocrine pancreas is constituted by acinar cells which 
secrete digestive enzymes in the small intestine through the pancreatic duct 
(Tsuchitani et al., 2016). The exocrine pancreas has a basic common structure among 
mammals being composed of two epithelial cell types, acinar and ductal epithelial 
cells. The acinar epithelial cells make up the major portion of the pancreas, and the 
ductal system is composed of centroacinar cells, followed by the intercalated, 
intralobular, interlobular, and main ducts (Pandol et al. 2010; Longnecker, 2014). 
The acinar cells produce a variety of digestive enzymes, such as proteases, amylases 
and lipases (Kim et al., 2010).   
Endocrine pancreatic cells are organised in ‘Islets of Langerhans', These islets are 
located in different part of the pancreas and secretes various hormones that regulate 
glucose metabolism in the body (Tsuchitani et al., 2016) (Table 1.1). 
Extra-insular endocrine cells are scattered randomly as single cells or as clusters. 
(Edlund, 2002; Tsuchitani et al., 2016). The islet of Langerhans displays a 
remarkable variability in cellular composition and morphology producing insulin (β-
cells ), glucagon (α-cells), somatostatin (δ-cells), vasoactive intestinal polypeptide 
(VIP) (β-cells), pancreatic polypeptide (PP-cells) and substance P/serotonin 
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(enterochromaffin cells). Gastrin-producing G cells are present in foetal but not adult 
pancreatic islets (Lechner et al., 2005; Lopez et al., 2010; Fendrich et al., 2012). The 
topographic distribution and number of islet endocrine cells differ between the lobes 
of the pancreas and species (Kim et al., 2010; Steiner et al., 2011). For instance, total 
β- cell mass increases proportionately to compensate the demand for insulin in the 
body (Kim et al., 2010). Therefore this difference in the islet structure results from 
different metabolic requirements (Steiner et al., 2011). 
 
1.2.1  Canine pancreas 
 
1.2.1.1 Gross anatomy 
In dogs, the pancreas has got the form of an inverted-V, and it is divided into three 
parts: the right lobe, the body and the left lobe (Evans, 1993; Tsuchitani et al., 2016). 
The right lobe is a thin structure whereas the left lobe is thicker and wider. They are 
united in the body, which lies caudomedial to the pylorus. The right lobe lies in the 
meso-duodenum extending caudally from the body along the duodenum. The left 
lobe extends caudo-sinistrally from the body to the hilum of the spleen (Evans, 1993; 
Tsuchitani et al., 2016) (Figure 1.1 A). 
1.2.1.2 Histology 
The canine pancreatic islets are composed of a core of β-cells (>50% of the islet) 
surrounded by peripherally located α-cells (<30%) (Figure 1.2 A). The δ-cells, in this 
species, tend to be randomly distributed through the islet. The α-, β- and δ-cells tend 
to congregate in organised islets in the left lobe, whereas the right lobe contains 
small scattered islets (Steiner et al., 2011). Flattem et al. (2001) showed that, in the 
canine pancreas, β-cells and α-cells collaborate very efficiently to respond even to 




1.2.2 Human Pancreas 
 
1.2.2.1 Gross anatomy 
The human pancreas is divided into four parts: head, neck, body, and tail. In humans, 
the pancreas has a J-shape and the head constitutes 50% of its volume (Longnecker, 
2014). The human pancreas is a compact organ protected from severe trauma by 
lying close to the posterior abdominal wall in the upper abdomen. The tail of the 
pancreas and spleen are in the left upper quadrant of the abdomen, and the head of 
the pancreas is in the right upper quadrant just to the right of the midline. The head 
of the pancreas is surrounded by the duodenum in its concavity. The tail of the 
pancreas lies near the hilum of the spleen, and the body lies posterior to the distal 
portion of the stomach (Pandol et al. 2010; Longnecker, 2014) (Figure 1.1 B).  
 
1.2.2.2 Histology 
Human islets have a more “disorganised structure” where the α-, β- and δ-cells do 
not have a specific distribution throughout the islet. The adult human islet contains 
about ~50% β-cells, ~40% α-cells, 10% δ-cells and few PP-cells (Figure 1.2 B). This 
structure is functional for β-cell to respond to low concentrations of glucose (<1 
mM) (Kim et al., 2010).  
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Figure 1.1 Gross anatomy of canine and human pancreas. A: Anatomical localisation of 
canine pancreas. R=right. L=left. (adapted from illustration of A. Gardiner & M. Raynor, 
The Dog Anatomy Workbook: A Guide to the Canine Body, J.A. Allen (London)). B: 
Anatomical localisation of human pancreas. (Illustration from Anatomy & Physiology, 





Figure 1.2 A: Histology of canine pancreatic islets. Immunoperoxidase staining with 
insulin of formalin-fixed, paraffin-embedded canine pancreatic islet. B: Histology of 
human pancreatic islets. Picture shows H&E staining of human pancreatic islet (adapted 
from binipatia.com, 2013; licensed under the Creative commons attribution 3.0). 
 
Table 1.1. Hormones of the pancreas and their effects on regulating the glucose 
metabolism in the body (adapted from Tsuchitani et al., 2016). 
Pancreatic hormones 
Hormones Cells Effect 
Insulin Beta cells Reduce blood glucose levels 
Glucagon Alpha cells Increase blood glucose levels 
Somatostatin Delta cells Inhibits insulin and glucagon 
Pancreatic polypeptide (PP) PP cells Role in appetite 
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PNETs typically occur sporadically in humans and dogs (O’Brien et al., 1987; Bailey 
and Page, 2007; Ro et al., 2013; Rossi et al., 2014). In humans, they can also be 
components of familial syndromes such as multiple endocrine neoplasia syndrome 
type 1 (MEN1), von Hippel-Lindau disease (VHL), neurofibromatosis type 1 (von 
Recklinghausen disease), tuberous sclerosis, and Mahvash disease (due to 
inactivating glucagon receptor mutation) (Crabtree et al. 2016; Yu 2016). PNETs are 
frequently divided into two groups based on their capacity to produce, store, and 
secrete peptides or hormones that may induce clinical syndromes (Grande et al., 
2011). Functioning PNETs are the most common and they can be distinguished into: 
INS (the most common PNET in human and veterinary oncology), gastrinoma, and 
rare tumours such as vasoactive intestinal polypeptide (VIP)-oma, glucagonoma, 
carcinoids, somatostatinoma, and exceedingly rare neoplasms like pancreatic 
polypeptide (PP)-oma, adrenocorticotropic hormone (ACTH-oma), growth hormone-
releasing factor (GHRF-oma), calcitonin-producing tumours, parathyroid hormone-
related peptide-producing tumours and others (Höpfner et al., 2003; Polton et al., 
2007; Okabayashi et al., 2013; Finotello et al., 2014; Rossi et al., 2014; Crabtree et 
al., 2016) (Table 1.2). Non-functioning PNETs cause non-specific signs related to 
the mass-effect of metastases, mainly in the liver, such as pain, anorexia, and weight 
loss, and are often an incidental findings (Jutting et al., 1997; Ro et al., 2013; Rossi 
et al., 2014).  
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Table 1.2 Hormone-producing pancreatic neuroendocrine tumours (adapted from 
Höpfner et al., 2003; Polton et al., 2007). VIP, vasoactive intestinal polypeptide; PP, 
pancreatic polypeptide; ACTH, adrenocorticotropic hormone; GHRF, growth hormone-
releasing factor 
Tumour Clinical signs Hormone 
Insulinoma Hypoglycaemia Pro-insulin, Insulin 
Gastrinoma Peptic ulcer and diarrhoea Gastrin 
VIPoma Watery diarrhoea, 
 hypokalaemia 
VIP 
Glucagoma Anaemia, diabetes Glucagon 
Somatostatinoma Diabetes, diarrhoea, steatorrhea Somatostatin 
GHFRoma Acromegaly GHRF 




1.3.2 Diagnosis, treatment and prognosis 
 
Endocrine testing, imaging, and histological evidence are necessary to accurately 
diagnose PNETs. The diagnosis of PNETs rests upon confirming the neuroendocrine 
nature of the malignant cells and immunohistochemical stainings with markers such 
as chromogranin A, synaptophysin and neuron-specific enolase. Nevertheless, these 
tumours can have heterogeneous microscopic findings. Thus it can be difficult to 
assess the degree of malignancy of pancreatic endocrine tumours. Accepted 
histological criteria for malignancy, such as nuclear pleomorphism or infiltration of 
adjacent tissue, are unreliable in the evaluation of PNETs in humans and dogs (Ro et 
al., 2013; Buishand et al., 2014). 
For human PNETs, the current World Health Organisation (WHO) classification 
provides guidance in that respect (Table 1.3). Using the TNM (tumour, node, and 
metastasis) system, PNETs are divided into four main stages of tumour advancement 
(Table 1.3). Using proliferative markers such as mitotic count and Ki67 index, 
PNETs are categorised as low- (G1), intermediate- (G2), or high-grade (G3) (Table 
1.3) (Ito et al., 2012; Reid et al., 2014; Rossi et al., 2014). PNETs grade and stage 
are the major determinants of prognosis in humans (Ito et al., 2012). Therefore, 
before treatment a complete histological assessment of the tumour is usually required 
(Ro et al., 2013; Zhang et al., 2013). 
This system has been adapted for staging canine PNETs (Table 1.4). Previous studies 
showed that in dogs, together with TNM stage, increased nuclear size, 
pleomorphism, Ki67 and DNA content are considered valuable histological features 
to predict the biological behaviour of PNETs (Jutting et al., 1997; Buishand et al., 
2010). However, in both human and dogs, the presence of metastases, mainly located 
in the liver, represent the only definitive feature that characterises these tumours as 
malignant (Jutting et al., 1997; Halfdanarson et al., 2008; Ehehalt et al., 2009; 
Buishand et al., 2013; Baudin et al., 2014).  
 
Considering their high heterogeneity, treatment options for PNETs are highly 
variable. Small, benign neoplasms like benign INS are readily curable by surgical 
resection (Vaidakis et al., 2010). Still, the majority of PNETs have a less favourable 
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prognosis depending on local invasiveness and liver metastases and often require 
adjuvant medical therapy (Corroller et al., 2008; Ehehalt et al., 2009; Fendrich et al., 
2012). The treatment of patients diagnosed with advanced metastatic, hormonally-
active PNETs has two primary goals. First, to control the hormone oversecretion 
which can lead rapidly to complications and death. Secondly, to reduce the growth 
and spread the PNET itself (Ito et al., 2012). 
A supervised diet and somatostatin analogues constitute the major medical therapy 
for canine patients diagnosed with malignant PNETs (Jutting et al., 1997; Goutal et 
al., 2012). In dogs, chemotherapy has not been shown to be beneficial as adjuvant 
therapy post-resection of liver metastases due to the high level of toxicity and side 
effects (Jutting et al., 1997; Northup et al. 2013). In dogs, Caywood et al. (1998) 
have shown that patients with distant metastasis with or without local lymph node 
involvement (stage III) had a significantly shorter survival time compared to dogs 
with localised pancreatic lesions (stage I and II). All stage III dogs died by 18 
months post-surgically (Caywood et al., 1998). 
In humans, medical treatment of malignant PNETs often includes the use of 
chemotherapy (De Herder et al., 2011; Ro et al., 2013; Baudin et al., 2014; Rossi et 
al., 2014). However, complete responses are rare, and the median responses are short 
(6–20 months). For example, combinations of streptozotocin and 5-fluorouracil (5-
FU), with or without doxorubicin, have shown an objective response rate of 20–45%. 
Moreover, streptozotocin-based treatments have considerable morbidity, with most 
of the patients developing side-effect, including nausea/vomiting and 15–40 % 
developing renal toxicity with long-term treatment (Ehehalt et al., 2009; Ro et al., 
2013). (Ro et al., 2013; Reid et al., 2014). In humans, only 25% of the patients with 
advanced PNETs have up to 5-year survival time (Borson-Chazot et al., 2013; Reid 
et al., 2014).  
Even though PNETs are considered uncommon in human and veterinary oncology, 
they still cause significant morbidity and mortality. Unique challenges facing PNETs 
studies include prolonged disease course, the difficult access to pancreatic tissue 
during surgery, and the heterogeneity of these tumours (Bernard et al., 2013; Carter 
et al., 2013; Wang et al., 2013; Zhang et al., 2013; Baratelli et al., 2014; Reid et al., 
2014; Fujino et al., 2015; Krampitz et al., 2016). In this study will focus on the most 
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commonly diagnosed PNETs in human and veterinary oncology to design specific 
treatment therapy and improve the diagnosis of human and canine patients bearing 
INS. 
 
Table 1.3 TNM classification and disease staging for pancreatic neuroendocrine tumours 
(PNETs) in humans. HPF, high power field (adapted from Ehehalt et al., 2009) 
Stage and grade of PNETs in humans 
T: Primary tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour limited to the pancreas and size>2cm 
T2 Tumour limited to the pancreas and size 2–4 cm 
T3 Tumour limited to the pancreas and size >4 cm 
T4 Tumour invading adjacent organs or the wall of large vessels 
N: regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M: distant metastases 
MX Distant metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases 
Stage 
I T1 N0 M0 
IIa T2 N0 M0 
IIb T3 N0 M0 
IIIa T4 N0 M0 
IIIb Any T N1 M0 
IV Any T Any N M1 
Grade Mitotic count 
(10HPF) 
Ki-67 index (%) 
1 < 2 <2 
2 2-20 3-20 




Table 1.4 TNM classification and disease staging for pancreatic neuroendocrine tumours 
(PNETs) in dogs. HPF, high power field (adapted from Buishand et al., 2010) 
 
Stage and grade of PNETs in dogs 
T: Primary tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
T1 Tumour limited to the pancreas and size>2cm 
T2 Tumour limited to the pancreas and size 2–4 cm 
N: regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M: distant metastases 
MX Distant metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases 
Stage 
I T1 N0 M0 
II T2 N0 M0 
III Any T N1 M0 
IV Any T Any N M1 
Grade Mitotic count 
(10HPF) 
Ki-67 index (%) 
1 < 2 <2 





1.4 Canine and Human Insulinomas: comparative aspects of a well-
defined tumour syndrome 
 
1.4.1  Epidemiology 
 
In dogs INS usually occur sporadically and it is often diagnosed in older dogs with 
no sex predilection (Trifonidou et al., 1998; Polton et al., 2007; Goutal et al., 2012; 
Buishand et al., 2013). Medium to large breeds including Labrador retrievers, golden 
retrievers, German shepherds, Irish setters and Boxer seems to be the most common 
breeds diagnosed with INS (Siddons, 1976; Goutal et al., 2012). INS are considered 
rare neoplasms but the occurrence of metastases in dogs is as high as 95% of the 
cases compared with only 5% to 16% in humans (Polton et al., 2007; De Herder et 
al., 2011; Goutal et al., 2012; Mathur et al., 2012; Buishand et al., 2014).  
In humans, INS can occur sporadically (90%) or constitute a part of MEN-1 (16%) 
(Dotzenrath et al., 2000; Jonkers et al., 2006; Vaidakis et al., 2010). INS associated 
with MEN-1 tends to broadly affect individuals at younger ages compared with 
sporadic INS (median age at presentation is 25 years or less) (Dotzenrath et al., 
2000; Fontanière et al., 2006). The median age of diagnosis for sporadic INS is 60 
years old (Giuroiu and Reidy-Lagunes, 2015).  
 
1.4.2  Clinical findings 
 
The clinical signs of INS result from excessive insulin secretion, which leads to an 
increased rate of transfer of glucose from the extracellular fluid to body tissues and 
thus to severe hypoglycemia (Okabayashi et al., 2013). The malignant behaviour of 
INS is usually related to recurrence of clinical signs of hyperinsulinemia-induced 
hypoglycaemia after surgery due to the outgrowth of micrometastases in lymph 
nodes and liver (Anlauf et al., 2009; Buishand et al., 2012; Northrup et al., 2013; 
Okabayashi et al., 2013).  
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Clinical findings are similar for canine and human INS, and they are majorly related 
to the central nervous system (Table 1.4). The predominance of clinical signs relating 
to the central nervous system demonstrates the primary dependence of the brain on 
the metabolism of glucose for energy. When the brain is not supplied with glucose, 
cerebral oxidation decreases and manifestations of hypoxia appear (Mohseni, 2014). 
Neuroglycopenic symptoms include abnormal behaviour, seizures and coma. In 
addition, hypoglycemia can cause catecholamine release and adrenergic sympathetic 
nervous system activation (Table 1.4). Clinical signs are episodic and occur initially 
at widely spaced intervals and become more frequent and severe in the later stage of 
the disease (Jordan and Carithers, 1980; Lurye and Behrend, 2001; Jonkers, 
Ramaekers and Speel, 2007; Polton et al., 2007; Okabayashi et al., 2013). The lack 
of specificity of the clinical signs makes the diagnosis of INS quite difficult 
particularly at an early stage. Certain stimuli such as excitement, fasting or exercise, 
preceded the most onset of clinical signs (Jordan and Carithers, 1980; Lurye and 
Behrend, 2001; Jonkers et al., 2007; Polton et al., 2007; Okabayashi et al., 2013). 
Administration of glucose rapidly alleviates the signs (Jordan and Carithers, 1980; 
Trifonidou et al., 1998; Goutal et al., 2012). If untreated, repeated episodes of 
prolonged and severe hypoglycemia may result in irreversible neuronal degeneration 
throughout the brain (Mohseni, 2014). Permanent neurologic disability probably 
accounts for the terminal coma, unresponsiveness to glucose, and eventual death of 




Table 1.4 Clinical signs of insulinoma in dogs and humans (adapted from Jonkers et al., 
2007; Polton et al., 2007; Goutal et al., 2012) 




Disorientation Blurred vision 
Apparent blindness Amnesia 
Change of temperament Anxiety 
Ataxia Confusion 
Collapse Abnormal behaviour 
Seizures  Seizures 
Coma Coma 












The diagnosis of INS is achieved on the combination of hyperinsulinemia, 
hypoglycaemia and the exclusion of alternative diagnoses such as exogenous insulin 
administration (Polton et al., 2007; Druce et al., 2010; Goutal et al., 2012; 
Okabayashi et al., 2013). 
Diagnosis of INS was previously obtained by documenting Whipple’s triad (Figure 
1.3); however, it is now evident that many other disorders could respond similarly. 
For this reason, additional tests are often needed to confirm the diagnosis of INS-
induced hypoglycaemia (Figure 1.3) (Jordan and Carithers, 1980; Jonkers et al., 
2007; Goutal et al. 2012). 
In dogs, a blood glucose curve should be done when a history of periodic weakness, 
collapse, or seizures is recorded in an older dog. Blood analysis evaluating the 
amended insulin-to-glucose ratio may be warranted. This assay assesses the lack of 
response to physiologic negative feedback inhibitory loops that decreases insulin 
secretion following hypoglycemia. A positive insulin-to-glucose ratio demonstrates 
an inappropriately elevated insulin level in the setting of low glucose level. 
Insulin:glucose ratio greater than 4.2 is considered diagnostic (Thrall et al., 2011).  
In humans, with symptoms of neuroglycopenia or documented low blood glucose 
levels, the gold standard for biochemical diagnosis remains measurement of plasma 
glucose, insulin, C-peptide, and proinsulin during a 72-h fast (Okabayashi et al., 
2013). This test has the advantages of evaluating both the correlation between 
hypoglycaemia and the patient's symptoms, and the inadequately elevated insulin 
concentrations compared with the low blood glucose levels (Vaidakis et al., 2010; 
Athanasopoulos et al., 2011; Borson-Chazot et al., 2013) (Figure 1.3).  
 
1.4.3.1 Imaging 
Imaging should be used as a complementary tool for diagnosing INS. In particular, 
imaging is usually used for preoperative localisation of INS. However, diagnosis and 
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location accuracy of INS remains challenging regardless of the imaging modality 
used in both humans and dogs (Druce et al., 2010; Goutal et al., 2012).  
In dogs, abdominal ultrasound (US) represents the most common tool used to 
visualise masses in the pancreas. Ultrasound is often also a useful tool to detect 
metastatic lesions in different organs and lymph nodes (Goutal et al., 2012). INS 
usually present either spherical or lobular shape and are hypoechoic compared with 
the surroundings tissues (Figure 1.4 A-B). Nonetheless, the sensitivity of US in 
detecting INS in dogs is reported to range from 28% to 75% and be highly operator-
dependent (Fukushima et al., 2015).  
In humans, the sensitivity of transabdominal US for localising pancreatic 
insulinomas is 9–64% (Nakamura et al., 2015). Computed tomography (CT) is 
commonly used in human medicine as a preoperative imaging technique as it is a 
more sensitive imaging examination than the non-contrast US, thus, being superior to 
the US for INS localisation and staging (Nakamura et al., 2015). However, the cost 
and requirement for specialised equipment, as well as the need for anaesthesia, have 
currently limited routine use of these techniques in veterinary medicine (Figure 1.4 
C) (Goutal et al., 2012; Fukushima et al., 2015).  
 
1.4.3.2 Pathological and histopathological findings  
INS usually appear as single, yellow to dark red, spherical, small (1–3 cm) nodules 
visible from the serosal surface of the pancreas and encapsulated in fibrous 
connective tissue that separates the neoplasm from the adjacent parenchyma. 
Occasionally INS appears as multiple nodules in the same or different lobes of the 
pancreas (Wouters et al., 2011; Goutal et al., 2012; Okabayashi et al., 2013).  
Definitive diagnosis of INS can be obtained only with histopathology that usually 
reveals tumour cells arranged in trabecular and glandular pattern separated by 
vascular stroma. The nuclei are usually highly pleomorphic, vesicular with 1-2 
nucleoli (Srivastava and Hornick, 2009; Buishand et al., 2010). Anaplastic features 
are often mild or inconsistent, even though INS are often malignant in dogs, thus the 
lack of anaplastic features should not be used to predict the biologic behaviour of 
INS (Goutal et al., 2012; Buishand et al., 2010; Zhu et al., 2016). 
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Human INS presents a characteristic deposition of amyloid that can be visualised by 
immunohistochemistry together with insulin (Hawkins et al., 1987; O’Brien et al., 
1994; Williams et al., 1992), whereas in dog the deposition of amyloid is less 
common (O’Brien et al., 1987). In both dogs and humans, immunohistochemically, 
INS stain positively for insulin, pro-insulin, chromogranin A, synaptophysin, neuron-
specific enolase, cytokeratin and Ki-67 (O’Brien et al., 1987; Heitz et al., 1982; 
Buishand et al., 2010; Buishand et al., 2012). 
 
Figure 1.3 Flowchart outlining the diagnosis and the subsequent clinical tests for the 
detection of insulinomas in human and dogs.*indicates diagnostic tests optional in dogs 





Figure 1.4 A-B: Pictures representing transabdominal ultrasound of canine insulinoma . 
A: Arrow indicates an irregularly shaped hypoechoic mass in pancreatic body approx. 2.7 
x 2cm. Margins defined by hyperechoic peripancreatic fat surrounding the lesion. B: 
Arrow indicates a 3 cm hypoechoic lesion with irregular pattern and well-defined margins 
in the left lobe of the liver. C: Pictures representing triple-phase computer tomography of 
canine insulinoma. Arrows indicate a 1.6cm soft tissue nodule with hyperattenuation on 
arterial and portal phase images. It is possible to appreciate how insulinomas have a 
stronger contrast enhancement on the arterial phase and a hypoattenuation in later phase. 
Pictures are courtesy of the Hospital for small animals, Royal (Dick) Vet School, UK. 
 




1.4.3.3 Differential diagnosis 
For the differential diagnosis it is important to evaluate the duration and progression 
of signs, as INS usually have a history of prolonged seizures often associated with 
fasting periods and exercise both in humans and in dogs (Jordan and Carithers, 1980; 
Trifonidou, Kirpensteijn and Robben, 1998; Polton et al., 2007; Goutal, Brugmann 
and Ryan, 2012; Okabayashi et al., 2013; Giuroiu and Reidy-Lagunes, 2015). 
Differential diagnoses for INS include other causes of hypoglycaemia that can be 
broadly classified into three main groups: (i) diseases associated with excess 
secretion of insulin or insulin-like factors, in which excessive production of insulin 
can be related to islet hyperplasia or extra-pancreatic paraneoplastic syndromes; (ii) 
differential diagnoses could include diseases where the metabolism of glucose is 
altered, such as hypoadrenocorticism, hunting dog hypoglycaemia, hepatic 
insufficiency, glycogen storage diseases, and sepsis; (iii) hypoglycaemia could be 
caused by iatrogenic insulin over-dose and toxic causes of insulin release like high 
dose of beta-blockers ( Lurye and Behrend, 2001; Polton et al., 2007; Vaidakis et al., 
2010; Goutal et al., 2012; Okabayashi et al., 2013; Vinik, 2017)(Table 1.). 
A diagnosis of INS is also associated with other symptoms such as recurrent 
seizures. In case of seizures, several differential diagnoses must be included such as, 
idiopathic epilepsy, brain tumour, encephalitis, lead poisoning, hypoparathyroidism, 
and cardiovascular or respiratory diseases (as they could lead to cerebral ischemia 




Table 1.6 Differential diagnosis associated with different causes of hypoglicaemia in 






Islet hyperplasia Nesidioblastosis (islet hyperplasia) 
Extra-pancreatic tumours, 





Liver disease Liver disease 
Hypoadrenocorticism 
(Idiopathic in working 
dogs) 
Hypoadrenocorticism  




Specific enzymatic defects 
Growth hormone deficiency Growth hormone and corticotropin 
deficiency 
Hunting dog hypoglycemia Fanconi syndrome (renal loss of 
glucose) 
Factitious Excessive insulin 
administration 
Excessive insulin administration  
 
Excessive administration of 
sulfonylurea, xylitol, 







separation of serum) 
Laboratory artefacts (incorrect 
anticoagulant/delayed separation of 
serum) 
Systemic disease Severe polycythaemia  Severe polycythaemia  
Septicaemia or endotoxic 
shock 





1.4.4 Treatment approaches 
 
The elective curative treatment for both human and canine INS is surgery (Jonkers et 
al., 2007; Polton et al., 2007; Buishand et al., 2010). Optimally, control of the insulin 
secretion is achieved preoperatively to stabilise the patient’s status before surgery, 
and surgical resection of the primary and metastatic lesions should be attained 
whenever feasible to improve the survival time (Jordan and Carithers, 1980; 
Vaidakis et al., 2010). Depending on its location, INS enucleation they might require 
partial or distal pancreatectomy or a pancreatic-duodenectomy (Vaidakis et al., 2010; 
Goutal et al., 2012). Medical treatment palliates clinical signs, and it is mostly 
indicated for the preoperative control of blood glucose levels and non-surgical 
candidates (Trifonidou et al., 1998; Steiner et al., 2011; Buishand et al., 2013; 
Baudin et al., 2014).  
The management of canine INS is usually based on frequent small feedings at least 
every 4–8 hr and food should contain high levels of proteins, fats, and complex 
carbohydrates. Glucocorticoids are also commonly used in conjunction with diet and 
exercise modifications as they stimulate hepatic gluconeogenesis and interfere with 
the insulin receptors for glucose (Trifonidou et al., 1998; Polton et al., 2007; Goutal 
et al., 2012). Adjuvant therapy with diazoxide is also commonly recommended. 
Diazoxide promotes glycogenolysis and hepatic gluconeogenesis, and it effectively 
reduces hypoglycaemia directly suppressing insulin production by pancreatic beta-
cells (Trifonidou, et al., 1998; Polton et al., 2007; Goutal et al., 2012). 
Chemotherapy does not represent the elective treatment in canine INS (Trifonidou et 
al., 1998; Polton et al., 2007; Goutal et al., 2012). Previous studies reported that 
streptozocin (STZ) can be safely used to manage canine INS. Nonetheless, serious 
adverse effects such as diabetes mellitus were seen in 50% of the patients, resulting 
in euthanasia or death of the patients (Northrup et al., 2013). Additionally, STZ is a 
known nephrotoxin and fatal nephrotoxicity has been reported in dogs due to 
necrosis of renal tubular epithelium (Bailey and Page, 2007; Northrup et al., 2013). 
Whereas, in humans, STZ, as a beta-cell-specific chemotherapeutic, represents the 
standard antitumor therapy for patients with metastatic or non-resectable INS. 
Toxicity is dose-related and cumulative (Vaidakis et al. 2010; Mathur et al. 2012).  
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Alternatively, combinations with 5-FU or doxorubicin are commonly used (Vaidakis 
et al., 2010; Baudin et al., 2014). In humans, adjuvant medical treatment to control 
hormone hypersecretion and clinical signs of INS includes somatostatin analogue 
such as octreotide. By inhibiting the production of insulin and growth hormone, 
octreotide has been shown to control hypoglycaemia efficiently in 35% to 50% of 
patients. Unfortunately, the decrease of insulin concentration is transient, and long-
term therapy usually results as ineffective (Mathur et al., 2012; Baudin et al., 2014; 
Giuroiu and Reidy-Lagunes, 2015).  
Additionally, in humans, continuous glucose monitoring and oral glucose intake after 
hypoglycaemia are considered an effective alternative to octreotide therapy to reduce 
hypoglycaemic episodes before they develop neuroglycopenic symptoms 




Prognosis for human and canine patients with benign INS is very favourable. They 
are anticipated to live a normal lifespan after a successful surgical resection. 
Conversely, regardless of the miscellaneous therapeutic modalities for patients with 
malignant metastatic INS prognosis is still poor (Anlauf et al., 2009; Buishand et al., 
2014). 
In dogs, at the time of diagnosis, metastases are usually present (Polton et al., 2007; 
Buishand et al., 2010). Due to the presence of (micro)metastases in lymph nodes and 
liver undetectable at the time of surgery patients diagnosed with malignant INS often 
show recrudescence of clinical signs (Trifonidou et al., 1998; Buishand et al., 2010; 
Wouters et al., 2011; Buishand et al., 2012; Goutal et al., 2012). In dogs, the median 
survival time is 6-14 months after surgery, and the major cause of death is the 
recrudescence of clinical signs. When surgery is not performed the survival time is 
approximately of 2-3 months (Trifonidou et al., 1998; Lurye and Behrend, 2001; 
Polton et al., 2007). 
Human INS are often curable by surgery as metastases are present in just 10% of all 
the cases (Jonkers et al., 2007; Corroller et al., 2008; Callacondo et al., 2013).  
However, for patients diagnosed with malignant INS, the prognosis is highly variable 
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and often poor (30-60% overall survival) (Borson-Chazot et al., 2013; Rossi et al., 
2014; Giuroiu and Reidy-Lagunes, 2015). As a treatment strategy, surgery on its own 
is not effective whereas aggressive multimodal therapy with a combination of 
chemotherapy and somatostatin analogues reported overall and symptom-free 




1.5 Molecular pathogenesis and targeted therapy of insulinoma 
 
In recent years, substantial progress has been made in the diagnosis and treatment of 
PNETs, especially in the pathogenesis and targeted therapy. Preclinical and clinical 
studies on the molecular biology of PNETs indicate unique PNET signalling events 
that are different from those in pancreatic ductal adenocarcinomas (Zhan et al., 2012; 
Zhang et al., 2013; Yu, 2016). Genetic syndromes account for 15–20% of PNETs, 
but the remaining 80–85% of PNETs are considered sporadic. Previous studies have 
shown that a set of somatic mutations in a number of genes involved in the 
mammalian target of rapamycin (mTOR) pathway, and, to a lesser extent, TP53 
might be involved in sporadic PNET carcinogenesis (Crabtree et al. 2016). Using 
human PNET cell lines available including BON1, derived from a metastatic human 
carcinoid tumour of the pancreas (Lopez et al., 2010), and CM, a cell line obtained 
from peritoneal ascites of a patient affected by a primary pancreatic INS (Gragnoli, 
2008), some of the mechanisms involved in sporadic PNET carcinogenesis have 
been elucidated (Höpfner et al., 2003; Buishand et al., 2016). Various tyrosine 
kinase receptors were overexpressed in PNET cell lines and tumours; since then a 
number of inhibitors of growth factor cascades have been developed (Fazio et al., 
2010; Ito et al., 2012; Ro et al., 2013; Zhang et al., 2013; Rossi et al., 2014). 
 
1.5.1 Molecular pathogenesis  
 
INS are the most frequently detected functioning PNETs. They clearly differ from 
other PNET subtypes with respect to their clinical behaviour and low MEN1 
mutation frequency (Jonkers et al., 2006; Jonkers et al.,  2007). For instance, in dogs, 
INS usually occur sporadically whereas in humans less than 10% of the cases are 
related with MEN1 syndrome (Pelengaris and Khan, 2001; Fontanière et al., 2006; 
Zhang et al., 2013). MEN1 inactivation by mutation plays a minor role in human 
sporadic INS (Dotzenrath et al., 2000). In dogs, mutations of MEN1 are not involved 
in the development of malignant INS (Goutal et al.,  2012). 
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One of the central signalling pathways involved in tumourigenesis of sporadic INS is 
the phosphatidyl-inositol-3 kinase (PI3K)/AKT/mTOR sequence, which is frequently 
over-activated in PNETs. In brief, PI3K-encoded by the PI3KCA gene is activated 
by different receptor tyrosine kinases such as insulin growth factor receptor (IGFR) 
and epidermal growth factor receptor (EGFR) and in turn activates AKT which leads 
to activation of mTORC1/p70S6K, cell proliferation and tumour growth (Figure 1.5) 
(Nölting et al., 2017).  
One of the growth factor receptors that seems to trigger the PI3K/Akt pathway is the 
IGF-R. Insulin-like growth factor (IGF) 1 and 2 binds to IGF-R type 1 or 2, 
respectively, and have been indicated to play a role in INS (Figure 1.5). In humans, 
IGF1 and IGF-1R were expressed in 70% (7/10) and 90% (9/10) of INS (Jonkers, et 
l., 2007). Of interest, previous studies in canine INS  showed an expression of IGF-1 
in 90% (9/10) of primary INS (Buishand et al., 2012). Moreover, Buishand et al. 
(2012) showed a higher expression of IGF-1 in canine INS metastases compared to 
primary lesions suggesting a role of IGF-1 in the growth advantage of metastases 
over primary canine INS (Buishand et al., 2012). Increased expression of IGF-1 was 
also significantly correlated to higher expression of GH mRNA in canine INS 
metastases, suggesting the existence of a functional autocrine or paracrine GH/IGF-1 
axis in metastasised INS cells related to metastatic spread of canine INS (Buishand et 
al., 2012).  
Cell cycle deregulation is one of the defining features of cancer (Zhan et al., 2012; 
Zhang et al., 2013). Cyclin-dependent kinase 4 (CDK4), together with its regulatory 
subunit cyclin D, governs cell cycle progression through the G1 phase. In particular, 
deregulation of the cyclin D/CDK4 complex has been observed in a variety of human 
cancers (Zhang et al., 2013). Cyclin D1 was shown to be overexpressed in 36% of 
INS, when compared to normal pancreatic islets, suggesting that this oncogene is 
involved in the tumourigenesis of at least a subgroup of sporadic INS (Jonkers et al., 
2007). In INS, mTOR upregulates cyclin D1/ CDK4 showing an important role in 
cell proliferation and cell growth during tumorigenesis (Figure 1.5) (Fazio et al., 
2010; Zhan et al., 2012). mTOR is a ubiquitous, highly conserved serine/threonine 
kinase that regulates cell survival, proliferation, and motility. In humans, previous 
data showed that mTOR and its downstream protein P70S6K were activated in 58% 
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(24/41) and 75% (31/41) of INS tissues, at a much higher level than in the islet 
tissues (Zhan et al., 2012). The Akt1 gene has also been described to induce β-cell 
proliferation in a CDK4 dependent manner by increasing cyclin D1 and cyclin D2 
levels (Figure 1.5) (Fatrai et al., 2006). AKT, also known as protein kinase B, plays a 
key role in many cellular processes such as apoptosis, cell migration, and 
proliferation, as well as glucose metabolism. Its upregulation has been documented 
in multiple cancer types, including NETs (Ghayouri et al., 2010; Fatrai et al., 2006). 
In fact, previous studies showed that 61% to 76% of gastroenteropancreatic NETs 
have increased AKT activity (Ghayouri et al., 2010). In PNET cell lines, inhibition 
of AKT signalling resulted in inhibition of PNET proliferation and a reduction in 
NET marker expression such as chromogranin A. In vivo, transgenic mice models 
overexpressing active Akt1, exhibited a striking increase in β-cell mass, 
proliferation, cell size, and malignant tumour formation thus providing evidence for 
the role of this kinase in islet physiology (Fatrai et al., 2006). 
PTEN (phosphatase with tensin homology) is a potent negative regulator of the 
PI3K/Akt signalling pathway (Figure 1.5). Previous in vivo studies have suggested 
that PTEN plays an integrative role in regulating growth and metabolism in normal 
pancreatic islets. PI3K activation and PTEN downregulation have been found in 
most PNETs (Krausch et al., 2011). Microarray expression profiling of PNETs 
showed downregulation of PTEN in the majority of primary PNETs (Krausch et al., 
2011). Interestingly, loss of PTEN was associated with poorer disease-free time and 
overall survival in malignant human INS (Jonkers et al., 2007). 
Furthermore, immunohistochemical studies in benign and malignant INS suggested 
that activation of the proto-oncogenes, c-Myc and Ras, and overexpression of 
transforming growth factor (TGF-alfa), p53 tumour suppressor and anti-apoptotic 
Bcl-2 protein orchestrated the cell death/tumour growth and thus the malignant 
progression of human INS (Pelengaris and Khan, 2001).  
Activation of Myc appears as an early event, being present at both the hyperplastic 
stage and in benign and malignant INS; whereas, Ras, TGF-alfa, and p53 proteins are 
undetectable in normal islets, but weak immunostaining is detected in benign INS, 
becoming strongly positive in malignant INS (Pelengaris and Khan, 2001). TGFα has 
previously been described to be associated with the development of INS. TGFα 
 29 
secreted by tumour cells can bind to EGFR, leading to an autocrine activation of the 
Ras signalling pathway and, putatively, to its oncogenic activity (Figure 1.5) 
(Jonkers et al.,  2007).  
The ability of tumour cell populations to expand is not only determined by the rate of 
cell proliferation but also by the rate of cell death. Acquired resistance toward 
programmed cell death (apoptosis) is a hallmark of most types of cancer including 
INS (Hager and Hanahan, 1999; Pelengaris and Khan, 2001). c-Myc often acts as an 
inducer of both cell proliferation and apoptosis in vitro. It has been previously 
demonstrated that the net balance of Myc-induced growth and death may be dictated 
by the presence of survival signals (Phesse et al., 2014). In INS, for instance, the 
observed oncogenic synergy between Myc and Bcl-2 is fundamental during 
malignant progression as it induces beta-cell growth and decrease of apoptosis 
(Pelengaris and Khan, 2001). Bcl-2 blocks apoptosis without affecting cell 
proliferation and its expression leads to indolent tumour growth (Figure 1.5). An 
increased expression of the Bcl-2 protein in comparison with normal pancreatic 
tissue has been reported in one-third of human INS, suggesting that suppression of 
apoptosis may contribute to the initiation, progression, or both, of these tumours 
(Pelengaris and Khan, 2001). Survivin, a member of another family of apoptosis 
inhibitors, is usually upregulated in response to increased expression of Bcl-2 (Figure 
1.5). Survivin acts as a bifunctional protein suppressing apoptosis and regulating cell 
division during INS tumourigenesis (Jonkers et al., 2007). As a consequence of an 
increase in proliferation and a decrease in cell death the islets become significantly 
enlarged (Jonkers et al., 2007).  
Modulation of apoptosis is one of the biological activities of the p53 protein. Wild-
type p53 is involved in the mediation of c-Myc induced apoptosis. When the 
wildtype TP53 gene is inactivated (predominantly by deletion), the negative growth 
regulatory functions of p53 are abrogated. The TP53 is mutated in more than 50% of 
all human neoplasms. Immunohistochemical detection of p53 is associated with the 
presence of a TP53 mutation in most cases (Pelengaris and Khan, 2001; 
Subramanian et al., 2005; Zlobec et al., 2006). Controversy exists with respect to the 
p53 status in INS (Jonkers et al.2006). A decrease in p53-dependent beta-cell death 
might result from inactivating mutations leading to increased stability of the p53 
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protein, although previous studies have shown that mutation of p53 is exceedingly 
rare in INS (Jonkers et al., 2006; Jonkers et al., 2007). The role of p53 in INS 
carcinogenesis still remains to be elucidated. It has been previously shown a direct 
correlation between gene expression of p53 and c-Myc in tumorigenesis of 
pancreatic islets. For instance, overexpression of c-Myc in pancreatic islets alone 
does not induce tumorigenesis unless apoptosis is blocked, for example, by p53 loss, 
Bcl-2 overexpression (Phesse et al., 2014). 
It is possible that mutations of the check-point genes such as PTEN in PI3K/mTOR 
signaling and p53 contribute to constant cell progression, leading to 
overgrowth/hypertrophy that is escaped from the controls mediated by environmental 
cues such as nutrients/glucose levels and DNA damage (Zhang et al., 2013).  
In summary, several proteins, including Akt1, IGF-1, mTOR have been suggested to 
stimulate cell proliferation in INS. However, because of the overall low proliferation 
rate in INS, it is tempting to speculate that instead of increased proliferation, evasion 
of apoptosis is an important mechanism in INS progression (Figure 1.5). This can 
occur by activation of anti-apoptotic proteins, such as Bcl-2, or by inactivation of 





Figure 1.5 Schematic representation of the mechanisms of molecular pathogenesis of 
sporadic insulinoma (Pelengaris & Khan 2001; Jonkers et al., 2007; Zhan et al., 2012; 
Zhang et al., 2013. Green represents upregulated protein; red represents loss/mutated 




1.5.2 Targeted therapy  
 
In humans, targeted therapy against multiple steps in the IGF-R1–activated 
PI3K/Akt/mTOR pathway has been developed for the treatment of PNETs including 
INS (Fazio et al., 2010; Bernard et al., 2013; Zhang et al., 2013; Baudin et al., 2014; 
Giuroiu and Reidy-Lagunes, 2015; Nölting et al., 2017). In 2011, randomized phase 
III studies in PNETs led to clinical approval of two new agents for the treatment of 
progressive or metastatic PNETs, the multitargeted tyrosine kinase inhibitor sunitinib 
and the mTOR inhibitor everolimus (Ito et al., 2012; Ro et al., 2013; Reid et al., 
2014; Rossi et al., 2014).  
Everolimus (RAD001) is an orally active mTOR inhibitor that has been shown to 
have anti-growth effects in a number of studies involving PNETs (Figure 1.6) (Fazio 
et al., 2010; Ito et al., 2012; Stevenson et al., 2013). In phase III clinical trials, 
overall survival in everolimus-treated patients (11 months) was longer than control 
patients (4.6 months). Successful control of PNET progression in everolimus-treated 
patients supports the notion that mTOR signalling plays a critical role in PNET 
tumourigenesis (Ito et al., 2012; Zhang et al., 2013) (Figure 1.6). As the activation of 
the PI3K/AKT/MTOR pathway is essential for inhibiting hepatic gluconeogenesis by 
insulin, hyperglycaemia is a frequent side effect of everolimus therapy, and this 
finding makes the drug appealing to manage INS (Figure 1.6) (Bernard et al., 2013; 
Baratelli et al., 2014; Baudin et al., 2014). In INS, it has been shown that everolimus 
controlled the glucose level in spite of the high insulin level and disease progression 
(Baratelli et al., 2014). Previous studies in patients diagnosed with metastatic INS 
recorded a median time to the first recurrence of symptomatic hypoglycaemia of 6.5 
months (Bernard et al., 2013; Baratelli et al., 2014). However, drugs-related adverse 
effects have been reported mainly related to hyperglycaemia probably due to a 
decrease of insulin or everolimus-induced peripheral insulin resistance (De Herder et 
al., 2011). 
Due to the high vascularisation of PNETs trials of targeted therapy have been 
developed against pro-angiogenic molecules. Sunitinib malate is a multitargeted 
protein tyrosine kinase inhibitor that targets vascular endothelial growth factor 
(VEGF) receptors 2 and 3, platelet-derived growth factor receptors (PDGFRs) α and 
 33 
β, and stem-cell factor receptor (c-kit) (Figure 1.6). Numerous in vitro and in vivo 
studies, as well as randomised phase III study, have demonstrated that sunitinib has 
anti-growth activity in PNETs, including INS (Figure 1.6) (Ito et al., 2012; Bernard 
et al., 2013; Baudin et al., 2014; Giuroiu and Reidy-Lagunes, 2015). In 2011, the 
FDA approved sunitinib for the treatment of progressive, well-differentiated PNETs 
in patients with unresectable locally advanced or metastatic tumours (Ito et al., 2012; 
Giuroiu and Reidy-Lagunes, 2015). Previous studies showed that sunitinib caused 
tumour shrinkage and prolonged progression-free survival from 5.5 to 11.4 months 
in patients with advanced PNETs. The success of this trial provided evidence that 
targeting distinctive tumour-related signalling pathways could improve clinical 
outcomes and should be the future approach to the development of therapeutic 
interventions for PNET. These include the possibility of overcoming resistance to the 
mTOR inhibitors that frequently emerges over time with continued treatment, in part 
due to the up-regulation of AKT via the IGF-1R/PI3K pathway (Ito et al., 2012).  
Although progression-free survival improved, objective response rates for 
everolimus and sunitinib in the treatment of advanced PNETs are less than 10% 
(Zhang et al., 2013). Both sunitinib and everolimus have a potent effect on inhibition 
of angiogenesis, which may cause adaptive resistance, a phenomenon where cancer 
cells initially sensitive to the therapy, developed resistance mechanisms (Ito et al., 
2012; Zhang et al., 2013; Reid et al., 2014; Rossi et al., 2014; Giuroiu and Reidy-
Lagunes, 2015). Several preclinical studies have demonstrated that tumours develop 
adaptive resistance to antiangiogenic treatment. An increasing body of evidence also 
suggests that antiangiogenic agents alter the biology and the natural progression of 
tumours in an unfavourable manner increasing tumour invasion and metastatic 
behaviour (Zhang et al., 2013).  
Targeting angiogenesis and the PI3K/mTOR signal transduction delays progression-
free and overall survival; however, no curative treatment has been yet designed for 
different subtypes of PNETs. In the future, thanks to an increased understanding of 
the molecular pathogenesis of PNETs, treatment approaches could be planned based 
on the different behaviour of these tumours (Ro et al., 2013; Zhang et al., 2013; Reid 




Figure 1.6 Small molecules inhibitors available for targeted therapy of insulinoma and 
their mechanisms of action: everolimus and sunitinib. VEGFR, vascular endothelial 
growth factor receptor; PDGRF, platelet-derived growth factor receptor; cKIT, stem-cell 
growth factor receptor; IGF-I R, insulin-like growth factor-1 receptor; sst, somatostatin 
receptor subtype; PI3K, phosphatidylinositol 3-kinase; mTOR, mammalian target of 




1.6 Cancer stem cells: future opportunities for the treatment of 
canine and human insulinoma 
1.6.1  Origins of the cancer stem cell theory 
 
The current treatment approaches to different cancer types are often designed based 
on the pathologic characterisation of the entire tumour. Unfortunately, currently 
available drugs often have only transient effects on the neoplasms resulting in 
recurrent and more malignant disease (Dean et al., 2005; Wang et al., 2011; Pang et 
al., 2012; Franco et al., 2016; Lu et al., 2016). One reason for the failure of these 
treatments is the acquisition of drug resistance by the cancer cells as they evolve; 
another possibility is that existing therapies fail by selecting a more malignant 
subpopulation of cancer cells that are responsible for the tumour relapse (Reya et al. 
2001; Dean et al. 2005; Guo et al. 2006; Alison et al. 2011; Rybicka et al. 2016). 
Therefore, we now understand that studying the molecular genetics of tumours can 
give a better view of the complexity of this disease. During the last few years, cancer 
research has been focused on the presence of malignant tumours of a rare population 
of cancer cells that are capable of regenerating new tumours in vivo with the same 
heterogeneity as primary ones (Guo et al., 2006; Blacking et al., 2007; Pang et al., 
2011, 2012; Pattabimaran et al., 2014; Franco et al., 2016). This type of cell has been 
identified as cancer stem cells (CSCs) (Mitra et al., 2015). According to the CSC 
model, minimal residual disease and tumour recurrence would result from 
persistence of the therapy-resistant CSC fraction after treatment (Guo et al., 2006; 
Reya et al., 2001; Medema, 2013)(Figure 1.7). 
The cellular hierarchy of CSCs was first identified in hematopoietic malignancies 
(Franco et al., 2016). Post-therapeutic residual tumour cells were first isolated using 
specific stem cell surface markers in acute myeloid leukaemia and correlated with 
poor progression-free survival (Zhao, 2017). Then, CSCs were isolated from solid 
tumors of many cancer types including lung (Mao et al., 2014), colon (Paschall et 
al., 2016), brain (Zhu et al., 2011), head and neck (Zhao et al., 2016), and pancreatic 
cancers (Sakai et al., 2017). Additionally, several research groups have isolated 
CSCs from a range of canine solid tumours, including osteosarcoma (Wilson et al., 
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2008), squamous cell carcinoma (Pang et al. 2012), mammary carcinoma  (Pang et 
al., 2011; Rybicka et al., 2016) and glioma (Stoica et al., 2009; Pang et al., 2017).  
CSCs are clonogenic in vitro and in vivo. They typically represent only a small 
proportion of the tumour population (1%–5%), although some malignancies such as 
breast cancer (11%–35%) and glioblastoma (5%–30%) possess a larger population 
(Gaur et al., 2011). CSCs undergo asymmetric and symmetric division resulting in 
both expansions of the stem cell pool and the production of morphologically and 
functionally distinct differentiated daughter cells (Medema, 2013). CSCs possess 
unrestrained proliferative abilities, resistance to apoptotic cues, and aptitude to 
establish tumours in immunodeficient mice (Franco et al., 2016). They have an 
increased efficiency of DNA repair, changes in cell cycle parameters, and 
overexpression of anti-apoptotic proteins and/or drug transporters. These different 
pathways protect them from traditional chemotherapy and can contribute to minimal 
residual disease and cancer relapse (Zahreddine et al., 2013).  
There are two different theories regarding the origin of CSCs: (i) the “hierarchy 
model” states that only a subset of cancer cells have a tumour-initiating property and 
they derive from mutated adult stem cells; (ii) “the stochastic model” suggests that 
any differentiated cell can undergo a partial de-differentiation process, mainly 
through epithelial to mesenchymal transition (EMT) to obtain a CSC phenotype 




Figure 1.7 Diagram represents the cancer stem cell (CSC) model. CSCs represent a subset 
of the cancer cell population with self-renewal capability. Conventional chemotherapy 
selects for this population frequently causing tumour relapse. For this reason, a more 
CSC-targeted approach is necessary to have a proper tumour regression (adapted from 
Franco et al., 2016).  
 
Figure 1.8 Diagram represents different cancer stem cell (CSC) model. Two CSC models 
have been postulated. The stochastic model states that all cells within the tumour can 
potentially have tumour-initiating properties. The hierarchy model states that only CSCs 
are tumourigenic (adapted from Chandler et al., 2010). 
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1.6.2 Isolation and enrichment of CSC 
 
The identification of CSCs will likely be crucial for diagnosis and therapy, especially 
for future therapies targeting CSCs (Wang et al., 2011; Borah et al., 2015; Franco et 
al., 2016; Lu et al., 2016). Although identification of CSCs is a complicated process 
and it relies on different strategies, methods to isolate and identify CSCs have been 
developed in the last ten years using their characteristics to self-renew and to remain 
quiescent (Reya et al., 2001; Dean et al., 2005). According to the more recent 
literature, many approaches can be used to reach the CSC population in vitro. CSCs 
can be mainly isolated from cancer cell lines or primary tumours using methods 
based on the expression of specific surface markers or an intracellular enzyme 
activity and then assessed by specific anchorage-independent growth conditions 
(tumour sphere assays) and/or by their ability to initiate new tumour growth when 
xenotransplanted into immunocompromised mice (Yanagihara et al., 2004; Fan et 
al., 2006; Kreso et al., 2014). Because tumour initiation is one of the defining 
features of CSCs, xenografting is considered the gold standard to isolate CSCs. In 
addition to the gold standard in vivo assay, CSCs have been isolated using specific 
stem cell surface markers (Wilson et al., 2008; Pang et al., 2012; Hou et al., 2014; 
Mao et al., 2014; Liu et al., 2017). For instance, recent studies in pancreatic 
adenocarcinoma and glioblastoma have identified CD133 as a marker for CSCs (Fan 
et al., 2010; Zhu et al., 2011). Kreso et al. (2014) demonstrated that in pancreatic 
cancer three different stem cell markers represent CSC population: CD44, CD24 and 
CD133 (Kreso et al. 2014). Rybicka et al. (2016) showed that in canine mammary 
tumours enriched CD44+CD24− cells are highly tumourigenic and associated with 
poor prognosis (Rybicka et al., 2015).  Still, depending on the cancer type the tumour 
stem cell markers may vary within human (Figure 1.9 A) and canine cancer (Figure 
1.9 B) (Wilson et al., 2008; Magee et al., 2012; Hou et al., 2014; Franco et al., 
2016). 
Moreover, some proteins highly expressed in embryonic stem cells, like NANOG, 
OCT4, SOX9 and SOX2, are frequently present in poorly differentiated tumours 
with an adverse clinical outcome (Seymour et al., 2007; Wilson et al., 2008; Franco 
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et al., 2016). Therefore, expression of these embryonic stem cell markers is used to 
identify and select putative populations of CSCs (Wilson et al., 2008; Pang et al., 
2011). Considering the heterogeneity of CSCs within cancer cell population, 
coupling the isolating/enriching methods together with xenografting techniques in 
immunodeficient mice is seen, so far, as the best way to analyse the complexity of 






Figure 1.9 Diagram showing stem cell surface markers commonly associated with 
different tumour types in human (A) and canine (B) cancers (Stoica et al. 2009; Magee et 
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al. 2012; Pang et al., 2014; Pattabimaran et al., 2014; Franco et al. 2016; Rybicka et al., 
2016; Itoh et al., 2017; Kishimoto et al., 2017; Sakai et al., 2017) 
1.6.3 CSC-targeted therapy 
 
The future of cancer therapy is projected to eliminate the pool of cancer cells that are 
intrinsically resistant to conventional therapies, the CSC, while a concomitantly 
administered traditional agent would reduce the non-CSCs, which are known to be 
susceptible to existing cytotoxic therapies (Blacking et al., 2007; Borah et al., 2015). 
Given the apparent close connection between stem cells and the CSC state, various 
signalling pathways involved in the development and the maintenance of stem cells 
have been studied for their role in solid organ malignancies Since then, novel 
targeted therapies against multiple self-renewal pathways have been tested in a 
variety of tumours (Table 1.7 Small molecule inhibitors in clinical trials (Pannuti et 
al., 2011; Schott et al., 2013; Richter et al., 2014; Abetov et al., 2015; Borah et al., 
2015; Ran et al., 2017) (Wang, 2011; Borah et al., 2015; Buishand et al., 2016; 
Krampitz et al., 2016; Lu et al., 2016). For instance, LGK974, a Wnt inhibitor 
against Porcupine (an enzyme involved in the post-translational maturation of Wnt 
proteins) has shown effective results in patients with advanced melanoma, breast 
cancer, and pancreatic cancer in Phase I of clinical trials (Borah et al., 2015; Takebe 
et al., 2015). Wnt signalling is known to be fundamental for the balance of normal 
stem cells and also for the induction of the CSC state (Abetov et al., 2015; Takebe et 
al., 2015). 
Several small molecules inhibitors against various nodes of the Hedgehog (Hh) and 
Notch pathways also came into prominence for their ability to target CSCs (Rizzo et 
al., 2008; Ng & Curran, 2013). The first approved inhibitor of the Hh signalling 
pathway was cyclopamine. Unfortunately, due to limited oral bioavailability, low 
potency, rapid clearance, non-specific toxicity and chemical instability, novel 
inhibitors were developed and tested in clinical trials alone or in combination with 
chemotherapy (Ng & Curran, 2013; Borah et al., 2015; Takebe et al., 2015). IPI926, 
a derivative of cyclopamine, was recently tested in clinical trials for metastatic 
pancreatic cancer, in combination with 5-FU showing an increase of the cytotoxic 
action of 5-FU on the the tumour lesions (Ko, 2017). The first clinically approved 
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antagonist of Hh was vismodegib for the treatment of metastatic basal cell 
carcinomas (Pattabimaran and Weinberg, 2014; Takebe et al., 2015). Vismodegib 
monotherapy has been explored also for the treatment of glioblastoma showing a 
significant decrease of tumour-derived CD133+ cells to form neurospheres (Sloan et 
al., 2014). Unfortunately, resistance against currently used Hh signalling inhibitors 
has already been observed in basal cell carcinoma patients (Gonnissen et al., 2015). 
Several more small molecules against Hh have been clinically tested such as, 
inhibitors of Gli transcription factor GANT-61 and arsenic trioxide (Ng & Curran, 
2013; Franco et al., 2016).  
To block the Notch pathway small molecules inhibitors against the gamma-secretase 
have been developed. One of the most potent gamma-secretase inhibitors (GSIs) in 
clinical development is MK-0752. MK-0752 has shown to inhibit Notch signalling in 
human T-ALL and breast cancer (Brennan and Clarke, 2013; Schoot et al., 2013). In 
Phase I clinical trial patients with advanced breast cancer a combination of MK-0752 
and docetaxel showed a significant decrease of the tumour-derived CD44+/CD24- 
populations (Schoot et al., 2013). Another GSIs previously tested in clinical trials is 
RO4929097. RO4929097 has been successfully used in combination with 
gemcitabine to treat patients in advanced stages of different type of solid tumours 
showing partial response in nasopharyngeal cancer and stable disease (>4 months) in 
pancreas, tracheal, and breast primary cancers (Richter et al., 2014). However, recent 
studies have shown a high variability in the mechanisms and functional effects of the 
several GSIs in clinical development providing an important framework to evaluate 
results from ongoing and completed human trials with these compounds (Ran et al., 
2017).  
Given the crosstalk between the different embryonic developmental signalling 
pathways, combinations of agents have been used in clinical trials to inhibit possible 
compensatory escape mechanisms of CSCs (Pannuti et al., 2011; Richter et al., 2014; 
Takebe et al., 2015). For instance, phase I and phase Ib/II trials combining 
vismodegib to target the HH pathway and the GSI RO4929097 to inhibit Notch 
signalling were conducted in patients with breast cancer and sarcoma (Takebe et al., 
2015).  
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Targeting CSC via modification of the Wnt, HH and Notch embryonic signalling 
pathways holds the promise of preventing disease relapses. However, developing 
such agents is fraught with challenges. These inhibitors may either block the 
formation of new CSCs or also block mechanisms used by existing CSCs to maintain 
their quiescent state (Franco et al., 2016). Still, considering the similarities within 
CSCs and stem cells the question that remains unanswered is whether these agents 
will in fact target more efficiently neoplastic CSCs than the normal stem cells. The 
main issues in the development of agents targeting CSCs include: choice of the most 
appropriate inhibitor for each patient; identification of biomarkers for pathway 
inhibition; selection of mechanism-based combination regimens; and patient 
stratification according to recognised efficacy biomarkers (Takebe et al., 2015; Lu et 
al., 2016; Ran et al., 2017). In particular, more accurate preclinical models for 
testing CSC-targeted agents must be developed as the phenotype of tumour cells or 
CSCs is an output of the entire signalling network. Furthermore, molecular 
biomarkers that interrogate pathway activity and predict efficacy are fundamental for 
patient identification and stratification, and as biological correlatives of activity 
(Pannuti et al., 2011).  
In summary, the development of CSC-targeted therapy is still in its early stage, 
nonetheless, it holds promises to understand cell fate determination in tumours and 
target it therapeutically. Systems biology and personalised medicine will be essential 
to enable the design of a range of regimens in different subgroups of patients 
adapting treatment to clonal evolution within the tumour (Abetov et al., 2015; 
Takebe et al., 2015).  
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Table 1.7 Small molecule inhibitors in clinical trials (Pannuti et al., 2011; Schott et al., 
2013; Richter et al., 2014; Abetov et al., 2015; Borah et al., 2015; Ran et al., 2017) 
Stem signaling Small molecule inhibitor Tumours 
Wnt Phosphosulindac Breast 
Wnt Salinomycin Endometrial 
Wnt Acetaminophen Breast 
Wnt Celecoxib Colon 
Wnt Oximatrine Breast 
Wnt, hedgehog Sulforaphane Breast, pancreatic 
Hedgehog Cyclopamine Glioblastoma 
Hedgehog Erismodegib Prostate 
Hedgehog Vismodegib Pancreatic, Glioblastoma 
Hedgehog GANT-61 Pancreatic 
Notch DAPT Ovarian 
Notch MK-0752 Breast 
Notch Retinoic acid Brain 





1.6.4 CSC: limitations, controversies and future aims 
 
Despite extensive studies, there has been a long-lasting debate on the existence of 
CSCs and their roles in patients. The tumour environment is very heterogeneous, and 
the involvement of CSCs in tumour progression results from a plethora of stimuli 
(Reya et al., 2001; Franco et al., 2016). In the context of the CSC model, it has been 
recognised lately that extensive cellular variability exists within what was thought to 
be a uniform CSC population. This finding has substantial implications for 
therapeutic targeting as recent evidence has shown that CSCs are not static entities 
but can evolve over tumour development (Magee et al., 2012; Hou et al., 2014; 
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Kreso et al., 2014; Pattabimaran et al., 2014). As a result, more conservative terms 
(instead of CSC) have been used to name this population of cells such as, tumour-
initiating cells, tumour-propagating cells, tumour-progenitor cells or tumour stem-
like cells (Zhao, 2017). Nowadays, it is clear that tumours develop in a dynamic 
environment where many factors are involved. Mainly, when tumours progress and a 
number of mutations rise, more cells can acquire self-renewal capability and CSC 
properties. In this model, as cancers progress, tumour hierarchies become shallower, 
and it becomes difficult to divide the CSCs from the non-CSCs (Kreso et al., 2014). 
For these reasons, it becomes difficult to evaluate which assay would be reliable to 
test this phenotypic and genetic tumour heterogeneity (Magee et al., 2012; Kreso et 
al., 2014). 
Various hypotheses arose regarding the origins of CSCs including the malignant 
transformation of normal stem cells,  mature cancer cell de-differentiation through 
EMT or induced pluripotent cancer cells (Zhao, 2017). Recent studies have 
suggested that the differentiation of CSCs into non-tumourigenic cells may be 
reversible (Chaffer et al., 2011; Gupta et al., 2017). As said previously, cells that 
undergo EMT can acquire the properties of CSCs. Mani et al., (2008) showed that 
human mammary cancer epithelial cells after sustained expression of the 
transcription factors Snail or Twist, silencing of E-cadherin, or exposure to TGF-
beta, acquire a CD44+CD24- phenotype, as breast CSCs (Mani et al., 2008). 
According to these findings, it is not clear whether the CSC model would effectively 
describe the complexity of cancers. A tumour is not a static environment and for this 
reason elimination of the CSCs on its own may not suffice to induce an acceptable, 
durable clinical response, since new CSCs may be generated in CSC-depleted 
tumours via the spontaneous dedifferentiation of non-CSCs (Blacking et al., 2007; 
Magee et al., 2012). At the moment, a model that resembles this tumour 
heterogeneity does not exist as it becomes evident that xenograft models cannot 
faithfully reproduce the response of the patient to the drug targeted therapy (Kreso et 
al., 2014). Furthermore, the CSC markers used so far have shown many difficulties 
in isolating CSCs in a number of solid cancers (Guo et al., 2006; Blacking et al., 
2007; Zhao, 2017).  
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These results raise questions about whether we have overestimated the number of 
cancers that follow this model, underlining the importance of testing CSC markers in 
significant numbers of patients to appreciate the heterogeneity among individuals 
(Allison et al., 2011; Magee et al., 2012; Kreso et al., 2014). 
For these reasons, it is fundamental to understand the relevance of CSCs in tumour 
development. This way, we will be able to create drugs that specifically target this 
tumour environment improving in turn patients' outcome.  
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1.7 Comparative oncology and future opportunities for 
personalised cancer therapy in clinical trials 
 
In 2012, an estimated 14.1 million new cases of cancer occurred worldwide, from 
which an estimate of 8.1 million people have died because of it. The four most 
common cancers occurring worldwide are lung, female breast, bowel and prostate 
cancer. In the UK in 2014 more than 350,000 people have been diagnosed with 
cancer with a survival rate of 50% at 5 years (data from Cancer research UK). The 
survival rate has doubled in the last 40 years, but there is still a huge variation 
between types of cancer. Less than 20% of people diagnosed with cancer types that 
are difficult to diagnose/treat survive for ten years or more. For example, just 1% of 
the patients diagnosed with pancreatic adenocarcinoma survive more than ten years, 
and no improvement has been achieved in the last 100 years (Pang et al., 2017). 
Murine cancer models have been handy for underpinning the basic biology behind 
cancer initiation, promotion, and progression (Gordon et al., 2009). Unfortunately, 
due to differences in the physiology of these two species together with the artificial 
conditions of these cancer models, they frequently do not adequately represent many 
of the features that define cancer in humans, including long periods of latency, 
genomic instability, and the heterogeneity of both tumour cells and their surrounding 
microenvironment. Most importantly, murine models cannot reproduce the complex 
biology of cancer recurrence and metastasis, and therefore, it is not possible to 
evaluate the outcomes in human patients for the cancer drug development (Paoloni 
and Khanna, 2007). 
Considering the long and expensive process that characterised the drug development 
and the continuous failure of drugs to pass clinical trials, a quest for new solutions is 
needed. In this setting, about 50 years ago the concept of comparative oncology was 
born. Comparative Oncology refers to the discipline that integrates the naturally 
occurring cancers seen in companion animals and compares them with their human 
counterparts to achieve more insight into cancer biology and therapy (Figure 1.10) 
(Gordon et al., 2009). 
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A study in 2010 in the UK showed that almost 27% of purebred dogs have died of 
cancer (Dobson, 2013). As human cancer, canine cancer occurs in the context of an 
intact immune system and a tumour microenvironment and often shares similar 
features of pathophysiology and clinical presentation to the human counterpart. For 
this reason, the canine model could represent a more effective model compared with 
the murine induced one (Gordon et al., 2009; Schiffman and Breen, 2015; Pang and 
Argyle, 2016).  
As in humans, different type of cancer can occur in dogs, although, accurate studies 
about the incidence of cancer in dogs are very limited (Dobson, 2013). One study of 
insured dogs in the UK showed that cancer most commonly occurs in the skin and 
soft tissues with a standardised incidence rate of 1437 per 100,000 dogs/year, 
followed by mammary, urogenital, lymphoid, endocrine, alimentary, and 
oropharyngeal sites (Dobson, 2013).   
Different types of cancer in dogs and humans has got some striking similarities and 
differences in their overall incidence. For instance, breast cancer is the most common 
malignancy in both women and bitches, and it is highly dependent on endogenous 
hormones in both species. In contrast, carcinomas of the prostate are a prevalent 
condition in men related to hormonal stimulation, whereas in dogs they are 
uncommon and occur more frequently in neutered dogs (Dobson, 2013). 
Interestingly, lung and large bowel are the most common sites of occurrence for 
human tumours but they rarely occur in dogs. Contrarily, soft tissue sarcomas, which 
are rare in humans, are relatively common in dogs (Dobson, 2013). 
The great opportunities given by the comparative oncology approach have spurred to 
the recent completion of the canine genome sequence (Paoloni and Khanna, 2007). 
In 2005, the Canine Genome Project decoded 99% of the canine genome of about 2.5 
billion base pairs. Results show that human and canine genomes are similar enough 
to apply findings of one species to the other with almost ~19,000 genes identified in 
the dog genome that has a similar or orthologous gene in the human genome (Paoloni 
and Khanna, 2007). On average, cancer rate in purebred dogs is estimated to be over 
ten times higher than in humans. This increase in cancer susceptibility is caused by 
the numerous genetic bottlenecks created during the phenotypic selection of purebred 
traits. Some specific purebreds are more susceptible to certain types of cancer. For 
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example, Bernese mountain dogs develop commonly histiocytic sarcoma, as much as 
Golden retrievers develop lymphomas. Scottish terriers have a high incidence of 
urothelial carcinoma, as well as Boxers with glioblastomas (Nunney et al. 2015).  
Therefore, considering their features, natural-occurring tumours in companion 
animals can represent a better model for studying the natural progression of human 
cancer than induced murine models (Schiffman and Breen, 2015). Considering as 
well that clinical trials in pet dogs are not restrained to the strictness of the different 
phases trial design as in humans. Thus translational drug development studies in pet 
dogs with cancer could be the answer to fill the gap between conventional pre-
clinical models and human clinical trials and benefit both human and canine patients 
diagnosed with cancer (Figure 1.10) (Paoloni and Khanna, 2007; Gordon et al., 





















1.8  Rationale of the study: Hypothesis, aims and objectives 
 
Clinical challenges are often associated with definitive treatment of malignant INS in 
humans thus novel targeted therapy is required. Malignant INS is very common in 
dogs as metastases are present in 95% of the cases. Considering the similar clinical 
and pathological features of human and canine malignant INS, canine malignant INS 
could represent an appropriate model for studying the natural progression of human 
malignant INS.  
Based on CSC theory, within a heterogeneous tumour population, a subpopulation of 
cancer cells drives tumour growth, with the abilities to self-renew, differentiate and 
resist chemotherapy and radiation therapy. The presence of this small subset of 
therapy-resistant tumour-initiating cells might explain the failure to current 
treatments to eradicate solid tumours including INS. Based on these findings this 
project hypothesised that a subpopulation of CSC might drive the malignant 
behaviour of canine and human INS driven by a subpopulation of CSC. Therefore, 
the aim was to isolate the INS CSCs and identifying potential promising targets for 
novel CSC-targeted therapies.  
The specific objectives of this project were:  
1. To determine gene expression profiles of canine INS progression through 
analysis of global changes in RNA expression from normal pancreatic canine 
tissues to metastatic stages of canine INS. 
2. To isolate and characterise INS CSCs in both human and canine INS cell line 
using in vitro and in vivo techniques. 
3. To identify and in vitro and in vivo targeting gene signalling pathways 











2 Materials and methods 
 
2.1  Cell tissue culture 
 
2.1.1  Cell lines 
 
Two cell lines have been used for this study: CM, a human metastatic INS cell line 
and canINS, a recently established canine primary INS cell line, were provided by Dr 
Jan A. Mol and Dr Floryne Buishand, from the University of Utrecht (the 
Netherlands). (Details of the canine cell line validation and characterisation are 
included in section 8.1 and 8.2, respectively.) 
CM is a previously characterised human cell line derived from the ascitic fluid of a 
patient with a liver metastasis from a malignant INS. It does not produce insulin, but 
it expresses GLUT2, a gene intimately associated with insulin expression (Baroni et 
al., 1999). CM cells were successfully grown as monolayers, showing an epithelial 
morphology. The doubling time was approximately 48 hours. The human INS cell 
line CM was cultured in RPMI-1640 (Roswell Park Memorial Institute Media, 
Invitrogen, Paisley, UK) supplemented with 10% fetal bovine serum (FBS) 
(Invitrogen) and 1% penicillin-streptomycin and plasmid (Invitrogen).   
The canine INS cell line canINS was derived from a primary canine INS, TNM stage 
II (Buishand et al. 2010), resected from a 6-year old male Flatcoated Retriever at the 
Faculty of Veterinary Medicine, Utrecht University (Buishand, unpublished data). 
canINS cells were successfully grown as monolayers, showing a fibroblast-like 
morphology. The doubling time was approximately 24 hours. Using an insulin 
radioimmunoassay (Cisbio, Codolet, France), it was determined that the first passage 
of canINS produced 305 U/L insulin. However, insulin secretion was lost after the 
fourth passage (Buishand, unpublished data), like previously reported in the INS cell 
line (Labriola et al., 2009). canINS was cultured in RPMI-1640 supplemented with 
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10% FBS, 1% penicillin-streptomycin, 200ng/mL growth hormone (GH) (Source 
Biosciences, Nottingham, UK).  
 
2.1.2  Cell culture reagents and equipment  
 
Cells were maintained in an incubator (HERA cell 150i, Thermo Scientific, USA) at 
37
o
C and 5% CO2 in a humidified atmosphere. Unless stated otherwise, cells were 
grown in tissue culture treated disposable plates (Thermo Scientific, USA). 
Disposable plastic pipettes were used for cell culture (Corning, USA). Cell culture 
manipulations were performed within a BioMat 2 Class 2 Biological Safety cabinet 
(CAS). Media were stored at 4
o
C and were warmed to 37
o
C before use at room 
temperature. 
Unless stated otherwise, 15 and 50 mL plastic tubes were from Greiner. Small (0.5 
and 1.5 mL) tubes were from Eppendorf (Germany). Pipette tips were from Starlab 
(UK). In most instances, centrifugations of 0.5 and 1.5 mL tubes were done using the 
centrifuge 5415R (Eppendorf, Germany); 15 mL and 50 mL tubes were centrifuged 
using 5810R (Eppendorf, Germany).  
 
2.1.3  Freezing and thawing cells  
 
Cells were frozen by resuspending 2 x 10
6 
cells in 500 μL of ice-cold FBS (Gibco, 
USA). A solution of FBS + DMSO (20%) was then added dropwise to the cells, to a 
final volume of 1 mL. Cells were placed in cryovials (Corning, USA) and placed on 
ice. The vials were frozen overnight in a –80
o
C freezer, inside a Mr Frosty Freezing 
Container containing isopropanol (Thermo Scientific, USA). The following day the 
cells were transferred to a –150
o
C freezer for prolonged stock.  
To revive frozen cells, vials were thawed rapidly at 37
o
C and the cells transferred to 
a 15 mL tube with warm media added dropwise (to 10 mL). The tube was 
centrifuged at 300 × g for 5 min, the supernatant was removed, and cells were plated 
in a T75 flask with 12 mL of media.  
 
 57 
2.1.4  Passaging cells  
 
Both cell lines were routinely passaged at 80-95% confluency every 3-4 days. To 
passage cells, medium was removed by pipetting, and the cells were washed once 
with PBS before incubation at 37°C in 0.25% trypsin-EDTA (Gibco, USA) until 
detached. Once cells had become detached, complete medium (T75: 5-10mL, T150: 
10mL) was used to wash the cells from the base of the flask. Cells were split as 
required (1:10 to 1:20) and seeded directly into new culture vessels with fresh media.  
 
2.1.5  Determination of cell viability  
 
Detached cells were diluted 1:1 with Trypan blue dye (Gibco, USA). The mixture 
was visualized in a Neubauer counting chamber (SLS). The living cells (not stained 
by the Trypan dye) in the central 5 × 5 square were counted. Cell number was 
calculated by the following formula:  
Cells/ml = Cells in central square X 2 (dilution factor) X 104 
 
2.1.6 Primary insulinoma cell lines 
 
Attempts to establish a new canine INS cell line were made using the protocol 
developed at Utrecht University for the canine cell line (Buishand, unpublished 
data). 
After obtaining signed consent from the owners, samples were harvested during 
surgery from dogs with a definitive diagnosis of primary/metastatic INS. An 8 mm 
biopsy punch was harvested from the centre of the lesion. Half of the sample was 
stored in 10% formalin (Sigma-Aldrich, USA) to confirm the diagnose of INS. Half 
of the sample was harvested in cold, sterile Hank's Balanced Salt Solution (HBSS) 
and put on ice. Tissues were then washed three times in 10 cm Petri dishes (Corning, 
USA) and minced finely. Samples were then placed in a 50 mL Falcon tube and 
centrifuged for 3 min at 1000 rpm at 4oC. A solution of 3mg/mL of collagenase IV 
(Gibco, USA) with 0.004% DNAse (Sigma-Aldrich, USA) in Dulbecco’s modified 
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Eagle’s medium (DMEM) containing Glutamax-I (Gibco, USA) + 10% FCS + 1% 
Penicillin/Streptomycin was added to the pellet and then incubated for 75 minutes at 
37oC on a Titramax 1000. The solution was then centrifuged and washed twice in 
HBBS. In case of cells were not entirely dissociated a step of homogenisation using 
Dounce tissue grinder set (Sigma-Aldrich, USA) was performed. Cells were then 
filtered through a 70μm cell strainer. After counting the cells, they were seeded at a 
density of 2x106 in T75 Primaria flasks (Corning, USA) in RPMI1640 + 1% 
penicillin/streptomycin + 10% FBS + 200 ng/mL porcine GH + 1.25μg/mL of 
Fungizone (Gibco, USA).  
After 48 hours, flasks were examined for adherent cells and checked for signs of 
bacterial contamination. If contamination was heavy, flasks were discarded. If the 
medium was cloudy and the cells were attached, the medium was changed. Medium 
was changed twice weekly and replaced with 50% fresh: 50% conditioned medium 
(growth medium from flasks centrifuged to remove debris) after gently washing 
adherent cells twice with PBS. At 80-90% confluence, cells were transferred to 
larger (T75) culture flasks after dissociation of the monolayer using 0.05% Trypsin-
EDTA and then subcultured as necessary. Fifty percent conditioned medium was 
used for media changes and plating at subculture for up to 5-7 passages.  
 
2.1.7 Sphere assay protocol   
 
2.1.7.1 Tumorspheres culture 
Cells in monolayer were trypsinized as described previously and centrifuged at 1200 
rpm for 5 minutes. Cells were then counted and seeded at a density of 60,000 cells 
per well in 2 mL of N2 media in six-well low adhesion tissue culture plates (Corning, 
USA).  
Cells were grown in serum-free conditioned medium, which contained DMEM/F12 
supplemented with progesterone (20 nM), putrescine (100 μM), sodium selenite (30 
nM), transferrin (25 μg/mL), and insulin (20 μg/mL) (Sigma Biochemicals, Dorset, 
UK). Every two days, human recombinant EGF (10 ng/mL) and human recombinant 
basic fibroblast growth factor (bFGF) (10ng/mL) (Peprotech, USA) were added. For 
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maintaining canINS spheres B27 serum-free supplement (Invitrogen, UK) was also 
added to the media every two days. All experiments were conducted in triplicate. 
Plates were maintained at 37 °C in a humidified CO2. 
 
2.1.7.2 Tumorsphere passaging 
To passage spheres, cells were collected by pipetting, and the wells were washed 
twice with PBS to maximise collection. Tumorspheres were washed gently (1000 
rpm, 5 minutes) using at least an equal volume of PBS. 1 mL of 0.05% trypsin-
EDTA was added to the cells and incubated at RT for 5 minutes. Three mL of FBS-
free media were added to terminate trypsinisation and cells were collected by 
centrifugation at 1000 rpm for 5 minutes. The cell pellet was resuspended in 1 mL of 
PBS and counted as previously described and seeded at a density of 60,000 cells per 
well in 2 mL of N2 media.  
Once the spheres were passaged at least five times, images were captured using Zeiss 
Axiovert 40 microscope (Carl Zeiss, Germany) equipped with a cooled CCD camera 
and Axiovision software.  
 
2.1.8  Chemosensitivity Assays  
 
Cells were assessed for their sensitivity to different chemotherapy drugs over a range 
of concentrations, including at doses that can be achieved in plasma in vivo. Cells 
were treated with 5-Fluorouracil (plasma concentration: 800 ng/mL-2000ng/mL, 
5M-15M) (Danquechin-dorval and Gesta, 1996; Yamada, 2003; Blaschke et al., 
2012)  (R&D, USA) (Yamada, 2003) over the indicated range of concentrations. 
Cells were harvested, counted, resuspended in complete medium and plated in black 
96-well culture plates at 50 μL / 5x103
 
cells per well. Plates were incubated at 37°C, 
5% CO2. After 24 hours, drug dilutions were made in complete medium, and 50 μL 
of each dilution was added to triplicate wells. Fifty μL of medium only was added to 
triplicate wells as a control. Plates were incubated at 37°C, 5% CO2 for another 48-
72 hours.  
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The CellTiter-Glo® reagent was added to each well in 1:1 concentration with the 
media. The solutions were mixed on an orbital shaker for 2 minutes before being 
incubated at RT for 10 minutes. The luminescence was then recorded for 1 second 
per well using the Perkin Elmer 1420 Multilabel Counter Victor3TM plate reader.  
 
2.1.9  Colony formation assay 
 
Cells were counted and seeded at a density of 250 to 500 cells per 10 cm plate 
containing ten mL of standard or chemotherapy supplemented medium. The medium 
was changed, and the plates were checked for colony formation biweekly. When 
visible colonies had formed after 10 to 15 days, the colonies were fixed. The medium 
was removed from each plate, and the cells were washed twice in PBS. Five mL of 
cold methanol was then added to each plate and left to stand at RT for 5 minutes. The 
methanol was removed, and ten mL of 10% Giemsa stain (Sigma-Aldrich, USA) was 
used to stain the colonies for 20 minutes. The plates were rinsed thoroughly in tap 
water before allowing drying. The colonies were then counted manually. 
 
2.1.10 Chorioallantoic membrane assay  
 
The chick chorioallantoic membrane (CAM) assay has long been used as an in vivo 
model for the study of tumour behaviour. The assay is conducted within the 
protected environment of a developing chick embryo and is particularly useful 
because of the ready availability of fertilised eggs and the ease of access to a fully 
functioning membrane. Rejection of the grafted cells is minimised due to the natural 
immunodeficiency of the chick embryo. Moreover, the CAM assay allows rapid 
vascularisation and development of grafted tumour cells in an in vivo 
microenvironment (Vargas et al., 2007; Deryugina and Quigley, 2008; Lokman et 




Fertilised ISA Brown layer strain chicken eggs (Roslin Institute Poultry Unit, UK) were 
used to evaluate the capability of INS CSCs to invade and form tumours in an in vivo 
xenograft model. According to the UK Animals (Scientific Procedures) Act 1986 
regulated by the Home Office, as chick embryo chorioallantoic membrane experimental 
protocols were conducted and concluded during the first two-thirds of the incubation of 
the embryonated eggs, we did not require a licence (Home Office, 2014).  
 
2.1.10.2 Preparing eggs for xenografting 
Chicken embryonated eggs were incubated until day 11 of incubation without the need 
for a licence. Briefly, chicken embryonated eggs were incubated rocking (Brinsea 
Octagon 40 OX incubator) at 37.5
o
C until day 4 of development in a horizontal 
position. At this date, approximately two mL of egg albumin was removed with a 
syringe and a 24 gauge needle (Becton Dickinson), to detach the CAM from the shell 
and to disclose the underlying CAM vessels. A 1 cm × 1 cm window was opened on the 
shell with scissors, having the egg in the horizontal position. Two drops of 
penicillin/streptomycin (Gibco, USA) diluted 1:10 in PBS were added to the surface of 
the CAM to minimise the risk of infection. The shell window was sealed with 
microporous surgical tape and incubation at 37.5
o
C (RCOM Maru Digital Incubator) 
was continued until day seven without turning.  
 
2.1.10.3 Graft and incubation of cells 
On day 7, single cell suspensions of trypsinised adherent cells or spheres (both CM 
and Nielson) were labelled with PKH26 (Sigma-Aldrich), a red fluorescent live cell 
membrane dye, according to manufacturers’ instructions. Cells were suspended in a 
1:1 mixture of serum-free media and Matrigel Phenol Red Free (Corning, USA), and 
2x105 cells inoculated directly onto the CAM. The shell windows were resealed and 
incubated without turning (Figure 2.1).  
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At day 11, pictures were taken using Axio ZoomV16 coupled with AxioCAM HRM 
camera (Zeiss). Images were processed using Zeiss pro image software and then the 
fluorescence was calculated using the software ImageJ 1.46 software (open source). 
 
2.1.10.4 Harvesting and fixation of CAM 
The embryos were sacrificed by decapitation. The area of CAM inoculated with the 
fluorescent cells was harvested and stored in 10% neutral buffered Formalin solution 
(Sigma-Aldrich, USA) for 48hrs. Then the excess of Formalin was removed and the 
CAM embedded in an agarose block by pouring the agarose into a small plastic 
weigh boat and then transfer the tissue from PBS to liquid agarose. Tissue was then 
embedded in fresh paraffin. Tissue blocks were then trimmed and 4μm sections were 
cut and mounted onto glass microscope slides.  
 
2.1.10.5 Immunostaining 
Sections were rinsed in PBS Tween 20 for 2x2 min then incubated with the primary 
antibody for 1 h at room temperature or overnight at 4oC with Monoclonal Mouse 
Anti-Human Cytokeratin (Clone MNF116) (1:50) (Dako, Denmark).  
Sections were rinsed in PBS Tween 20 for 2x2 min then blocked with Dako 
REALTM Peroxidase-Blocking Solution (Dako) for 10min at room temperature.  
 Sections were rinsed with PBS Tween 20 for 3x2 min then incubated with the 
secondary antibody Dako REALTM EnVisionTM/HRP Mouse (ENV) for 40 min at 
room temperature. 
The cutting and staining with a cytokeratin pan antibody (MNF116) were performed 
by Neil MacIntyre and the R(D)SVS pathology laboratory. Images were taken using 
a Nikon Eclipse Ni Brightfield Microscope (Nikon) and after that processed with 




Figure 2.1 Pictures showing chorioallantoic membrane of chicken embryo. Cells have 
been labelled with red fluorescent marker and seeded on the membrane on a plastic ring. 
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2.2  Isolation and quantification of nucleic acids 
 
2.2.1  RNA extraction, quantification and Reverse Transcription (RT) 
 
The RNeasy mini kit (Qiagen, UK) was used according to the manufacturer’s 
instructions.  
Depending on whether the extraction was performed on tissues or cell pellets 
different protocols were used for lysation. Information regarding specific protocols 
will be detailed in each chapter. DNA digestion was performed using DNase I 
(Qiagen, UK) at the recommended point in the RNA extraction protocol. Total RNA 
was quantified, and purity checked using absorbance spectrophotometry at 260 and 
289 nm (Nanodrop 1000, Thermo, UK).  
RNA was converted to cDNA using the Omniscript reverse transcription kit (Qiagen, 
UK) according to the manufacturer’s instructions. Omniscript RT was carried out by 
mixing the following reagents: 10 x Buffer RT; dNTP (to 0.5 mM of each dNTP, 
Promega); Specific primers (to 1 μM); Random nonamers (to 10 μM, Sigma); RNase 
inhibitor (10 units, Promega); Omniscript reverse transcriptase (4 units); template 
RNA (1 μg); water to 20 μL. Unless stated otherwise, the reaction was incubated for 
60 min at 37°C.  
 
2.2.2 Primer design and preparation  
 
Where available, previously published primers were checked using NCBI Primer- 
blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast). For primer design, the NCBI 
nucleotide database was used. In primer design, it was attempted to maintain the 
primer melting temperature similar to the pair (within 57-63 degrees) and to avoid 
primer hairpins, self-dimers and heterodimers that involved the 3'-end of the 
sequence. The parameters mentioned were quantified using the IDT OligoAnalyzer 
online program (https://www.idtdna.com/calc/analyzer). Primers were produced by 
Eurofins Genomics. All primers were diluted to 100 pmol/μL with nuclease-free 
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water and stored at -20 °C. A detailed list of the primers used is available in 
Appendix 8.6. 
2.2.3  Polymerase Chain Reactions (PCR)  
 
PCR reactions were set up using HotStarTaq® DNA polymerase (Qiagen, UK) PCR 
kits according to the manufacturer's instructions. To ensure consistency, all 
experiments were performed on the same thermal cycler (Labtech G-Storm GS-4822, 
France) following the cycling protocol as described in Table 2.1. To assess the 
consistency of sample loading and PCR conditions between separate experiments, 
primers that amplified cDNA of transcripts from the human and canine housekeeping 
gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were included in 
separate reactions (Pang et al., 2014). 
 
 Table 2.1 Optimised cycling protocol for HotStarTaq DNA Polymerase. 
Initial activation step 15 min 95° 






Annealing 1 min 50-68° 
Extension 1 min 72° 
Number of cycles 35  
Final extension 10 min 72° 
 
2.2.4  Agarose gels  
 
Gel concentrations between 1% and 2% were used depending on the size of the 
product to be resolved. Gels were made by dissolving agarose powder (UltraPure 
Agarose, Invitrogen) at the stated concentrations in TAE buffer (40 mM Tris, 20 mM 
acetic acid, and 1 mM EDTA). The mixture was heated in a microwave until the gel 
was completely dissolved. Gel Red (Biotium) was added in 1:1000 dilution. The gel 
was then poured into a mould and allowed to set. A volume of 12 μL of PCR product 
was added to 4 μL of 6 X Blue/Orange Loading Dye (Promega, UK). A 100 bp 
ladder or 1.5 Kb DNA (Promega, UK) was used to assess product size. Gels were run 
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for approximately 2 hours at 100-130V, and then the products were visualised using 
a BioRad Molecular Imager GelDoc.  
 
2.2.5  Real-time polymerase chain reaction (qPCR)  
 
The Platinum Sybr Green qPCR Kit (Invitrogen, UK) was used in all qPCR reactions. 
The master mix is outlined in Table 2.2. Reactions were performed on the Stratagene 
MX3000P (Agilent, UK). For primer optimisation, cDNA from CM and Nielson cell 
lines was diluted in ten-fold steps to 100,000, and 9 μL of this was added to each well. 
Primer efficiency, and dissociation curves were calculated using MXPro software 
(Agilent, UK), specificity was assessed by agarose gel electrophoresis. Relative gene 
expression was performed using cDNA, diluted 1:20 and 9 μL of this added to each 
well. Each reaction was performed in triplicate and three no-template controls were also 
included for each primer using 9 μL of nuclease-free water. Relative gene expression 
levels were obtained by normalisation to the expression levels of housekeeping gene 
GADPH. Calculations were made using the Delta Delta Ct Method (Pfaffl, 2004). 
 
 Table 2.2 qPCR master mix Reaction conditions were 2 minutes at 50°, 2 minutes at 95°C, 
then 40 cycles of 95° x 15secs and 60°C x 30secs. The final cycle was 95°C for 1 minute 
then cooling to 60°C before monitoring for dissociation to 95°C. The dissociation curve 
produced and lack of amplification of the no template controls were checked using MXPro 
Software (Agilent, UK). 
Component Volume (μL per reaction) 
SYBR Green Mix 12.5 
Forward primers 1 
Reverse primers 1 
ROX 0.5 






2.2.6  mRNA sequencing using Next Generation Sequencing (NGS) 
 
2.2.6.1 Assessment of RNA quality 
All sequencing was performed by The University of Edinburgh sequencing service 
(Edinburgh Genomics, Ashworth Laboratories, King’s Buildings, Edinburgh). 
Samples were prepared in clearly labelled RNase free tubes. Samples were checked 
for quality by the 2100 Bioanalyzer (Agilent) with the Agilent RNA 6000 Nano kit 
or by the Agilent 2200 Tapestation with the RNA analysis screen tape (Agilent). 
These two methods provide an accurate and objective assessment of total RNA 
degradation the RNA integrity number (RIN) as measurement. The RIN is a software 
output that estimates the integrity of total RNA samples based on the entire 
electrophoretic trace of the RNA sample rather than just the ratio of the ribosomal 
bands, 28S and 18S. This includes the presence or absence of degradation products. 
The assigned RIN is independent of sample concentration, instrument and analyst, 
and therefore it is considered a de facto standard for RNA integrity (Griffin et al., 
2012). Samples sent for sequencing accomplished all the following requirements: 
RIN > 6; concentration >30ng/uL; A260:280 >1.9. Good quality of RNA is critical 





Figure 2.2 Example of an RNA quality analysis report with 2100 Bioanalyzer (Agilent) 
(A) and 2200 Agilent Tapestation (B).  
 
 
2.2.6.2 Library preparation for mRNA sequencing 
Library preparation from mRNA before sequencing is necessary to obtain a clear 
view of the coding transcriptome with strand-specific information (Corney et al., 
2013).  
The mRNA library was prepared by The University of Edinburgh sequencing service 
(Edinburgh Genomics, Ashworth Laboratories, King’s Buildings, Edinburgh) using 
Tru Seq Stranded mRNA Library Prep Kit (Illumina). Library preparation consists of 
the following steps: 
1. RNA fragmentation.  mRNAs are typically fragmented to smaller pieces of 
RNA to enable sequencing. 
2. Reverse transcription. First and second strand cDNA is reverse transcribed 





3. Adapter ligation. The 5' and 3' ends of cDNA are repaired, and adapters 
(containing sequences to allow hybridization to a flow cell) are ligated.  
4. Library clean-up and amplification. Libraries are enriched for correctly 
ligated cDNA fragments and amplified by PCR to add any remaining 
sequencing primer sequences. 
5. Library quantification, quality control and sequencing. Library 
concentration is assessed using qRT-PCR and Bioanalyzer and is ready for 
sequencing (Corney et al., 2013). 
 
2.2.6.3 Sequencing 
At the moment, Illumina sequencing is the most commonly used RNA-sequencing 
method. It uses a “sequencing by synthesis” (SBS) approach (Metzer et al., 2010).  
After library preparation is completed, the libraries are denatured and undergo a 
process known as "bridge amplification" to create clonal clusters of single-stranded 
DNA molecules. Briefly, once the fragments attach on the flow cell, DNA is 
sequenced by adding polymerase resulting in a covalently bound full-length 
complementary copy of the cDNA fragment. The cDNA fragment obtained is 
subjected to several rounds of PCR amplification to produce clones that can be 
optically resolved during sequencing. Obtaining optimal cluster density is critical 
since it will determine the number of reads obtained. Therefore, the cDNA is labelled 
with dNTPs (nucleoside triphosphate). Each of the dNTPs is labelled with a specific 
fluorescent colour. After laser excitation, different emitted fluorescent waves are 
recorded for each cluster. Based on the fluorescence emission the base of each 
cluster is identified. Because the clusters contain identical DNA sequences, the entire 
cluster is read as one base. A camera records this base reads across the entire flow 
cell. This takes place between 50 and 100 cycles to create about 150-200 million 
50bp to 100bp reads. When two separate read cycles occur in both directions, it is 
called paired-end reads. This kind of read will provide data about both sides of the 
fragment of interest (Metzer et al., 2010). 
For this study, we sequenced fragments of 75bp to a yield of at least 290milion 




2.3  Bioinformatic NGS analysis 
Bioinformatic analyses were performed by The University of Edinburgh sequencing 
service (Edinburgh Genomics, Ashworth Laboratories, King’s Buildings, 
Edinburgh). The process of analysis is described as follows: 
1. Raw reads were filtered for quality (Q30) and adapter using cutadapt (v1.8.3). 
2. Trimmed reads were then aligned to Canis_lupus_familiaris_v3.1.84 using 
tophat2. 
3. Read counts were obtained using HTSeq v.6.0.1 with mode 'union'. 
4. Differential gene expression was then carried out using edgeR (version 3.12.0). 
Genes with less than 20 reads were discarded from this analysis. Further down, only 
genes with uncorrected P-value < 0.05 were retained. 
5. Functional analysis (Gene set enrichment analysis) was conducted using GSEA2-
2.2.2. Gene sets with a False Discovery Rate (FDR) <0.05 were considered as 
significantly enriched. 
 
2.4  Recovery and detection of protein 
2.4.1  Cell lysis 
 
All manipulations were performed on ice. Cells, either growing as monolayer or as 
spheres, were harvested washing twice with cold PBS. After that, cells were 
centrifuged at 1200 rpm x 5 min. The pellet obtained was then frozen, and a volume 
of chilled urea buffer with protease inhibitor mix was added. The pellet was then 
mixed by pipetting until no cell clumps were visible and incubated for 10 minutes on 
ice. Then cells were transferred to 0.1 mL Bioruptor®Microtubes (Diagenode, 
Belgium) and sonicated using pre-chilled Bioruptor® Pico sonicator (Diagenode, 
Belgium) with the following settings:  
Sonication cycle: 30 sec ON/30 sec OFF  
Total sonication time: 3 - 5 cycles  
Temperature: 4°C  
The cell lysates were cleared by centrifugation at 4°C at 15,000 x g for 15 minutes, 
snap frozen on dry ice, and stored at -70°C.  
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2.4.2  Protein quantification  
 
The Bradford assay was used for protein quantification. The sample proteins were 
added and mixed in a transparent 96-well plate in concentrations that were within the 
standard range. Subsequently, 200 μL of the ready-made reagent (QuickStart 
Bradford reagent, Bio-Rad, UK) were added to the samples prepared in triplicates. 
To create the standard curve, BSA was used in increasing concentrations, in 
triplicates: 0, 0.12, 0.25, 0.5, 1, 2 and 4 mg/mL. The wells were mixed to allow the 
development of the blue colour and left at RT for 5 min. The plate was then read in a 
Victor3 plate reader (Perkin Elmer, USA) at 595 nm.  
 
2.4.3  Western blots and gel stains  
 
Protein samples were resolved on denaturing SDS-polyacrylamide gels by 
electrophoresis. The SDS-polyacrylamide gels were prepared and assembled using 
the Bio-Rad Protean II minigel system. The gel was allowed to set at RT. Twelve 
percent resolving polyacrylamide gels were prepared (based on anticipated protein 
product size of 15-150kDa), along with 5% stacking gels, on the day of 
electrophoresis.  
Gels were made using the protocol as follows: 30% acrylamide/0.8% bisacrylamide 
solution (National Diagnostics, USA); 1.5 M Tris-Cl with 0.4 % SDS, pH 8.8 (3.75 
mL); distilled water to 15 mL; 10 % ammonium persulfate (50 μL, Bio-Rad, USA); 
TEMED (5 μL, Bio-Rad, USA). These were mixed and poured to 2/3 of the height of 
Mini-Protean glass plates of either 1 – 1.5 mm, depending on the sample volumes 
(Bio-Rad, USA). The gel was covered with distilled water and allowed to set. After 
setting, the water was removed and the stacking gel was added to the plates (30% 
acrylamide/0.8% bisacrylamide solution (0.65 mL), 0.5 M Tris- HCl with 0.4 % 
SDS, pH 6.8 (1.25 mL), distilled water (3.05 mL), 10% ammonium persulfate (50 
μL), TEMED (5 μL)). The plastic comb was added into the poured stacking gel to 
shape the wells. The gel was allowed to set. The samples were prepared by the 
addition of 6 × sample buffer (Tris-Cl/SDS, pH 6.8 as above (7 mL), glycerol (3.8 g 
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or ∼ 3 mL), SDS (1 g), DTT (0.93 g), bromphenol blue (1.2 mg), water (to 10 mL if 
needed)). Unless stated otherwise, samples were heated at 95°C for 5 min after the 
addition of the sample buffer. The samples were pipetted into the wells of the gel. 
The size standard used was Precision Plus Protein Dual Colour (5 μL, Bio-Rad). The 
gel was run at 120 V until the samples were resolved. 
On completion of electrophoresis, the gel was removed from the glass plates, and the 
stacking gel was removed. The gel was then used to transfer proteins to a 
nitrocellulose membrane. The transfer cassette (Bio-Rad, USA) was assembled in the 
following order, from the anode (white) to the cathode (black) side: sponge, filter 
paper, nitrocellulose membrane (GE Healthcare), gel, filter paper, sponge. The 
cassette was placed in a transfer apparatus with transfer buffer (Tris base (18.2 g), 
glycine (86.5 g), methanol (1200 mL), distilled water (to 6 l)). The transfer was 
performed at 100 V for 1 h at 4
o
C.  
If necessary, the membrane was stained using Ponceau red (Ponceau S (Sigma- 
Aldrich, USA), 0.5 g dissolved in 1 mL glacial acetic acid. The staining solution was 
placed on the nitrocellulose membrane and incubated for 30 sec mixing. The stain 
was returned to the container for reuse. The membrane was washed with distilled 
water until the bands were visible.  
Depending on the primary antibody used, the membrane was either blocked with 
Tris-Buffered Saline Tween20 (TBST; 10 mM Tris HCl, 150 mM NaCl, 0.1% (v/v) 
Tween 20) + skimmed milk (5 %) or with TBST + BSA (5%) for 1 hour at RT.  
The membrane was then incubated at 4°C overnight with the primary antibody 
diluted in the specific blocking buffer. After incubation overnight, the membrane 
was washed in TBST/0.1%Tween20 three times (15 minutes each) and then probed 
with secondary antibody. Horseradish peroxidase- (HRP-) conjugated secondary 
antibodies were obtained from Dako (Goat anti-Rabbit-HRP; Rabbit anti-Mouse-
HRP). The appropriate secondary antibody was diluted 1:1000 (Rabbit anti-Mouse-
HRP) or 1:2000 (Goat anti-Rabbit-HRP) in blocking solution and applied to the 
membrane. After incubation at RT for 1 hour, blots were washed for 3 x 5 minutes in 
TBST/0.1%Tween20. Table 2.3 shows a list of the primary and secondary antibodies 
used. The following antibodies were optimised and validated for both human and 
canine INS cell lines. 
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2.4.4 Chemoluminescent detection  
 
The enhanced chemoluminescence reagent (GE Healthcare) was prepared in a 1:1 
dilution and applied to blots. After 1-2 minutes, excess reagent was drained, and 
blots were transferred to a Saran wrap folder secured within a film cassette. In a 
darkroom, radiographic film was loaded into the cassette and allowed to expose for 
2-20 minutes depending on signal strength. After developing, the molecular weight 
marker sizes were labelled on to the radiographic film to allow determination of 
protein band size.  
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 Table 2.3 Primary antibodies used for western blotting. 









Rabbit Monoclonal 1:600 TBST+5% 























2.5 Flow cytometry and Fluorescence-activated cell sorting (FACS) 
sorting 
 
Fluorochrome-conjugated antibodies have been used to label and then sort CM and 
canINS cell line using BD Fortessa or FACS-Aria flow customers (both BD 
Biosciences, USA). Specific protocols and antibodies are detailed in each chapter. 
Following a general protocol, cells were harvested, washed and adjusted to a 
concentration of 0.5-1x 106 cells per condition in ice cold PBS. Cells have been 
strained using 70μm cell strainers to avoid clumps that could block the flow 
cytometer.  Cells were then stained in polystyrene round-bottom 12x75 mm. Control 
samples (cells incubated with equivalent concentration of isotype-matched control 
antibody / unstained cells) were evaluated for each experiment. A secondary 
antibody control was added as a negative control.  
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At least 100,000 events were acquired for analysis. The optimal concentration of the 
test antibody was determined for each cell line, such that the fluorescence of the 
concentration-matched isotype control sample was equivalent to that of the unstained 
aliquot. Doubling dilutions of test antibody and concentration-matched isotype 
control antibody were made in PBS, with the manufacturers’ recommended 
concentration as the initial dilution. All stainings were performed at 4°C protected 
from light. Cells were then analysed in the flow cytometer by a laser at different 
wavelengths depending on the conjugated fluorochrome. Cells were gated by 
adjusting the size (forward scatter/FSC) and granularity or complexity (side 
scatter/SSC) of the cells to the middle of an FSC × SSC graph. Red fluorescent 
emission (Alexa Fluor 647) was excited by the 670nm laser line. Yellow-green 
fluorescent emission (Phycoerythrin-PE) was excited by the 586 nm laser line. Cell 
debris and dead cells were excluded from the analysis based on scatter signals and 
Sytox Blue (Invitrogen, UK) or Zombie Violet (Biolegend, UK) fluorescence. Both 
dead cell discriminators were excited by a violet laser at a wavelength of 450 nm. 
Post-acquisition analysis was performed using FlowJo (Treestar, USA). Results were 
analysed after setting the gate on the cellular population, eliminating debris. The 
percentage of positive cells was determined by comparison to the negative 
(secondary antibody or isotype) control level.  
 
2.6 Statistical analysis 
 
All experiments were repeated at least on two separate occasions. Quantitative analysis 
was based on a minimum of three replicates. Data were analysed using Minitab® 17 
Statistical Software (Minitab Ltd., Coventry, UK) and all graphs and diagrams were 
generated using Microsoft Office 2011 software (Microsoft Corporation). P-values 
<0.05 were considered statistically significant. When data followed a normal 
distribution, two sample t-tests were used to compare differences between two samples, 
or one-sample t-tests to determine whether the sample mean was statistically different 
from a known or hypothesised mean. IC50 values were calculated using GraphPadPrism 
6 (GraphPad Software, La Jolla, CA, USA). To assess combined treatment effects on 






3 Investigating molecular mechanisms of canine 




Insulinomas (INS) are the most common functioning pancreatic neuroendocrine 
tumours (PNETs) in dogs. Although considered to be ‘indolent’ tumours, at the time 
of diagnosis approximately 95% of the cases in dogs develop micrometastases 
resistant to chemotherapy and there is no curative treatment for metastatic INS. 
Using RNA-sequencing technologies, differential gene expression and pathway 
analysis were combined to conduct a pilot study and gain new insight into the 
underlying molecular mechanisms of this disease. The hierarchical clustering 
analysis suggested that normal tissues had a different gene expression profile 
compared to primary and metastatic lesions. When comparing normal pancreas with 
primary INS, 1900 differentially expressed genes were identified (P < 0.01, 
FDR<0.05; logFC>2); whereas, comparison between primary INS and metastatic 
lesions revealed that only 164 were differentially expressed (P < 0.01, FDR<0.05; 
logFC>2). This study confirmed a number of identified genes previously implicated 
in the malignant subtypes of human INS, such as INSM1 and IAPP, and also 
provided new findings. We revealed a gene signature that might be indicative of 
early carcinogenesis and that could aid in the identification of malignant subtypes of 
canine INS. For instance, genes related to pancreatic endocrine development and 
insulin secretion such as PDX1, INS, PAX4, NKX2 and NESTIN were upregulated in 
primary INS when compared to normal pancreatic tissues. Using Gene set 
enrichment analysis and Reactome tool, we confirmed these data showing that 
significantly disrupted biological processes were mainly related to beta cell 
differentiation, pancreatic development and also to protein transcription and 
extracellular matrix. In this study, the combination of differential gene expression 
with pathway and network analyses represented a starting point into an in-depth 
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understanding of this poorly studied cancer. These integrative computational 
approaches could be the key to future effective early cancer diagnosis and treatment 





INS are rare neoplasms that can arise from pancreatic beta cells in humans and dogs 
(Okabayashi et al., 2013; Buishand et al., 2014). In 10% of the cases, INS in humans 
occur as part of an autosomal dominant familial cancer syndrome, MEN 1, but the 
majority arise as sporadic lesions (Dotzenrath et al., 2000); whereas, in dogs INS 
occur sporadically (Goutal et al., 2012). 
Canine INS are more often malignant (95% of the cases metastasise to liver/lymph 
nodes) compared to human ones which are usually benign (5-16% of the cases 
metastasise to liver/lymph nodes) (Jonkers et al., 2007; Buishand et al., 2010). If INS 
is detected early, it can be cured by surgical resection. Nevertheless, there is no 
curative treatment for metastatic disease (Goutal et al., 2012; Okabayashi et al., 
2013).  
Previous studies showed that in human INS, grading and TNM stage had prognostic 
significance for disease-free interval (DFI) and survival time (ST) in INS (De Herder 
et al., 2011; Zhu et al., 2016). Similarly, in dogs, previous studies demonstrated that 
tumour size, TNM stage, the Ki67 and necrosis are prognostic factors related both to 
DFI and ST (Buishand et al., 2010; Buishand et al., 2014). In particular, stromal 
fibrosis is significantly predictive of survival, while tumour size, the Ki67 index, and 
TNM stage are significant prognostic marker of DFI and ST (Buishand et al., 2010). 
These factors have also been reported as prognostic markers in human INS biopsies 
(La Rosa et al., 2007, 2009). Additionally, tumour cell nuclear cytoplasm and 
nuclear density (number of nuclei per square millimetre) have been identified as 
discriminators between metastatic and non-metastatic tumours in both human and 
canine INS (Jutting et al., 1997; Anlauf et al., 2009). Numerous studies have 
demonstrated the utility of several NE biomarkers, such as chromogranin A, 
synaptophysin, and CD56 to give a definitive diagnosis of INS (Jonkers et al., 2006, 
2007; Buishand et al., 2014; Fujino et al., 2015). In particular, a few biomarkers 
have been identified for their prognostic significance in human and canine INS. For 
instance, IGF 1 and 2 bind have been indicated to play a role in INS in both human 
and canine INS. In human INS, IGF1 and IGF1R were expressed in 70% and 90% of 
tumours, respectively (Jonkers et al., 2007). These findings were confirmed in dogs 
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where expression of IGF1 was related to highly metastatic INS (Buishand et al., 
2010). Whereas IGF2 has been related with a more benign phenotype of PNETs in 
dogs (Finotello et al., 2014).  
Today it is clear that each type of tumours has a unique gene signature that promote 
tumour growth. Therefore, further investigations of the transcriptomic alterations and 
underlying molecular mechanisms are essential for early diagnosis and treatment 
(Höpfner et al., 2003; Kuboki et al., 2016; Liu and Chang, 2016). However, the 
molecular pathways underlying the development and progression of INS are yet 
poorly understood.  
A novel approach in human oncology is the use of therapeutics that specifically 
target gene products that promote tumour growth and metastasis. Therefore, 
identifying potential biomarkers and novel targets can improve treatment and 
outcome of patients diagnosed with malignant INS (Fazio et al., 2010; Rossi et al., 
2014; Giuroiu and Reidy-Lagunes, 2015). The study of spontaneously occurring 
tumours in the dog, a species that has a genetically stronger relationship to the 
human than mice, can potentially enrich the knowledge of rare human cancers. This 
could lead to more insight in the pathogenesis of the disease and facilitate the 
identification of therapeutic targets valuable for dogs and humans (Gordon et al. 
2006).  
In this chapter, the aim was to develop integrative computational approaches to 
identify differentially expressed genes and altered pathways to unravel the 
mechanisms of tumourigenesis of malignant INS. Considering the higher incidence 
of malignant INS in dogs compared to humans, we investigated the gene expression 
profiles of malignant INS in dogs as a model for studying tumour progression of the 
human malignant tumours. Conventional mRNA profiling tools, such as Northern 
blot, real-time PCR, and microarray, rely on the design of gene-specific primers 
(Higgins et al., 2010; Boerkamp et al., 2013; Buishand et al., 2014); due to 
differences in length, GC content, and target regions of the primers, these mRNA 
profiling tools are not able to quantify and compare the real abundance of transcripts 
between genes (Cui et al., 2012). RNA-Seq instead represents a highly sensitive and 
accurate device for measuring expression across the transcriptome (Soneson et al., 
2013). Compared to the previously used microarray it provides an increased dynamic 
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range of the differentially expressed genes and the ability to detect and quantify the 
expression of previously unknown transcripts and isoforms (Cui et al., 2012; 
Soneson et al., 2013; Conesa et al., 2016). For these reasons, RNA-seq was chosen 
over microarrays for studying this poorly characterised tumour as it would offer a 
broader insight of the differential gene expression of INS compared to the previously 
used microarray (Buishand et al., 2013). In particular, RNA-sequencing that uses 
next-generation sequencing (NGS) methods to quantify the messenger RNA 
(mRNA) provide a quantification of transcripts at high levels of sensitivity and 
accuracy and an unbiased detection of transcript variants (Cui et al., 2012; Soneson 
et al., 2013). For instance, this technology sequences cDNA from RNA samples to 
produces millions of short reads that are mapped to a reference genome and then 
analysed for differentially expressed genes between conditions (Soneson et al., 
2013). Since the canine genome sequence became available, RNA-seq has already 
proven its value in the research of various canine tumours but not yet in INS (Davis 
& Ostrander 2014; Hoeppner et al., 2014).  
Therefore, the purpose of this study was to quantify the mRNA abundance of 
differentially expressed genes in canine INS using a computational approach with 
edgeR. edgeR software is designed for finding changes between two or more groups 
when at least one of the groups has replicated measurements (Robinson et al., 2010).  
Despite the discoveries of differentially expressed genes and genetic mutations, the 
knowledge of biological pathways involved in the disease is limited. In general, 
pathway analysis in dogs has its constraints because pathway identification relies 
heavily on existing functional annotation, which is still limited for this species 
(Boerkamp et al., 2013). However, pathway analysis provides an additional way to 
analyse expression data across species. In order to obtain improved data convergence 
and ensure a systematic insight into the pathways altered during INS pathogenesis, a 
combination of RNA-sequencing data, gene-set enrichment analysis (GSEA) and 
Reactome was used to categorise expression patterns on the differentially expressed 
genes (Subramanian et al., 2005; Croft et al., 2011). GSEA and Reactome pathway 
analysis revealed that differentially expressed genes were significantly enriched in a 
few biological pathways known to have a role in cancer, as well as previously 
unreported pathways, thus providing new insights into the regulatory mechanisms of 
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malignant INS. Through comprehensive differential gene expression, pathway and 
network analyses, this study improved our understanding of the functional processes 
involved in canine INS carcinogenesis. 
 
3.3 Materials and methods 
 
3.3.1 Clinical samples 
RNA sequencing analysis was performed on 16 samples including controls (4 
pancreas and 3 mediastinal lymph nodes) and tumour lesions (6 primary INS and 3 
metastatic lymph nodes). Canine patients diagnosed with INS were staged according 
to the TNM notation system (Buishand et al., 2010) (Control and samples outlined in 
Table 3.1 and Table 3.2). 
3.3.2 RNA isolation 
 
3.3.2.1 Normal pancreas 
Pancreatic tissues were isolated from four dogs (Table 3.1). A protocol from Griffin 
et al. 2012 was optimised for isolating high-quality RNA from canine pancreatic 
tissue harvested during autopsy (Griffin et al., 2012). Briefly, the pancreas was 
perfused with RNA later® (Qiagen) using a 5 ml syringe with a 26 gauge needle to 
obtain a homogeneous distribution of the RNA later® in the various acini of the 
pancreas. Tissues were then cut into small pieces, placed in cryovials, snap frozen in 
liquid nitrogen and stored at −80°C. Tissue homogenisation was performed using 
mortar and pestle, and RNA was extracted using Qiagen RNeasy Mini Kit (Qiagen, 
Germany). The optional DNase digestion step was done to prevent genomic DNA 
contamination (Griffin et al., 2012).  RNA concentrations were quantified by 




3.3.2.2 Normal lymph nodes 
Mediastinal lymph nodes were isolated from 3 healthy dogs without breed or sex 
predilection. Briefly, lymphatic tissues were harvested and immersed into RNA 
later® for 24 hours at 4oC then placed in cryovials, snap frozen in liquid nitrogen and 
stored at −80°C. Tissues were then cut into small pieces and homogenised using 
mortar and pestle. Finally, RNA was extracted using Qiagen RNeasy Mini Kit 
(Qiagen, Germany). The optional DNase digestion step was performed to prevent 
genomic DNA contamination. RNA concentrations were quantified by 
spectrophotometry (NanoDrop ND-1000, Isogen Life Sciences). 
 
3.3.2.3 Insulinomas and metastatic lymph nodes 
All tumour samples were confirmed as being spontaneously occurring INS and were 
obtained from family-owned dogs with informed owner consent. Six primary canine 
INS and three metastatic lymph nodes were resected at the Faculty of Veterinary 
Medicine, Utrecht University, from 1993 to 2014 from FO Buishand and J 
Kirpensteijn (Table 3.2). Portions of tissue (5–15mm diameter) for RNA extraction 
were removed from the central portion of the tumours, placed in cryovials, snap 
frozen in liquid nitrogen and stored at −80°C. Tissue fragments were fixed in 10% 
neutral-buffered formalin for 24–36 h for histopathology to confirm the diagnosis of 
INS (Buishand et al., 2012).  
Tissue was homogenised using rotary homogeniser (#SHM2, Stuart) with an 
additional first step of beta-mercaptoethanol to denature the RNases and obtaining 
high-quality RNA. Total RNA was then isolated using the RNeasy Mini Kit 
(Qiagen). To prevent contamination of the samples with genomic DNA, an on-
column DNase treatment was performed. RNA concentrations were quantified by 
spectrophotometry (NanoDrop ND-1000, Isogen Life Sciences).  
 
3.3.3 RNA quality control 
Following RNA extraction, RIN were obtained using Agilent 2100 bioanalyzer 
system and Agilent RNA screen tape (Agilent Technologies, Inc., Santa Clara, CA). 
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This system determines the integrity of RNA and automatically calculates RNA 
concentration in relation to the relative ratio of 18S and 28S ribosomal peaks. The 
RIN software uses a numbering system from 1 to 10, with 1 being the most degraded 
profile and 10 being the most intact RNA.  RIN values above 6.5 were considered 








Table 3.1 Clinical features and RNA-quality of control samples samples used in this study. RIN, RNA integrity numbers. 
Breed Age 
(years) 





Strattforshire 10 Female Control Pancreas 7.0 490 NP4 
Strattforshire 2 Male Control Pancreas 7.8 185 NP1 
Mediastinal lymph node 7.5 386 LN1 
West highland 9  Male Control Pancreas 7.7 225 NP2 
Mediastinic lymph node 9.7 318 LN2 
Pitbull 2 Male Control Pancreas 7.5 240 NP3 

































11 Male 3.3 31 
 
0 Tumour I Pancreas 6.7 217 BEN 
Flatcoated 
Retriever 
7 Male 3.0 25 LTF Tumour II Pancreas 6.7 100 N17 
Boxer 7 Male 2.9 Unknown 1 Tumour III Pancreas 6.5 275 H30 
Cocker 
Spaniel 
10 Male 1.6-5.0 Unknown 1 Tumour IV Pancreas 6.7 445 D35 
Scottish 
shepherd 
10 Male 1.5-2.2 Unknown 1 Tumour IV Pancreas 7.3 100 W36 
Boxer 8 Male 3.0 46 LTF Metastatic IV Lymph 7.0 258 B13 
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Figure 3.1 Flowchart outlining the pipeline for RNA extraction and quality check for 
normal pancreatic tissues. 
 
3.3.4 RNA sequencing pipeline 
 
After isolation of high quality RNA (RIN value > 6.5 and concentration >100 ng/μl), 
samples were processed for mRNA library preparation, sequencing, differential gene 
expression and functional analysis by Edinburgh Genomics (Edinburgh, UK) (Figure 
3.2).  
3.3.4.1 Library preparation and mRNA sequencing 
Briefly, cDNA libraries were prepared from total RNA, using Tru-Seq Stranded 
mRNA Library Prep Kit (Illumina) following manufacturer's instructions and were 
subjected to 75-bp paired-end sequencing on an Illumina HiSeq40000 Platform 
(Illumina, San Diego, CA) from Edinburgh Genomics service (Edinburgh, UK).  
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The RNA-seq reads were generated in fastq format. After removing reads containing 
sequencing adapters and low-quality reads with more than five unknown bases by 
cutadapt v1.8.3, high-quality reads from the fastq files were mapped to the canine 
reference genome (CanFam 2.0) (Hoeppner et al., 2014) resulting in around 95-99% 
sequences mapped using TopHat2 (v3.1.84) with default parameters (Kim et al., 
2013). The output files in the compressed binary version of the Sequence 
Alignment/Map (BAM) were then assembled and counted using HTSeq (v6.0.1) with 
mode "union" (Anders, Pyl and Huber, 2015).  
3.3.4.2 Differential gene expression 
Differential gene expression was then carried out using edgeR (version 3.12.0). 
edgeR estimates the genewise dispersions by conditional maximum likelihood, 
depending on the total count for that gene. An empirical Bayes procedure was used 
to shrink the dispersions towards a consensus value. Finally, differential expression 
was assessed for each gene using an exact test analogous to Fisher's exact test but 
adapted for overdispersed data. edgeR was chosen for this study as it is the only 
software that can account for biological variability with only one or two replicates 
per sample. (Robinson et al., 2010). edgeR software was used for the identification 
of differences in gene expression of pairwise comparisons organised as follows: (i) 
normal pancreas against primary INS; (ii) primary INS against metastatic lymph 
nodes; (iii) normal lymph nodes against metastatic lymph nodes. Genes with less 
than 20 reads were discarded from the analysis. Genes were considered differentially 
expressed only at a P-value <0.05 and at FDR < 0.05. Genes with log2-fold changes 
of more than 2 or less than 2 were then selected to ensure that only robust changes 
were considered. Differentially expressed genes were identified by hierarchical 
clustering analysis. In hierarchical clustering, each cluster is subdivided into smaller 
clusters, forming a tree-shaped data structure or dendrogram. Agglomerative 
hierarchical clustering starts with the single-gene clusters and successively joins the 
closest clusters until all genes have been joined into the supercluster (D’haeseleer, 
2005). Heatmaps were generated using the package called heatmap.2 in R which 
normalised counts were used for all differentially expressed genes (cpmall). By 
default, "heatmap.2" does hierarchical clustering using hclust which further uses 
euclidean distance matrix. The Euclidean distance is the square root of the sum of the 
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square differences and takes into consideration the differences between the 
expression values, considering the solid red gene to be the furthest, and the solid 
green to be the closest (Gibbons and Roth, 2002).  The algorithm is initialised 
assigning each gene to the cluster to the nearest centroid, which is randomly set at 
the beginning. Next, the centroids are reset to the average of the genes in each 
cluster. This process is continued until no more genes change cluster (D’haeseleer, 
2005).  
3.3.4.3 Functional Annotation  
To examine whether certain pathways are over- or under-represented in the gene list, 
all genes significantly differentially expressed between INS, metastatic lymph nodes 
and normal tissues, were introduced into GSEA (GSEA version 2.2.2). GSEA 
employs the (weighted) Kolmogorov-Smirnov (K-S) statistic to test whether genes 
contributing to the phenotype are ‘enriched’ in each gene-set (Boerkamp et al., 
2013). Thereby, GSEA evaluates how genes in queried pathways are distributed in 
the fold change ordered list generated by the data. This distribution is quantified by 
using the Enrichment Score (ES) that evaluates if the members of the pathway are 
randomly distributed or found at the extremes (top or bottom) of the list (Boerkamp 
et al., 2013). For each gene set, GSEA looks if differentially expressed genes in a 
pathway rank are enriched at the top fold change list (up-regulated genes), then the 
ES will be close to 1. Conversely, if the ES = −1, then genes are enriched at the 
bottom of our fold change data (down-regulated genes) (Lowes et al., 2010). Also, 
Reactome (http://www.reactome.org) was performed based on the dysregulated 









3.3.5 PCR and agarose gels 
 
PCR reactions were set up using HotStarTaq® DNA polymerase PCR kits (Qiagen, 
UK) according to the manufacturer's instructions. To ensure consistency, all 
experiments were performed on the same thermal cycler (Labtech G-Storm GS-4822, 
France). To assess the consistency of sample loading and PCR conditions between 
separate experiments, primers that amplified cDNA of transcripts from the canine 
housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were 
included in different reactions. A volume of 12 μL of PCR product was added to 4 
μL of 6 X Blue/Orange Loading Dye (Promega, UK). This was loaded into the cell 
of 1.5% agarose gel. Gels were made by dissolving agarose powder (UltraPure 
Agarose, Invitrogen) at the stated concentrations in TAE buffer (40 mM Tris, 20 mM 
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acetic acid, and 1 mM EDTA). A  1.5 Kb DNA  ladder (Promega, UK) was used to 
assess product size. Gels were run for approximately 2 hours and then visualised 
using a BioRad Molecular Imager GelDoc (BioRad, UK).  
3.3.6 Quantitative real-time PCR 
 
Following the outcome of the RNA-sequencing profiling, 13 genes were selected. 
Selection of these genes was based on significantly differential expression; fold 
changes and potential biological function in relation to tumour development. 
(Primers are listed in Table 3.3). 
The Platinum Sybr Green qPCR Kit (Invitrogen, UK) was used in all qPCR reactions 
according to manufacturer's instructions. Reactions were performed on the 
Stratagene MX3000P (Agilent, UK). Primer efficiency and dissociation curves were 
calculated using MXPro software (Agilent, UK), specificity was assessed by agarose 
gel electrophoresis. Each reaction was performed in triplicate and three no-template 
controls were also included for each primer using nine μL of nuclease-free water. 
Relative gene expression levels were obtained by normalisation to the expression 
levels of housekeeping genes (RPS19 and GADPH). Calculations were made using 
the Delta Delta Ct Method (Pfaffl, 2004). 
3.3.7 Statistical analysis 
 
P-values were adjusted for multiple hypothesis corrections using the Benjamini-
Hochberg approach, which controls the false discovery rate (FDR). Probesets with 
FDR<0.05 and log fold change >2 were considered differentially expressed. All 
analyses were carried out using R programming language (www.R-project.org). 
GSEA was conducted using GSEA software 
(http://software.broadinstitute.org/gsea/index.jsp). Power size calculation was made 




Table 3.3 List of primers for validation of RNA-sequencing data. 
Gene 
symbol 
Primer forward Primer reverse 
KRT19 F: GCCCAGCTGAGCGATGTGC R:TGCTCCAGCCGTGACTTGAT
GT 







PA F: GGTTCAGATTTCTCCACCC R: ACTCACAGCATTCCCACAC 
PAX4 F:GGCACTGGAGAAAGAGTTCC R: CTTGAGCTTCTCTTGCCGAC 
PDX1 F: TCCCGTGGATGAAGTCTACC  R: CGTGGCCTCGAGATGTATTT  







IAPP F:GAGCTGGGAAAGGTGTGAAG R:ATCCCAAATCTGCTCCTCCT 
INSM1 F: TGCTAGTGTTCGCTGTGTCC R:CCAGACTCCAGCAGTTCACA 
RSP19  F: CCTTCCTCAAAAAGTCTGGG R:GTTCTCATCGTAGGGAGCAA
G 










3.4.1 Quality analysis of RNA-sequencing data 
 
RNA-Seq generated for each sample, between 50 and 110 million 75bp paired-end 
reads and around 95-99% of the reads were mapped to the canine genome by 
Tophat2 (Kim et al., 2013).  
Multidimensional scaling (MDS) was used as a type of unsupervised clustering to 
check the quality of RNA-seq data in the three pairwise comparisons. MDA is a plot 
of the RNA samples in which distances correspond to leading log-fold-changes 
between each pair of RNA samples (Yang et al., 2014). MDS analysis of the 
expression profiles (normal pancreas vs primary INS; normal lymph nodes vs 
metastatic lymph nodes) revealed a separation of the control tissues from the tumour 
samples in dimension 1 (horizontal) (Figure 3.3). In dimension 2 (vertical) control 
tissues clustered together whereas tumour samples were heterogeneously distributed 
(Fig. 3.3). MDS analysis of the expression profiles of tumours and normal samples 
showed that the normal samples (both pancreas and lymph nodes) formed a 
homogenous cluster while the tumour samples (primary INS and metastases) were 
more heterogeneous (Figure 3.3). This observation is consistent with previous 
findings, thus suggesting that compared with normal tissues, tumours have 
expression hypervariability caused by DNA hypomethylation blocks (Hedegaard et 
al., 2014). 
 
3.4.2 Differential expression gene analysis 
3.4.2.1 Normal pancreas and primary insulinomas 
MDS analysis showed a separate gene profile between normal pancreas and the 
primary INS (Figure 3.3 A). The primary INS samples represented a heterogeneous 
group while the normal pancreatic tissues clustered together (Figure 3.3 A). 
Increased transcriptome heterogeneity among tumours samples compared to the 
normal tissue may have arisen from expression variability. Using edgeR, genes 
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showing increased expression variability were identified. P-values, FDR and fold 
changes were used as selection criteria. Paired statistical tests (P-value < 0.01; 
FDR<0.05) revealed 3212 genes to be differentially expressed between primary INS 
and normal pancreas (Appendix 8.4: Table 8.1). When only looking at 2-fold 
changes or larger, 1900 features remained (1590 upregulated genes and 310 
downregulated genes). MA (log ratio versus abundance) plots can be created using 
the plotSmear function, allowing results to be displayed graphically and highlighting 
the set of altered genes (Figure 3.4 A). Next, hierarchical clustering analysis of the 
coding profiles was performed. According to the heat-map, two major clusters were 
generated between normal pancreatic tissue and primary INS. Interestingly, a trend 
of transition in the gene expression profiles was observed from the normal pancreatic 
tissues to the highly metastatic INS lesions (Figure 3.5). Hierarchical clustering 
showed that primary INS lesion in non-metastatic clinical stage (TNM 1) clustered 
together with normal pancreatic tissues, separate from primary lesions from patients 
with malignant metastatic disease (TNM 2,3,4) (Figure 3.5).  
As we interrogated the details of the differentially expressed genes many of the 
upregulated genes are involved in beta cell differentiation [paired homeobox 4 
(PAX4), NK-homeobox2 (NKX2), insulinoma-associated gene 1  (INSM1)] and 
insulin secretion [tetrapanin1 (TSPAN1), glucokinase (GCK)] or metabolism and 
transport of the glucose [glutathione peroxidase 3 (GPK3), solute carrier 7 family 1 
(SLC7A1)] together with transmembrane proteins (TMEM130, TMEM59L) (Table 
3.4) (Appendix 8.4: Figure 8.5).  
This study showed that genes involved in the secretory pathway of insulin such as 
insulin (INS) and Nestin (NESTIN) were highly expressed in INS tissue. 
Furthermore, genes related to pancreatic development were upregulated such as with 
Hes-related family BHLH transcription factor 1 (HEY1), pancreatic duodenal 
homeobox 1 (PDX1) and SRY-Homeobox 17 (SOX17) (Table 3.4)(Appendix 8.4: 
Figure 8.5).  
 
3.4.2.2 Normal lymph nodes and metastatic lymph nodes 
MDS analysis revealed a clear separation in dimension 1 (horizontal) within normal 
lymph nodes and metastatic ones.  On dimension 2 (vertical), normal lymph nodes 
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formed a homogenous cluster while the metastases were more heterogeneous (Figure 
3.3 B). When comparing metastatic lymph nodes with normal lymph nodes, 6,349 
features were differentially expressed. In this comparison, when only looking at 2-
fold changes or larger, 3876 elements remained of which 2353 genes were 
upregulated and 1535 were downregulated. An MA plot displayed differentially 
expressed genes (Figure 3.4 B). According to the hierarchical clustering analysis 
mediastinal lymph nodes and metastatic lymph nodes formed two separate clusters 
with different gene expression patterns (Figure 3.6). 
 
3.4.2.3 Primary insulinomas and metastatic lymph nodes 
In the unsupervised clustering analysis, primary and metastatic INS did not separate 
into unique clades (Figure 3.3 C). For instance, primary lesions derived from patients 
with highly metastatic disease and metastatic lymph nodes had a similar gene profile 
(Figure 3.3 C). An MA plot graphically showed the differentially expressed genes 
(Figure 3.4 C). Hierarchical clustering analysis of the coding profiles was then 
performed confirming that primary lesions derived from patients with highly 
metastatic disease (TNM stage IV) clustered together with the metastatic lymph 
nodes (Figure 3.7), as previously seen in the literature (Buishand et al., 2013). When 
comparing primary INS with metastatic lymph nodes, only 164 genes were 
differentially expressed with 2-fold changes or larger showing an increased genetic 
similarity between tumour samples compared to normal tissues (80 genes 
upregulated and 84 downregulated) (Appendix 8.4: Table 8.2). Relative expression 
variances showed that acinar-related genes were down-regulated in metastatic lesions 
including pancreatic lipase (PNLIP) chymotrypsinogen B2 (CTRB2), pancreatic 
amylase (PA), chymotrypsin-like (CTRC) together with epithelial genes 
[Cytocherathin 19 (KRT19)] and serin-peptidase genes  [serine peptidase inhibitor, 
Kazal type 1 (SPINK1) and serpin peptidase inhibitor, clade I, member 2 
(SERPINA1)] (Table 3.5) (Appendix 8.4: Figure 8.6). These results were consistent 
with previous data that showed that exocrine markers were downregulated in canine 
INS metastases (Buishand et al., 2013). Furthermore, claudin 10 (CLDN10), claudin 
19 (CLDN19), and gap junction protein beta 1 (GAPJB1), whose transcripts 
contribute to the formation of tight junctions, were downregulated in metastatic 
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lymph nodes (Table 3.5) (Appendix 8.4: Figure 8.6). Additionally, small cytokines 
previously related to tumourigenesis such as C-X-C motif chemokine receptor 5 
(CXCR5), chemokine (C-X-C motif) ligand 13 (CCL13) and tumor necrosis factor 
receptor superfamily member 11b (TNFRS11B), were upregulated (Table 3.5) 










Figure 3.3 Multi-dimensional scaling (MDS) plot of RNA sequencing data of three pairwise comparisons. In MDS plots distances correspond to 
leading log-fold-changes between each pair of RNA samples. Dimension 1 is the direction that best separates the samples, without regarding 
whether they are treatments or replicates. Dimension 2 is the next best direction, uncorrelated with the previous one that separates the samples. NP, 








Figure 3.4 Smearplot of RNA sequencing data of three pairwise comparisons. Multidimensional Analysis plot where differential expressed genes 
results are displayed graphically. For instance, each red dot represents a gene differentially expressed in the comparison between control and 
sample. The axes of the plot correspond to the logarithm count per milion (logCPM) and Fold change (logFC) columns of the results. NP, Normal 



































Figure 3.5 Gene heatmap generated using edgeR analysis showing clustering of six primary insulinoma vs four normal pancreas. TNM, 

















Figure 3.7 Gene heatmap generated using edgeR analysis showing clustering of  three metastatic lymph nodes vs six primary insulinomas. TNM, 

































Table 3.4 Top differentially expressed genes in primary insulinoma vs normal pancreas. In bold genes used for validation with qRTPCR.2 
Gene Gene symbol logFC P-Value FDR Role 
Pancreatic duodenal homeobox 1 PDX1 2.13 0.0001 0.003 Beta cell differentiation 
Paired homeobox 4 PAX4 6.23 3.32E-09 3.92E-06 
Insulinoma associated 1 INSM1 5.021 3.40E-07 5.17E-05 
NK2 homeobox 2 NKX2 5.32 3.40E-09 3.92E-09 
Nestin NES 2.53 0.0001 0.003 
Delta/notch-like EGF repeating containing 
ligand 
DNER 4.41 3.05E-07 4.83E-05 Early pancreatic development 
Notch 2 NOTCH2 3.19 5.17E-07 6.94E-05 
SRY-box 17 SOX17 2.20 0.009 0.04 
SRY-box 18 SOX18 2.89 0.003 0.02 
Hes-related family BHLH transcription 
factor 1 
HEY1 2.46 0.0009 0.01 
RAB37, member RAS oncogene family RAB37 7.92 6.71E-08 2.00E-05 Cell cycle 
Cyclin-dependent kinase 5 CDK5 6.00 8.11E-08 2.16E-05 
Cyclin and CBS domain divalent metal cation 
transport mediator 1 
CNNM1 5.11 6.71E-08 2.00E-05 
Glutathione peroxidase 3 GPX3 4.73 3.91E-08 1.42E-05 Metabolism of glucose  
                                                 







Gene Gene symbol logFC P-Value FDR Role 
Glucokinase GCK 5.37 3.13E-08 1.23E-05 
Solute carrier 38 family 8 SCL38F8 9.65 9.63E-08 2.35E-08 Insulin secretion 
Calcium bynding protein 1 CA1 5.09 1.66E-08 8.82E-06 
Potassium voltage-gated channel subfamily H 
member 2 
KCNH2 5.47 7.40E-09 6.63E-06 
Otoferlin (calcium sensor) OTOF 5.56 9.07E-08 2.32E-05 
Tetraspanin 1 TSPAN1 5.46 5.95E-08 1.97E-05 Insulin production 
Insulin-degrading enzyme IDE -2.29 7.33E-06 0.0003 
Insulin growth factor receptor 2 IGF2 4.33 9.30E-06 0.0004 
Insulin like 6 INS 3.21 0.007 0.04 
Insulin receptor  INSR -2.62 1.00E-07 2.35E-05 
Islet amyloyde polyptide IAPP 4.37 2.32E-06 0.0001 Amyloid deposit 
Prolactin releasing hormone receptor PRHR 5.94 7.49E-08 2.12E-05 Stimulate insulin production 
Transmembrane protein 130 TMEM130 5.46 3.76E-08 1.41E-05 Transmembrane proteins overexpressed in 
pancreatic cancer Transmembrane protein 59 like  TMEM59L 4.89 6.88E-08 2.02E-05 
Chromogranin A CHGB 4.58 1.33E-07 2.79E-05 Pancreatic neuroendocrine tumours 
markers Secretogranin II SCG2 4.97 1.11E-07 2.49E-05 
Synapsin I SYN1 5.59 7.87E-09 6.68E-06 







Gene Gene symbol logFC P-Value FDR Role 
Nerve growth factor  NGR 5.89 6.24E-08 1.97E-05 Signalling molecule in neuroendocrine 
tissue 
Pseudopodium-enriched atypical kinase 1 PEAK1 -3.09 6.10E-09 5.78E-06 Metabolism of glucose 
Solute carrier 7 family 1 SLC7A1 -3.03 2.37E-07 4.13E-05 
RELT tumour necrosis factor RELT 3.93 2.08E-07 3.87E-05 Tumour necrosis factors 
C1q and tumour necrosis factor related protein 
6 
C1QTNF6 5.40 1.00E-07 2.35E-05 
Carbonic anydrase III CA3 -7.63 3.54E-10 1.30E-06 Lipid metabolism 











Table 3.5 Top differentially expressed genes in metastatic lymph nodes vs primary insulinomas. In bold genes used for validation with qRTPCR.3 
 
Gene Gene symbol logFC P-Value FDR Role 
Chimotripsinogen 2 CTRB2 -8.72137 0.000178 0.033077 Exocrine markers 
Pancreatic lipase PNLIP -8.54384 0.000343 0.04279 
Pancreatic amylase PA -4.79146 0.000451 0.047458 
Chymotrypsin-like CTRC -8.86682 0.000427 0.046186 
Cytocherathin 19 KRT19 -8.38703 0.000115 0.027504 Cell adhesion 
matrix metallopeptidase 23B  -4.53596 0.000367 0.044113 
contactin associated protein-
like 2 
 5.298697 8.31E-05 0.02421 
A-kinase anchoring protein 4  -9.34709 0.000102 0.026348 
Serpin peptidase inhibitor, 
clade I, member 2 
SERPINA1 -8.809 0.00035 0.043207 Serine peptidase 
activity 
Serine peptidase inhibitor, 
Kazal type 1 
SPINK1 -8.55149 0.000344 0.04279 
Claudin 10 CLDN10 -7.19894 0.000195 0.034024 Cell junction 
Claudin 19 CLDN19 -7.69326 2.40E-05 0.012854 
Gap junction protein beta 1 GAPJB1 5.41801 0.000178 0.033077 
                                                 







Gene Gene symbol logFC P-Value FDR Role 
adhesion G protein-coupled 
receptor F4 
 7.871758 0.000116 0.027504 
transmembrane protein 154  3.598028 2.64E-05 0.012854 
transmembrane protein 252  6.496054 0.000112 0.027179 
C-X-C motif chemokine 
receptor 5 
CXCR5 3.178023 0.000205 0.03415 Inflammation 
Chemokine (C-X-C motif) 
ligand 13 
CCL13 4.853102 8.30E-05 0.02421 
Tumor necrosis factor receptor 
superfamily member 11b 
TNFRS11B 3.551235 5.59E-06 0.005778 
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3.4.3 RT-PCR Validation of the mRNA sequencing data 
Determining the expression levels of 13 representative genes of interest validated the 
results from the RNA-seq data. Compared with the RNA-seq analysis, quantitative 
RT-PCR provides a much wider dynamic range (5-6 orders of magnitude) and thus a 
more accurate measurement of the relative gene expression values (Pfaffl, 2004). 
Changes in mRNA levels assessed by qRTPCR were concordant with those observed 
by RNA-seq analysis. When comparing primary INS with normal pancreatic tissues, 
there was a significant upregulation of genes involved in beta-cell differentiation 
including PDX1, INSM1, PAX4, NKX2, SOX17 (Figure 3.8). Moreover, islet amyloid 
polypeptide (IAPP), NESTIN and INS were upregulated in primary INS compared to 
control pancreatic tissues (Figure 3.8). Significant down-regulation of acinar genes 
such as PNLIP, CTRB2, PA and epithelial genes such as KRT19 was observed when 




Figure 3.8 qRTPCR validation of RNA-sequencing data on 13 selected genes. NP, normal 
pancreas; PI, primary insulinoma; ML, metastatic lymph nodes. 
 
3.4.4 Genes commonly differentially expressed between datasets 
When merging the three datasets, we revealed that 12 genes were differentially 












































































TNFRS11B, were upregulated in both primary INS and metastatic lymph nodes. 
Moreover, genes involved in cell adhesion [von Willebrand factor A (VWA5A)  and 
adhesion molecule with Ig like domain 2 (AMIGO2)] and extracellular matrix 
[Fibrilin 2 (FB2)] and genes related to insulin resistance [pappalysin 2 (PAPPA2) 
and glutamate decarboxylase 3 (GAD3)] and transport of glucose [solute carrier 
family4 (SCL4A8)] were also upregulated both in primary INS and metastatic lymph 
nodes (Appendix 8.4: Table8.3). 
3.4.5 Functional analysis 
3.4.5.1 Normal pancreas and primary insulinomas 
To further consider the biological significance of these data, GSEA was used to 
identify pathways correlated with the malignant INS phenotype. Results of the 
GSEA revealed that 26 down- and 60 up-regulated pathways were present in this 
pairwise comparison.  
Within the most upregulated pathways in canine primary INS compared to normal 
pancreatic tissues we identified pathways related to extracellular matrix organisation, 
cell growth and differentiation, negative regulation of cell apoptosis, beta cell 
signalling pathway and pancreatic endocrine development, insulin secretion and 
insulin growth factor (Figure 3.9). The majority of the downregulated pathways were 
associated with ribosome, transcription and translation of proteins while others were 
involved in gene regulation such as histone methylation and histone acetylation 
systems (Figure 3.10). Names of these pathways are listed in Table 8.4 and Table 8.5 
in Appendix 8.5. 
Reactome analysis confirmed these findings as pathways upregulated in primary INS 
(30 pathways) were related to four functional clusters: beta cell fate, cell signalling, 
cell cycle and extracellular matrix organisation (Appendix 8.5: Table 8.6). Of note, 
analysis with Reactome of the top 100 genes revealed that two major pathways were 
upregulated in primary INS (FDR<0.05): regulation of gene expression in endocrine-
committed (NEUROG3+) progenitor cells (FDR=0.006); regulation of beta cell 
development (FDR=0.008). Additionally, 15 pathways were downregulated mainly 




3.4.5.2 Primary insulinoma and metastatic lymph nodes 
Pathway analysis of the down- and up-regulated genes between primary INS and 
metastatic lymph nodes revealed significantly downregulated pathways majorly 
related to ribosome, translation and serine-peptidase activity (Appendix 8.5: Table 
8.9). Using Reactome tool, 14 pathways were identified in the downregulated set 
majorly associated with translation, metabolism and transport of proteins. 
Interestingly, the only pathway upregulated in metastatic lymph nodes was related to 
gamma signalling through PI3K gamma. Of note, PI3K pathway has been identified 
as one of the primary pathway associated with human INS carcinogenesis (Zhan et 
























3.5 Discussion  
 
The treatment of metastatic canine INS remains a significant challenge, thus more 
studies are required to reveal its pathogenesis (Polton et al., 2007; Buishand et al., 
2012; Schermerhorn, 2013). Transcriptome analysis is an essential tool for 
characterisation and understanding the molecular basis of phenotypic variation in 
biology, including disease (Higgins et al., 2010; Cui et al., 2012; Hedegaard et al., 
2014; Lu et al., 2015). Using microarrays, previous studies have identified altered 
expression of genes and deregulation of gene signalling pathways in primary canine 
INS and their corresponding metastases (Buishand et al., 2013). However, no studies 
have yet analysed changes occurring in early stages of the disease. From the 
literature, significant changes linked to the development of neoplasms often occur in 
early stage of the disease (Kosari et al., 2005; Tian et al., 2014; Yang et al., 2014; 
Zeng et al., 2014; Slattery et al., 2017; Zhang et al., 2017). Thus, variations in gene 
expression was examined by comparing primary INS and metastatic lesions, from a 
previously characterised cohort of canine INS patients (Buishand et al., 2012,2013), 
with normal control tissues, such as pancreas and lymph nodes.  
Using mRNA profiling with NGS analysis, we identified a panel of differentially 
expressed genes between control tissues and primary and metastatic INS lesions that 
might be characteristic of early and late tumorigenesis. Thus, this analysis not only 
revealed potential therapeutic avenues for the patient in question but also highlighted 
biological processes of interest for this type of tumours. 
Considering that progenitor pancreatic cells and epithelial cells have been involved 
in INS tumourigenesis (Jonkers et al., 2007; Regitinig et al., 2001; Vortmeyer et al., 
2004 Buishand et al., 2013), the normal pancreas was chosen as control tissue 
instead of isolated beta cells. Previous studies showed that pancreatic islet tumours, 
including INS, arose not only from beta cells but also from both ductal and acinar 
cells (Regitinig et al., 2001; Vortmeyer et al., 2004). For instance, Regitinig et al., 
2001 described exocrine and ductal features in metastatic lesions of INS due to the 
presence of pluripotent cells (Regitinig et al., 2001). Additionally, Vortmeyer et al., 
(2004) demonstrated that initiation of neuroendocrine tumourigenesis in the 
ductal/acinar system rather than in pancreatic islets, raising the question of whether 
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analysing only the isolated beta cells would have given us the full complexity of the 
INS carcinogenesis. In normal pancreas, during embryogenesis, islet cell 
development appears to be initiated in from primary tubules of epithelial precursor 
cells (Vortmeyer et al., 2004). Additionally, in the adult pancreas, after injury, islets 
can regenerate from ductal cells, suggesting that ductal epithelium retain totipotency 
even in the adult life. Of interest, a plethora of studies have shown that insulin-
producing cells can be generated in vitro from both exocrine and ductal tissues in 
anchorage-independent growth conditions (Bayens et al., 2005; Wang et al., 2013; 
Seyedi et al., 2015). Thus, we hypothesed that tumour initiating cells in INS might 
be of non-islet origin and might derive from ductal and acinar cells. Thus for this 
study, the whole pancreatic tissue was considered as a better control compared to the 
isolated beta cells for evaluating the complexity of the INS carcinogenesis. 
 
Even though we did not use matched sets of samples for the identification of 
differentially expressed genes, unsupervised clustering of the RNA-seq data 
separated the tumour samples from non-neoplastic tissues, thus suggesting a good 
quality of our data. Using edgeR, we evaluated the expression levels of genes in the 
different pairwise comparisons. edgeR was used as it has the advantage of 
implementing the method based on negative binominal distribution, and model 
overdispersion for digital gene expression data even with small replicates (Robinson 
et al., 2010).  
In this study, data showed that between normal pancreas and primary lesions 1900 
genes were differentially expressed (P < 0.01, and |log(FC)| > 2 and FDR <0.05). 
These findings suggested that the majority of the changes in gene expression 
occurred in the early stages of INS carcinogenesis, as previously shown in a variety 
of human cancer such as, clear cell renal carcinoma (Yang et al., 2014; Kosari et al., 
2015), pancreatic adenocarcinoma (Zhang et al., 2017), breast cancer (Tian et al., 
2014), colon cancer (Slattery et al., 2017). Moreover, the expression of 2300 genes 
was altered when comparing normal lymph nodes and metastatic lymph nodes, 
confirming that the metastatic lymph nodes had a gene signature that mostly 
resembled the neoplastic tissues rather than the normal lymph nodes. When 
comparing primary INS with metastatic lesions, only 164 genes were differentially 
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expressed. These findings suggested that primary INS lesions and metastases had a 
similar gene expression profile compared to non-neoplastic lesions. Previous 
microarray analyses have shown that primary canine INS lesions with high-
metastatic potential cluster together with their correspondent lymph node and liver 
metastases identifying a homogeneous gene signature (Buishand et al., 2013). These 
observations proposed that an altered gene expression resulting in metastatic 
potential in canine INS, might be already identified in the primary lesions.   
When interrogating the single differential expressed genes between primary INS and 
normal pancreas, the upregulated genes were majorly involved in beta cell 
differentiation and insulin secretion such as PDX1, INSM1,IAPP. INS, TSPAN1 and 
PAX4. Considering that the prominent characteristic of INS is hyperinsulinism 
(Goutal et al., 2012), it is not surprising that the predominance of the genes 
participating in the insulin secretory pathway is upregulated in canine INS tissues. 
Therefore indicating that regulation of secretion may be a major mechanism by 
which insulin release is abnormally increased in patients with INS as previously 
shown in human INS (Wang et al., 2004). Some of these genes, such as INSM1 and 
IAPP, have been previously reported as negative prognosticator in human NET 
including PNETs (van Hulst et al., 1999; Fujino et al., 2015, 2017; Rosenbaum et 
al., 2015). For instance, INSM1 mRNA expression has been previously correlated 
with metastatic disease in NET (Rosenbaum et al., 2015). INSM1 is a transcription 
factor involved in the terminal steps of the pancreatic endocrine development. It acts 
as a transient negative feedback regulator during pancreatic development by 
regulating the expression of downstream genes, such as PAX4 and NKX2, which are 
responsible for beta cell differentiation (Lan & Breslin 2009; Osipovich et al. 2014). 
One of the main features that makes INSM1 an interesting target is that it is absent in 
adult tissues and it is expressed at a high level only in NET and pancreatic 
progenitors (Lan and Breslin, 2009; Rosenbaum et al., 2015; Fujino et al., 2017). 
Despite the understanding of INSM1 in basic research, its relevance as a novel 
prognostic marker in INS remains mostly unclear (Rosenbaum et al., 2015).  
Islet Amyloid Polypeptide (IAPP), also named amylin, is the predominant protein 
component of amyloid deposits in human INS (van Hulst et al. 1999). In humans, 
IAPP is co-produced with insulin by islet beta cells; although, in INS, expression of 
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the IAPP and insulin are not coupled (van Hulst et al., 1999). Immunohistochemical 
studies showed that, in dogs, amyloid deposition in INS lesions is uncommon 
(O’Brien et al., 1987).  
According to the data, large clusters of genes functioning in the pancreatic endocrine 
development were overexpressed. For instance, PAX4 and NKX2 were within the top 
upregulated genes in primary canine INS lesions. PAX4 and NKX2 are expressed in 
the early pancreas, but are later restricted to beta cells and not expressed in mature 
islets, suggesting an important role of these genes in differentiation and development 
of pancreatic islet (Edlund, 2002). Previous studies have already shown that PAX4 
mRNA was highly expressed in human INS tissues compared to normal islets 
(Miyamoto et al., 2001) and that in vitro PAX4 plays an essential role in INS cell 
survival (Brun and Gauthier, 2008) . Furthermore, in this study we identified that the 
transcript encoding gene necessary for insulin biosynthesis and embryologic 
pancreatic development, PDX-1, was highly expressed in primary INS tissue. PDX-1 
is well known as an essential regulator of many pancreatic endocrine genes such as 
neurogenin3, insulin, glucokinase, islet amyloid polypeptide, glucose transporter 
type 2, pancreatic polypeptide and somatostatin, and thus plays a critical role in 
glucose homeostasis and islet maintenance in the adult pancreas (Baeyens et al., 
2005; Srivastava & Hornick 2009; Stevenson et al., 2009; Liu et al., 2012). 
Interestingly, PDX1 has been previously identified as a therapeutic target for human 
pancreatic adenocarcinoma and PNETs (Liu et al., 2012).  
When comparing primary INS and metastatic lymph nodes, our data showed that 
acinar exocrine pancreatic enzymes genes such as PNLIP, PA, CTRC and CTRB2 
were downregulated in the metastases, confirming the data previously published by 
Buishand et al., (2013). Of note, Buishand et al., (2013) speculated that the 
downregulation of acinar-related genes in metastatic tissues might be related to a 
decrease in the stem-like cells population in the metastases suggesting that these cells 
might not be able to migrate (Buishand et al., 2013). Additionally, KRT19 was 
downregulated. These findings are also consistent with the results previously shown 
by Buishand et al. 2013.  KRT19, which encode for CK19 protein, has been proposed 
as a predictor of survival in human PNETs, including INS (Jonkers et al., 2006). For 
instance, previous studies showed that CK19 immunoreactivity is useful for 
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predicting poor prognosis of INS (Sakai et al., 2017). Considering that CK19 is 
widely expressed in (pre)malignant cells of epithelial origin and it is usually 
expressed in the exocrine ducts of the pancreas, we can speculate that CK19 may be 
involved in tumour growth during early stages but plays a minor role in the 
metastatic spread.  Further studies are needed to confirm this hypothesis.  
Additionally, tight junctions-related proteins such as claudins were downregulated in 
metastatic lymph nodes. According to the literature, downregulation of claudins 
causes loss of cell adhesion, which in cancer is an essential step towards metastatic 
spread (Zeng et al., 2014). These findings suggest that this mechanism could be 
important in the development of metastatic disease in INS. 
Furthermore, this study revealed that genes involved in the chemokine signalling 
pathway were overexpressed in metastatic lymph nodes. CXCL13, also known as B 
lymphocyte chemoattractant and its receptor CXCR5, were found to be upregulated 
in the metastatic lymph nodes. Interestingly, CXCL13-CXCR5 network has been 
already related to tumour growth, migration, and EMT in a variety of cancer such as 
of colon cancer (Zhu et al., 2015) and breast cancer (Biswas et al., 2014). Notably, 
targeted disruption of CXCL13 or its receptor CXCR5 in prostate cancer cells 
impaired their migratory and tumourigenic properties (Garg et al., 2017). Therefore, 
the in-depth study of the adjustment mechanisms of CXCL13 expression might be 
beneficial in the development of novel treatments for metastatic canine INS. 
On a final note, when we analysed the altered genes in common within the three 
pairwise comparisons, 15 genes were identified, related to insulin secretion, 
chemokine activity and cell adhesion. These findings might strengthen our previous 
speculations on the role of these mechanisms in canine INS carcinogenesis. 
 
Genome analysis provides a large quantity of information concerning molecules that 
are involved in disease pathogenesis and may be used to interpret diseases (Soneson 
et al., 2013). While it is not difficult to obtain the gene expression profiles, the 
extraction of biological insight from such information remains a major challenge. 
Pathway analysis is a frequently used analytical tool for a better detection of 
biological processes related to a wide distribution throughout the whole network of 
genes (Lowes et al., 2010; Yang et al., 2014; Zeng et al., 2014). GSEA compared to 
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single-gene methods gives a better overwiew of the complex biological altered hubs 
such as metabolic pathways and transcriptional programmes. GSEA can capture the 
subtle but coordinated changes in a gene-set and has been commonly used to find 
important pathways or functions in various diseases and cell conditions from 
microarray data (Yoon et al., 2016). Reactome is a peer-reviewed pathway database 
of human pathways that have additional types of annotations to support pathway 
curation including a variety of biological processes such as signalling, metabolism, 
transcriptional regulation, apoptosis and synaptic transmission (Croft et al., 2011). 
In this project, combined analysis with GSEA and Reactome tools revealed a set of 
mechanisms dysregulated in primary and metastatic canine INS lesions. For instance, 
when comparing normal pancreatic tissues and primary INS we identified that the 
majority of the upregulated pathways were involved in the extracellular matrix 
organisation, cell growth, beta cell development and insulin secretion.  
The extracellular matrix represents a complex network of macromolecules with 
distinctive physical, biochemical, and biomechanical properties (Lu et al., 2012). 
Extracellular matrix changes are often seen during cancer progression causing cell 
migration and metastasis. Importantly, extracellular matrix anomalies also deregulate 
behaviour of stromal cells, facilitating tumour-associated angiogenesis and 
inflammation, and thus lead to generation of a tumourigenic microenvironment (Lu 
et al., 2012). These observations suggest that alterations of the extracellular matrix 
could potentially be an important mechanism of INS tumourigenesis. Besides, we 
identified that downregulated functions were mostly related to methylation, ribosome 
activity, translation and protein and mitochondrial transcription in both primary INS 
and metastatic lymph nodes. It should be noted that a deregulation in the protein 
synthesis machinery has been previously related with cancer (Kosari et al., 2005; 
Yang et al., 2014; Zeng et al., 2014). Cell growth and division require first of all 
protein synthesis, and for having protein synthesis, the ribosome is necessary. 
Translation is one of the last steps of gene expression and later synthesis of proteins. 
A growing body of evidence indicates that the translation process per se plays a 
crucial role in tumorigenesis (Goudarzi and Lindström, 2016). In particular, 
ribosome plays a pivotal role in the maintenance of the efficiency and accuracy of 
the translation. It is known that the synthesis of ribosomes is a mechanism regulated 
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and balanced at multiple levels, and that ribosome proteins (RPs) produced in excess 
are rapidly degraded in the nucleus (Goudarzi & Lindström 2016; Wei Wang et al. 
2016). One of the major mechanisms by which tumour cells alter ribosome 
biogenesis to drive selective translation of the cancer genome is through rRNA 
modifications, predominantly methylation on nucleotides in functionally important 
regions (Truitt & Ruggero, 2016). According to our data, these pathways were 
downregulated both in primary INS and metastatic lesions. Ribosome activity can 
have many roles in cancer including apoptosis, cell differentiation, DNA repair 
mechanisms and cell cycle control (Goudarzi & Lindström 2016; Wang et al., 2016). 
In particular, it has been previously shown that RPs are necessary for p53 activation 
and signalling and loss or impairment of RPs may lead to disruption of this tumour 
suppressor pathway, ultimately leading to carcinogenesis (Wang et al., 2016). 
Previously, Buishand et al., 2013 demonstrated that the ATM/ATR pathway was 
downregulated in the high-metastatic group of INS and metastases; thus, they 
speculated a correlation to an aberrant expression of p53 protein (Buishand et al. 
2013). According to our data, a decrease in apoptosis and an increase in cell cycle 
functions have been recorded in primary and metastatic INS. Considering the 
important role of the mTOR pathway and p53 in human INS tumourigenesis (Zlobec 
et al., 2006; Zhan et al., 2012), we can speculate that these mechanisms collaborate 
with an altered ribosome activity to potentially induce INS carcinogenesis in dogs.  
Taken together, these findings suggest that downregulation of ribosome function in 
INS may contribute to ineffective cell cycle arrest and inadequate apoptotic 
responses after DNA damage. Thus, ribosome biogenesis could be exploited as a 
target in future INS anticancer therapy given that it can play a key role in INS 
carcinogenesis (Goudarzi and Lindström, 2016).  
 
3.6 Conclusions, limitations and future directions 
 
In summary, our experimental analyses identified a panel of altered gene expression 
profiling involved in early and metastatic stage of canine INS progression.  
The selection of cases in our study included both staging of the patients and 
pathologic features. However, the main shortcomings of this study were the small 
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number of cases enrolled and the lack of matched control and tumour samples. 
Nonetheless, considering the good quality of the data obtained, this study provided 
useful guidelines for future analysis on larger-scale. For instance, considering that 
the total number of genes for testing was around 16000 and minimum average read 
counts among the prognostic genes in the control group is 150 (maximum dispersion 
0.5), if the desired minimum fold change is 2, 35 subjects will have to be studied for 
each group (power= 0.8, FDR<0.05). Additionally, isolated beta cells could be added 
to the experimental design for confirming the findings of this study. 
In conclusion, further analyses are required to determine the significance of the 
mechanisms highlighted from this project. Nevertheless, these data suggested that 
combining differential gene expression with pathway and network analyses could 
provide, in the future, efficient biomarkers for early cancer diagnosis and treatment 





4 Isolation and characterisation of insulinoma cancer stem 
cells in canine and human cell lines 
 
4.1 Abstract 
Insulinomas (INS) are the most common neuroendocrine pancreatic tumours in 
human and dogs. The long-term prognosis for malignant INS is still poor due to a 
low success rate of the current treatment modalities, particularly chemotherapy. A 
better understanding of the molecular processes underlying the development and 
progression of INS is required to develop novel targeted therapies. Cancer stem cells 
(CSCs) are thought to be critical for the engraftment and chemoresistance of a 
variety of tumours, including INS. The aim was to investigate isolated INS CSC with 
a view of developing new treatment strategy. 
Highly invasive and tumourigenic human and canine INS CSC-like cells have been 
successfully isolated based upon their sphere-forming ability and the presence of 
specific stem cell surface marker (CD34; CD133; CD90; CD24). These cells express 
stem cell markers (OCT4, SOX9), and exhibit greater resistance to 
chemotherapeutics commonly used in human INS therapy. Importantly, these cells 
have a greater invasive and tumourigenic phenotype in vivo compared to non-CSCs. 
Results show that CSCs can be isolated from human and canine INS and they could 




4.2  Introduction 
 
INS is the most commonly diagnosed neuroendocrine pancreatic tumour in dogs and 
humans (Corroller et al., 2008; Schermerhorn, 2013). In humans, INS are often 
benign and can be effectively treated by surgical excision (Anlauf et al., 2009; 
Mathur et al., 2012). However, a subset of human INS exhibits cellular 
characteristics and clinical behaviour consistent with malignancy and these are 
referred to as ‘malignant INS’ (Jonkers et al., 2007; Baudin et al., 2014). Because of 
the low incidence of human INS (four cases per million population per year), the 
availability of research material is limited, especially for malignant subtypes 
(Callacondo et al., 2013). Therefore previously, investigators have analysed changes 
in gene expression of malignant INS mainly as part of broad studies on PNETs 
(Speel et al., 1999; Zhao et al., 2001; Sakai et al., 2017). However, PNETs represent 
a heterogeneous group of tumours and therefore, the specific tumourigenesis of INS 
is still poorly understood. Canine INS are classified as malignant tumours in 95% of 
the cases due to the outgrowth of micrometastases in liver and lymph nodes 
(Buishand et al., 2010). In the dog, the biological course of INS most often 
resembles that of malignant INS in humans (Buishand et al., 2012; Goutal et al., 
2012; Schermerhorn, 2013). As in humans, canine patients with malignant INS often 
present relapse episodes of hyperinsulinaemia that can cause severe hypoglycaemia 
even after resection of the tumour (Jonkers et al., 2007; Goutal et al., 2012). Due to 
the recurrence of the hypoglycaemic symptoms, many clinical challenges are faced 
in the treatment of both human and canine malignant INS. For this reason, new 
therapeutic strategies are necessary to improve the prognosis of patients with this 
disease. 
The hypothesis of this study is that the malignant behaviour of INS is driven by a 
subpopulation of CSCs. According to the CSC hypothesis, different cell populations 
reside within a tumour including cancer cells with more malignant features that can 
drive tumour growth and are able to form tumours in animal models (Abetov et al., 
2015). Growing evidence supports the notion that this small subset of treatment-
resistant cells called CSCs are uniquely capable of resisting the effects of 
conventional chemotherapeutics and thereby survive for a long time, resulting in 
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tumour recurrence, metastasis and poor prognosis (Alison et al., 2011; Pang et al., 
2012; Mitra et al., 2015). Thus, eradication of these cells is necessary for the better 
treatment of patients diagnosed with cancer (Guo et al., 2006; Stevenson et al., 2013; 
Abetov et al., 2015; Ran et al., 2017). Despite the growing evidence to support the 
existence of CSCs in a wide array of solid tumours, a comprehensive characterisation 
of INS CSCs has not yet been reported. Previous immunohistochemical studies have 
identified a small population of cells with stem cell characteristics within human and 
canine INS (Ordonez, 2001; Buishand et al., 2013). These cells are called amphicrine 
cells and are characterised by the co-localisation of both endocrine and exocrine 
markers (Ordonez, 2001). Previous studies have demonstrated that CSCs can be 
isolated using ALDH activity in GEP-NETs (Gaur et al., 2011). Moreover, recent 
studies have identified CD90 as a potential marker for CSCs in human PNETs 
(Krampitz et al., 2016) and specifically in human INS cell line (Buishand et al., 
2016). However, there are no consensus markers available to identify INS CSC-like 
cells and additionally, recent studies show that several CSC populations may reside 
within one tumour (Hou et al., 2014; Krampitz et al., 2016). 
Considering the close resemblance of canine INS to human malignant INS, from a 
comparative oncology perspective, which aims to utilise spontaneous tumours in pet 
animals as natural models for the study of human cancer biology and therapy 
(Gordon et al., 2009), canine INS represents an interesting study model for human 
malignant INS. Using a comparative oncology approach, the first goal of this study 
was to isolate human and canine enriched INS CSC populations and characterise 
their malignant behaviour and their role in INS carcinogenesis.  
The ability to purify different populations of cells and assess their in vitro and in vivo 
behaviour presents unique challenges to obtaining a viable single cell suspension. As 
said previously, the hallmark traits of CSCs include their heterogeneity, interaction 
with microenvironments and plasticity (Zhao, 2016). The CSC model is a dynamic 
one with a functional subpopulation of cancer cells rather than a stable cell 
population responsible for tumour regeneration ( Dean et al., 2005; Blacking et al., 
2007; Islam et al., 2015). As such it is crucial to optimise each isolation step to 
maximize yields (Pastrana et al., 2011). Therefore, in this chapter two separate in 
vitro methods will be used to isolate INS CSCs: 1) an enriching INS sphere forming 
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method, based on enrichment of a heterogeneous population of INS CSCs; 2) an 
isolation method, based on isolating a single well-defined population of CSCs.  
4.2.1 Isolation of INS CSCs based on sphere forming ability 
 
 CSCs have been efficiently enriched using their sphere-forming ability in a plethora 
of studies (Michishita et al., 2011; Pastrana et al., 2011; Pang et al., 2012; Gao et al., 
2014). The sphere-forming assay is an in vitro assay based on the assumption that 
only individual CSCs will survive serial passages under non-adherent conditions 
(Pastrana et al. 2011). Often stem-like cells are cultured in low-density anchorage-
independent growth conditions, in media supplemented with EGF, hydrocortisone, 
insulin, progesterone, and/or heparin, in the absence of FBS (Franco et al., 2016). 
Therefore, the sphere-forming assay is often used to evaluate the stem-like properties 
of cancer cells (Pastrana et al., 2011; Franco et al., 2016). It is estimated that 
approximately 1% of tumour cells give rise to tumorspheres (Blacking et al., 2007; 
Pang et al., 2012). In order to characterise whether tumorspheres actually represent a 
subpopulation of undifferentiated cells, the expression of embryonic stem cell 
markers is usually evaluated. OCT4 and NANOG are most widely used for this 
purpose, as they are transcriptional determinants essential for self-renewal and 
maintenance of the undifferentiated state (Wilson et al., 2008). Members of the SOX 
transcription factors family, such as SOX2 and SOX9, are also commonly used as 
markers of a stem cell-like state (Seymour et al., 2007; Fridriksdottir et al., 2011). 
Highly invasive and tumourigenic INS CSCs were enriched from both canine and 
human INS cell line contributing to the evidence that these subset of cells might be 
involved in the malignant behaviour of canine and human malignant INS. 
 
4.2.2  Isolation of INS CSCs based on stem cell surface markers 
 
 CSCs are a rare subset of tumour cells that bear properties of stem cells (Guo et al., 
2006; Alison et al., 2011; Magee et al., 2012; Lee et al., 2017). Considering the close 
remsemblance within CSCs and stem cells, stem cell-associated surface markers are 
frequently used to isolate and analyse the functional behaviour of purified CSC 
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populations (Pastrana et al., 2011). To date, researchers have identified a few surface 
markers that enrich various CSCs from a primary tumour for the majority of cancer 
types (Fan et al., 2010; Hou et al., 2014; Zhu et al., 2014; Sukowati et al., 2015; 
Lubeseder-martellato et al., 2016). In some cases, these are well-established markers 
of normal stem and progenitor cells (for example, CD34 in the haematopoietic 
system)(Guo et al. 2006). For others (e.g. CD133, CD44) the situation is less clear 
(Zhao 2017). According to previous studies a set of stem cell surface markers have 
been most commonly associated with pancreatic stem cells, pancreatic tumours, NET 
and specifically PNETs, such as CD90, CD34, CD24 and CD133 (Stevenson et al., 
2009; Gaur et al., 2011; Zhu et al., 2014; Krampitz et al., 2016; Lubeseder-
Martellato et al., 2016; Lee et al., 2017). Therefore, in this chapter, the potential of 
these stem cell surface markers will be explored as valuable tools to isolate human 
and canine INS CSCs. 
 
CD90 is a glycophosphatidylinositol anchored cell surface protein. CD90 is a marker 
of human hematopoietic stem cells and a regulator of proliferation, metastasis, and 
therefore it is a potential candidate marker for CSCs (Kumar et al., 2016). For 
instance, immunohistochemical studies on pancreatic adenocarcinoma revealed that 
CD90 is an important prognostic marker as its expression is related to highly 
metastatic cancers (Zhu et al., 2014). Moreover, previous studies reveal that CD90 
expression marks a subset of tumour-initiating cells within PNETs (Krampitz et al., 
2016). Interestingly, a recent study has shown that CD90 has a role also in human 
INS (Buishand et al., 2016). Buishand et al., (2016) demonstrated an increased 
tumour-initiating potential in athymic nude mice when CD90+ CM cells were 
injected (Buishand et al., 2016). They demonstrated that anti-CD90 monoclonal 
antibodies decreased the viability and metastatic potential of injected cells in a 
zebrafish embryo INS xenograft model (Buishand et al., 2016). However, very little 
is currently known about CD90 signalling capabilities, and potential ligands are 
poorly characterised. Furthermore, many controversies have arisen from the use of 
CD90 as a CSC marker, due to its lack of specificity in isolating CSCs and also its 
action as a tumour suppressor in different types of tumours (Kumar et al., 2016).  
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CD34 is a cell surface sialomucin and the first CSC marker recognised in acute 
myeloid leukaemia (Alison et al., 2011). The expression of CD34 is associated with 
pancreatic ductal progenitors (Stevenson et al., 2009) and epithelial stem cells 
(Blanpain et al., 2004). Although its function has not been fully elucidated the 
consensus view in haematological malignancies is that the CD34+CD38− signature 
does identify most CSCs in acute myeloid leukaemia (Alison et al., 2011). Since then 
a range of malignant tumours has been associated to CD34-committed stem cell 
precursors including gastric cancer (Xu et al., 2015), mammary tumours (Rybicka et 
al., 2016) and osteosarcoma (Pang et al., 2012). However, its role in cancer 
development remains unclear, yet it is of particular interest since CD34 expression 
serves as a CSC marker. 
 
CD24 is a glycosylphosphatidylinositol-linked cell surface protein originally 
discovered in leucocytes (Lubeseder-martellato et al., 2016). CD24 regulates cell 
motility and invasion and its expression is often related to haematopoietic cells and 
some neuronal and epithelial tissues (Lubeseder-martellato et al., 2016). CD24 has 
been frequently used on its own or in combination with others to isolate CSCs in 
various type of cancer such as breast cancer (Ricardo et al., 2011) and pancreatic 
adenocarcinoma (Skoda et al., 2016). Pei et al., (2016) have also shown that CD24 is 
upregulated in various stages of pancreatic intraepithelial neoplasia (Pei et al., 2016) 
.  
CD133 (Prominin-1) is a pentaspan transmembrane glycoprotein. CD133 has been 
extensively associated in the literature with CSCs in a plethora of tumours, such as 
glioblastoma (Fan et al., 2010), pancreatic adenocarcinoma (Hou et al., 2014), 
prostate carcinoma (Kalantari et al., 2017) and melanoma (Argaw-Denboba et al., 
2017). For instance, in pancreatic adenocarcinoma, the expression of CD133 was 
associated with a lower 5-year survival rate (Hou et al., 2014). Sakai et al., (2017) 
have recently shown that CD133 expression appeared significantly associated with 
unfavorable pathological features and shorter disease-free periods in a subset of well-
differentiated PNETs, thus representing a valuable predictor for clinical outcomes 
(Sakai et al., 2017).  
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Results from this study suggested that canine INS CSCs could be isolated using both 
isolation and enrichment methods. According to our data, both CD133 and CD34 
represented valuable markers for isolating chemoresistant INS CSCs in canine INS 
cell line. Whereas, it was not possible to isolate chemoresistant INS CSCs from 
human INS cell line using the surface markers tested in this study. 
 
4.3  Materials and methods 
 
Basic methodological descriptions and brands not stated here are presented in 
Chapter 2. Specific materials and methods of this chapter are herebin described. 
 
4.3.1  Sphere-formation assay 
 
The sphere forming ability of human and canine INS cells was determined following 
the protocol described in section 2.1.7. 
 
4.3.2  Drug treatment of cells 
 
Cells were treated with 5-Fluorouracil (5-FU) (Tocris, R&D System, Canada) diluted 
in DMSO over the indicated range of concentrations. Equal volumes of the vehicles 
were used as control. The chemosensitivity of the cells was evaluated using cell 
profileration assays as described in section 2.1.8 and colony formation assays as 
described in section 2.1.9. 
 
4.3.3  Magnetic cell sorting (MACS) 
 
CD34 MicroBead Kit UltraPure, human (130-100-453) and CD133 MicroBead Kit, 
human–lyophilized (130-097-049) have been used to MACS sort the human and 
canine INS cell lines.  
 
 130 
Cells were labelled with CD34 or CD133/1 microbeads and sorted using the Miltenyi 
Biotec CD133/CD34 cell isolation kit according to the manufacturer’s protocol 
(Miltenyi Biotec, UK). Briefly, 1x 107 cells were resuspended in 300 μL of chilled 
separation buffer (PBS + 5% of BSA). One hundred μL of FcR blocking reagent and 
100 μL of CD133 MicroBeads were added and the solution was incubated for 30 
minutes at 4°C with rotation. The cells were washed by adding 5 mL of cold 
separation buffer and centrifuged at 300 x g for 10 minutes at 4°C before being 
resuspended in 1 mL of separation buffer and transferred to a pre-washed LS 
separation column mounted on the magnetic separator. 
Thereafter, cells were added to a pre-washed magnetic separation (LS) column on 
the magnetic holder. The column was washed in order to collect the negative 
fraction. The column was removed from the magnetic holder and the positive 
fraction was collected. The column was washed three times to collect the negative 
fraction. The column was removed from the magnetic holder and the positive 
fraction was collected adding 5 mL of separation buffer. The labelled and unlabelled 
fractions were counted and seeded at required densities for cell culture, or fractions 
were pelleted and snap frozen for RNA or protein analysis.  
 
4.3.4  Flow cytometry and Fluorescence-activated cell sorting (FACS) 
 
Cells have been sorted using the protocol as described in section 2.5. 
Briefly, CM and canINS were detached by trypsinisation, washed with PBS and 
subsequently incubated with labelled phycoerythrin (PE-Cy5)-conjugated CD90 
monoclonal antibody at the dilutions indicated by the manufacturers at 4°C for 30 
minutes in the dark. The antibodies used were anti-human CD90-PE-Cy5 (BD 
Biosciences, USA) and PE-Cy5-labeled isotype-matched immunoglobulin was used 
as a negative control (Appendix 8.7: Figure 8.9 and Appendix 8.8: Figure 8.15 and 
Figure 8.16). 
A different protocol has been followed to stain cells with the cell surface marker 
CD34 (Appendix 8.7: Figure 8.10) and CD24 (Appendix 8.7: Figure 8.11; Appendix 
8.8: Figure 8.15 and Figure 8.16). After fixation and washing with PBS, cells have 
been incubated with labelled phycoerythrin (PE)-conjugated monoclonal antibodies 
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at the dilutions indicated by the manufacturers at 4°C for 10 minutes in the dark. The 
antibodies used were anti-mouse IgG2a CD34-PE (Miltenyi Biotec, Surrey, UK) and 
anti-mouse IgG1k CD24-PE (Miltenyi Biotec, Surrey, UK). PE-labeled isotype-
matched immunoglobulin was used as a negative control. An unstained sample of 
cells was used as a negative control for all the experiments. Sytox blue (Invitrogen, 
UK) was used as a dead cell discriminator and added at 1:1000 dilution before 
processing the samples in BD Fortessa or FACS-Aria flow cytometers (BD 
Biosciences).  
 
4.3.5  RNA extraction and quantitative Real Time PCR 
 
Basic methods for RNA extraction and qRT-PCR are described in section 2.2. Total 
cellular RNA was extracted using RNeasy® kit (Qiagen, CA, USA) and RNA quality 
was determined by A260 measurement. Total RNA was reverse transcribed using the 
OmniscriptTM RT Kit (Qiagen, CA, USA) according to the manufacturer’s 
instruction. qRT-PCR was performed with the primers listed in Table 8.11 and Table 
8.12 (Appendix 8.6) using the Stratagene M63000p qRT-PCR system (Aligent, CA, 
USA), and the PlatinumH SYBRH Green qRT-PCR SuperMix-UDG (Invitrogen, 
CA, USA) according to manufacturer’s instruction. Relative gene expression levels 
were obtained by normalisation to the expression levels of housekeeping genes 
(canINS: Rps5 and Gapdh; CM: HPRT and GAPDH). Calculations were made using 
the Delta Delta Ct Method. 
 
4.3.6  Chorioallantoic membrane assay (CAM) 
 
The tumour forming and invasive ability in vivo of human and canine INS cells using 
CAM assay was determined following the protocol described in section 2.1.10. 
 




The invasive ability of cells was determined using the QCM™ collagen-based cell 
invasion assay kit (Millipore, MA, USA) according to the manufacturer’s instructions. 
Briefly, cells were seeded into the upper inserts at 1 × 105 cells per insert in serum-free 
RPMI. Cells were incubated at 37 °C with 5% CO2 for 48 hours. Non-invading cells 
were removed. Cells that migrated through the gel insert to the lower surface were 
stained and quantified by colorimetric measurement at 560 nm. Images were taken 
using a Nikon Eclipse Ni Brightfield Microscope and thereafter processed with Zeiss 
pro image software (Zeiss). 
 
4.3.8  Insulin and C-peptide ELISA kit  
 
CM and canINS cells were passaged up to 25 times for the adherent and 15 times for 
the spheres. Aliquots of medium were collected at several time points. Insulin 
released into the medium was measured by an ultrasensitive human/porcine/canine 
Insulin Quantikin ELISA kit (R&D System, Minneapolis, USA) according to the 
manufacturer’s instructions. C-peptide released into the medium was measured by an 
ultrasensitive canine C-peptide ELISA kit (AMSBiotechnology, Abingdon, UK) 
according to manufacturer’s instructions. 
 
4.3.9  Statistical analysis 
 





4.4  Results  
4.4.1  CSCs are enriched in human and canine INS spheres 
 
Tumorspheres have been cultured using an optimised protocol for both canine and 
human INS cell lines. Cells have been passaged for at least five times before testing 
into different assays as previously described (Pang et al., 2011, 2014). Canine 
(canINS) (Figure 4.1 A) cells gave rise to wheel-shaped and well-rounded spheres 
(Figure 4.1 B-C), whereas human (CM) (Figure 4.1 D) spheres had an irregular 
shape and appeared like agglomerates of cells (Figure 4.1 E-F). canINS CSCs tended 
to cluster quite tightly and formed larger (up to 200μm of diameter) but fewer 
spheres (Figure 4.1 B-C) compared to CM, which presented small but numerous 
tumorspheres (Figure 4.1 E-F). It was possible to culture both human and canine 
tumorspheres for extended passages (up to 15 passages). 
After isolation we characterised our INS CSC enriched tumorspheres on their multi-
differentiation potential and the expression of stem cells markers such as OCT4 and 
SOX9. OCT4 was not only a transcription factor determinant of pluripotency of 
embryonic stem cells but it has also been associated specifically with pancreatic 
endocrine precursor cells (Wang et al., 2009). SOX9 was a specific pancreatic stem 
cell marker, responsible for the maintainance of pancreatic progenitor pool (Seymour 
et al., 2007). Protein analysis showed that the expression of both markers was 
increased in canINS (Figure 4.1 G) and CM (Figure 4.1 H) tumorspheres compared 
to parental adherent cells. 
 Gene expression levels of a number of CSC-associated genes was evaluated 
including stemness markers (OCT4, NANOG, STAT3, SOX2, SOX9), stem cell 
surface related markers (CD133, CD24, CD90, CD34, CD44), epithelial-
mesenchymal transition markers (SNAIL, VIMENTIN), growth factor receptors 
(EGFR, LIFR, GHR, IGFR), Notch signalling pathway receptors and target genes 
(NOTCH1-4, JAG1-2, HEY1, HES1), and pancreatic neuroendocrine and exocrine 
markers (PA, PNLIP, PDX1, ISL1). Pancreatic progenitors markers OCT4, SOX2, 
SOX9 were upregulated in human and canine INS CSCs (Figure 4.2 A). Stem cell 
associated surface markers (CD133, CD90, CD34, CD24) were overexpressed in 
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human and canine INS (Figure 4.2 B). Pancreatic exocrine (PNLIP) and endocrine 
(ISL1 and INS) markers were overexpressed at the RNA level in human and canine 
spheres (Figure 4.2 C). NOTCH2 and HES1 were significantly upregulated in both 
human and canine INS tumorspheres compared with the adherent population. 
Additionally, target genes of the Notch pathway, such as HEY1 and SNAIL1, 
demonstrated a trend of upregulation in both human and canine spheres. No 
significant differences in gene expression were recorded for NOTCH1, whereas 
NOTCH3 and NOTCH4 showed a trend to downregulation in canine and human INS 
spheres (Figure 4.2 D). No significant differences in gene expression were recorded 
for mesenchymal markers such as VIMENTIN and CD44 in human spheres, whereas 
both markers were downregulated in canine spheres (Figure 4.2 E). (Additional data 
of tested markers with different relative gene expression patterns between canine and 




 Figure 4.1 Isolation of canine (canINS) and human (CM) insulinoma cancer stem cells. 
A-C: canINS in adherent (A) and tumorsphere (B-C) culturing conditions at different 
magnifications (B:10x; C:20x) (scale bar: 100μm). D-F: CM in adherent (D) and in 
tumorsphere (E-F) culturing conditions at different magnifications (B:10x; C:20x) (scale 
bar: 100μm). G-H: Western blot analysis of caniNS (G) and CM (H) stem cell markers 



















Figure 4.2 qRT-PCR of stem cell and self-renewal pathway related genes comparing CM 
and canINS in both adherent and sphere culturing conditions. The expression of 
embryonic stem cell genes (SOX9, OCT4, SOX2) (A) and stem cell associated surface 
markers (CD133, CD34, CD90, CD24)(B) RNA were upregulated. C: The expression of 
NOTCH receptor, (NOTCH1-4) and downstream target gene (HES1, HEY1, SNAIL1) and 
transcription factors (TCF3) was evaluated. NOTCH2 and HES1 were significantly 
overexpressed at the RNA level in canINS and CM spheres. HEY1 and SNAIL1 were also 
overexpressed. D: Markers of pancreatic progenitors cells (PDX1) as well as endocrine 
(ISL1, INS) and exocrine (PNLIP) cells were analysed. PNLIP, ISL1, INS were 
commonly overexpressed at the RNA level in canINS and CM spheres. E: No significant 
difference in relative gene expression of markers of mesenchymal cells (VIMENTIN and 
CD44)was recorded  in human and canine INS CSCs. The P-values represent the 
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comparison with a stated hypothesis (values >1) using one samples t-test. *P-values <0.05 
were considered statistically significant (adapted from Capodanno et al. 2017). 
 
4.4.2  INS CSC-enriched tumorspheres exhibit greater resistance to 
chemotherapy compared with adherent cells 
 
To validate these data, enriched INS CSCs were selected for functional assays of 
CSC behaviour using in vitro chemosensitivity assays. Human and canine parental 
cell lines were screened for a set of chemotherapeutics commonly used in the 
treatment of human INS (Table 4.1). There is little available information detailing 
expected serum concentrations of these drugs in dogs. Therefore, drug effects were 
assessed over a range of concentrations based initially on levels achieved at 
therapeutic doses in humans (TPC=Therapeutic Plasma Concentration).  
According to the IC50, canine INS cells have the optimal response to 5-FU at 0.5µM 
whereas human INS cells show the optimal response to 5-FU at 5µM. According to 
the literature, both concentrations reside within the TPC of 5-FU (800ng/mL - 2000 
ng/mL) (Danquechin-dorval and Gesta, 1996; Yamada, 2003; Blaschke et al., 2012). 
5-Fluorouracil (5-FU) is the second most commonly used chemotherapic in the 
treatment of human INS (after streptozocin) and present less toxicity effects at TPC 
(Blaschke et al., 2012). Results showed that isolated canine INS CSC spheres are 
more resistant to 5-FU than the non-CSC population (Figure 4.3 A-B), the same 




Table 4.1 Calculated IC50 values of chemotherapy drugs for canine (canINS) and human (CM) 
insulinoma cell lines. All cell viability assays were performed at a density of 5x102
 
cells. IC50 has 





Figure 4.3 Chemosensitivity and colony formation assays of canine (canINS) (A-B) and human 
(CM) (C-D) insulinoma cell lines. A-C: Chemosensitivity assay in canINS (A) and CM (C): cells 
were treated with increasing concentrations of 5-FU (from 0.5 to 5 μM) comparing the adherent 
population (dashed line) and the sphere population (continuous line). B-D: Colony formation assay 
canINS (B) and CM (D): Human and canine cells were treated with increasing concentrations of 
5-FU (from 0.5 to 5 μM) comparing the adherent population (dashed) and the sphere population 
(solid). Values represent mean of triplicates ± SD. The P-values represent the comparison using 2 
samples t-test within the adherent and the spheres. *P-value < 0.05 was considered statistically 
significant (adapted from Capodanno et al. 2017). 
 
4.4.3  INS CSC-enriched tumorspheres are highly invasive in vitro 
 
The invasive capacity of cells was tested in vitro using a collagen-based invasion 
assay. CSC-enriched cells displayed a significantly greater invasive potential 
compared to the bulk of INS cells (Figure 4.4 A). When quantified both canine 
(Figure 4.4 B) and human (Figure 4.4 C) INS CSC-enriched cells presented a 
























































































Figure 4.4 Invasive properties of insulinoma cancer stem cells in vitro. A: Representative 
images of invasive capacity of canine (top row) and human (bottom row) spheres against 
adherent cells using a collagen-based cell invasion assay kit. (scale bar: 20 μm) B-C: 
Canine (B) and human (C) invading cells were stained and quantified by colorimetric 
measurement at 560 nm Values are mean of 3 ± SEM.  *P-value < 0.05  (adapted from 
Capodanno et al. 2017).   
 
4.4.4  INS CSC-enriched tumorspheres have a more tumourigenic and 
invasive phenotype than adherent cells in vivo  
 
The in vivo malignant behaviour of the INS CSC-enriched cells was assessed using 
the in vivo CAM assay model. The figures below represent a series of experiments 
conducted with both the adherent cells (Figure 4.5 A1-B1) and the cultured spheres, 



























































and according to the results, the adherent population did not form tumours and did 
not migrate in this model (Figure 4.5 A1-B1), however the CSC population did 
migrate (Figure 4.5 A2-B2) and gave rise to substantial tumours (Figure 4.5 A3-B3). 
The red fluorescence was then quantified and a statistical significant difference was 
recorded between the canINS adherent and the enriched CSCs (Figure 4.5 C); 
whereas, no statistical difference was recorded in the human INS cell line (Fig. 4.5 
D).  
Immunohistochemical analysis showed that canINS and CM adherent cells (Figure 
4.6 A-B) were less able to invade through the deep layers of the CAM compared to 
human and canine INS CSC-enriched cells (Figure 4.6 C-D). According to the 
results, INS CSCs had an invasive behaviour moving from the outer ectoderm CAM 
layer through the mesoderm towards the endoderm (Figure 4.6 E-F). These findings 








    
 
Figure 4.5 Representative photographs taken 11 days after seeding a chicken embryo 
chorioallantoic membrane with either canINS (A) and CM (B) adherent cells (A1-B1) or spheres 




































































































with spheres (A3; B3).  A3 represents a magnified picture of the circles shown in A2. Magnification 
is specified on top of each picture. Pictures on the top row show merging of the brightfield channel; 
pictures on the bottom row show the red channel. C-D: Graph shows the differences in 
fluorescence between the canINS (C) and CM (D) adherent and spheres populations after 
quantification using ImageJ. Values are mean of 4 ± SEM.  *p-value < 0.05 (adapted from 





Figure 4.6 Invasive properties of insulinoma cancer stem cells in vivo. A-F: Representative images 
of immunohistochemistry of CAM sections embedded in agar and stained with pan cytokeratin that 
stains only human and canine cells (brown). The structure of CAM layers is comprised by ectoderm 
(ET), mesoderm (M) and endoderm (ED). Cancer cell matrigel grafts (CG) were seeded on the 
CAM. Pictures show the migration of CM adherent (A) and canINS adherent (B) and CM sphere 
cells (C) and canINS sphere cells (D) in the inner part of the CAM 11 days after being seeded. 
Results show that the CM adherent (A) and the canINS adherent (B) migrate less through the 
different layers of the CAM compared with the CM sphere cells (C) and the canINS sphere cells 
(D). High magnifications (20x and 60x) shows in details how the CM (E) and canINS (F) sphere 
 
 148 
cells disrupt the CAM membrane and invade through the CAM layers. Magnification is specified 




4.4.5  Canine INS CSC-enriched tumorspheres can produce insulin 
 
Clinical signs of INS are usually related to the endogenous hyperinsulinism that can 
cause a severe persistent hypoglycaemia in both humans and dogs (Anlauf et al., 
2009; Goutal et al., 2012; Okabayashi et al., 2013). Therefore, excessive insulin 
production is considered a feature of malignancy in INS (Jonkers et al., 2007; Polton 
et al., 2007). Considering that both the human and canine INS cell line in this study 
lost insulin production after early passages, after enrichment, CSCs were evaluated 
for insulin production.  
According to the mRNA expression, pancreatic endocrine markers, such as insulin 
(INS) and islet1 (ISL1), were overexpressed in canINS and CM spheres (Figure 4.2 
C). Results showed that when canINS cells were grown in non-adherent conditions 
the secretion of insulin and C-peptide, marker for insulin secretion, was reastablished 
(Figure 4.7 A-B), whereas for CM, it was not possible to reastablish insulin 





Figure 4.7 Insulin secretion in canine and human cancer stem cells. ELISA insulin and C-peptide 
test of different passages of both adherent and spheres of canINS (A-B) and CM (C-D). Results 
show an increase in insulin active release from the canINS cells when growing in spheres 
condition. Values are mean of 3 different passages (passages: 10,15,25 for adherent and 5,10,15 for 




















































































































4.4.6  Canine and human INS CSCs can be isolated using stem cell-
associated surface markers 
 
As previously said, stem cell-associated surface markers were upregulated in 
putative canine and human INS CSCs compared with the adherent cells (Figure 4.2 
B). Using flow cytometry, the protein expression of the following surface markers 
was assessed in both human and canine INS cancer cell lines:  CD90, CD34, CD24 
and CD133 (Figure 4.8 A). Results showed that the canine cell line has a high 
percentage of CD90+ (10%) and CD133+ (10%) cells. Whereas the human cell line 
has a high percentage of CD90 (30%) and CD24 (15%) positive cells (Figure 4.8 A). 
After treating canINS and CM sorted cells with different concentration of 
chemotherapy results showed that for canINS the CD133- and CD34- positive 
fraction had an increased resistance compared to the negative fraction of the 
population (Figure 4.8 B). Whereas, no differences was recorded between the 
positive and negative fractions of CM-sorted populations (Figure 4.8 C). Canine-
sorted CD133 and CD34 population were tested for a range of doses of 5-FU. 
Results showed that canINS CD133+ and CD34+ cells were more resistant to 5-FU 






Figure 4.8 Screening of different stem cell-associated surface markers for canine 
(canINS) and human (CM) adherent cell line. A: Percentage of positive fraction of CD90, 
CD133, CD24, CD34 cells was assessed in canINS and CM using flow cytometry (BD 
Fortessa). B-C: Chemosensitivity assay for canINS and CM of FACS and MACS sorted 
populations. B: canINS cells have been sorted according to the previous mentioned stem 
cell-associated surface markers and subsequently treated with different concentrations of 
5- Fluorouracil (5-FU) (0.5 µM and 1 µM). C: CM cells have been according to the 
previous mentioned stem cell-associated surface markers and subsequently treated with 
different concentrations of 5-FU (5 µM and 10 µM). D-E: Chemosensitivity assays for 
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concentrations of 5-FU (from 0.01 µM to 1 µM) comparing the CD34- (D) and the 
CD133- (E) negative population (dashed) and the CD34- (D) and the CD133- (E) positive 
population (solid). All data were normalised against the appropriate vehicle control. 




4.5  Discussion 
 
According to the CSC theory, the malignant behaviour of tumours is driven by a 
subset of cancer cells inherently resistant to conventional therapies that might have 
the ability to repopulate the tumours after treatment. This population is referred as 
CSCs (Guo et al., 2006; Pattabimaran et al., 2014; Mitra et al., 2015). In the last 
decade, CSCs have been identified and isolated in different type of human cancers 
(H. Wang et al., 2009; Abel et al., 2014; Gao et al., 2014; Hou et al., 2014).  Several 
groups have been able to isolate CSCs from a range of canine solid tumours 
including osteosarcoma (Wilson et al., 2008), rhabdomyosarcoma (Kishimoto et al., 
2017), hepatocellular carcinoma (Itoh et al., 2017), mammary carcinoma (Rybicka et 
al., 2016) and glioma (Pang et al., 2017). Although, CSCs have not been yet 
characterised in malignant INS. Therefore, the aim in this chapter was to isolate INS 
CSCs and evaluate their role in INS carcinogenicity.  
Results demonstrate that tumorspheres from both species have a statistically 
significant upregulation of stem cell-associated markers, such as CD133, CD34, 
OCT4, SOX9, and SOX2. Previously, OCT4, SOX2, SOX9 and CD133 have been 
identified as stem cell markers of pancreatic endocrine progenitor cells (Seymour et 
al., 2007; Koblas et al., 2008; H. Wang et al., 2009; Venkatesan et al., 2011). CD133 
has been previously studied as a valuable marker for a negative clinical outcome in 
PNETs (Sakai et al., 2017).  Furthermore, PNLIP, INS and ISL1 genes are 
upregulated in human and canine enriched INS CSCs. Previous studies have 
demonstrated that a 10% of the cancer cell population within primary canine INS 
present both endocrine and exocrine markers (Buishand et al., 2013). Additionally, 
ISL1 has also been described previously as a marker specific for human malignant 
INS (Hermann et al., 2011).  
This subpopulation of cancer cells are highly invasive and resistant to chemotherapy 
in vitro, similar to CSCs isolated in previous studies (Gaur et al., 2011; Pang et al., 
2011; Gao et al., 2014).  Chemotherapy is not commonly adopted in the treatment of 
canine INS (Goutal et al., 2012). Nevertheless, malignant human INS is commonly 
treated with a combination of different chemotherapeutics (Baudin et al., 2014), and 
5-FU represents the most commonly used one (Okabayashi et al., 2013). 5-FU is an 
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antimetabolite chemotherapy and pyrimidin analogue that blocks DNA replication 
interfering with the enzyme, thymilidate synthase (Yamada, 2003). 5-FU is not 
commonly used in the veterinary practice, nonetheless previous studies reported an 
increased survival time in canine patients diagnosed with metastatic breast cancer 
and gastric adenocarcinoma (Karayaponolou et al., 2001; Swann et al., 2002). 
Therefore, in this study 5-FU has been used to test chemoresistance of INS CSC 
population. According to the results in this study, enriched INS CSCs are more 
resistant to 5-FU compared to the adherent cancer cells. This is consistent with the 
CSC model stating that despite the sensitivity of bulk tumour cells to chemotherapy, 
CSCs are resistant and lead ultimately to the failure of cytotoxic chemotherapy, 
increasing the need for new CSC-targeted therapies (Guo et al., 2006). The 
aforementioned data suggest that a population of stem cell-like cells, resistant to 
chemotherapeutics, reside within the INS cancer cell population.   
Results from the in vivo CAM model show that enriched INS CSCs cells display a 
greater invasive potential compared to the bulk of INS cells. Within 4 days not only 
do CSCs from INS tumorspheres develop visible tumours, but they also escape the 
primary inoculation site and reach the inner layers of the CAM. The in vivo CAM 
assay results are consistent with cancer cell proliferation and invasion observed in 
the in vitro assays. For instance, the invasive behaviour of INS CSCs in the CAM 
model with its highly vascularised structure, closely mimics the mode of INS 
metastasis which involves INS cancer cells invasion and spread through the 
abdominal lymphatic system to reach the site of metastasis in either lymph nodes or 
liver. The CAM model has previously shown to be an interesting model for 
metastatic behaviour in other types of cancer such as breast, bladder, prostate, 
ovarian cancer and head and neck cancers (Vargas et al., 2007; Lokman et al., 2012). 
These findings suggest CSCs may play a role in INS carcinogenesis and support the 
use of canine as an appropriate comparative model for studying the involvement of 
CSCs in INS oncogenesis. 
As described previously, INS are insulin-secreting tumours, thus clinical signs are 
usually associated with excessive endogenous production of insulin (Okabayashi et 
al., 2013). Due to the high insulin production, INS cell lines have been previously 
used as a model to study beta-cells and the function of endocrine pancreas (Labriola 
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et al., 2009). However, insulin production in these INS cell lines is often lost after 
early passages (Skelin et al., 2010). For instance, in CM despite several beta-cell-
specific characteristics of this cell line, like expression of beta cells genes (GLUT2, 
glucokinase and insulin), long-term passage resulted in loss of insulin secretion 
(Baroni et al., 1999). Consistently with these findings, the newly isolated canINS cell 
line has also shown a loss of production of INS after early passages (Buishand, 
unpublished data). Previous studies have shown that insulin-producing cells can be 
generated from stem/progenitor cells (Sugiyama et al., 2007; Xia et al., 2009; 
Joglekar et al., 2010). Therefore, insulin production was tested in canINS and CM 
enriched INS CSCs. Results show that pancreatic endocrine related genes (INS and 
ISL1) are overexpressed in both human and canine enriched INS CSCs and that 
insulin production can be reastablished in canine enriched INS CSCs. Considering 
that alteration of the glucose metabolism are fundamental for cancer growth and 
survival, accumulating evidences indicates a central role of insulin and IGF 
signalling in the induction/maintenance of EMT and cell stemness during cancer 
progression (Belfiore and Malaguarnera, 2011; Malaguarnera and Belfiore, 2014). 
For instance, increased insulin receptor overexpression together with autocrine 
production of its ligand IGF2 is emerging as an important mechanism of normal and 
cancer stem cell expansion and as a feature of several malignancies (Belfiore and 
Malaguarnera, 2011; Malaguarnera and Belfiore, 2014). According to these results, it 
is possible that insulin production might be functional to the tumour 
microenvironment of canine INS CSCs. Nevertheless, insulin production cannot be 
reastablished in human enriched INS CSCs due to a mutation of the chromosome 11, 
where the insulin gene is located (Gragnoli, 2008).   
Tumorsphere culturing enriches for a heterogeneous cell population, containing stem 
cells, progenitors and more differentiated cells (Pastrana et al., 2011). In order to 
isolate and study the behaviour of purified populations of CSCs, stem cell surface 
markers are usually used. After screening human and canine INS cell lines for the 
presence of stem cell-associated markers, CD133 and CD34 result as valuable 
markers for the isolation of canine INS CSC populations. Whereas in human INS cell 
line the stem cell surface markers used has not been efficient to isolate 
chemoresistant INS CSCs. Considering the different tumour staging and species of 
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these two cell lines, the different expression of stem cell surface marker might be 
related to their different origin. CSC state is not static and it develops during the 
different phases of the tumour (Blacking et al., 2007), thus, particular care has to be 
taken when choosing the type of CSC marker. As shown before, some markers select 
for a heterogeneous population rather than isolate a specific CSC population. For 
instance in human INS, CD90 is a marker for both intratumoural fibroblasts and 
vascular endothelium (Buishand et al., 2016). These results confirm what described 
before, that even though, in the last decade, substantial progress has been made in 
understanding genetic and epigenetic changes in CSCs, cancer cell populations are 
often heterogeneous and surface markers may not unequivocally enrich all CSCs 
(Blacking et al., 2007). 
4.6 Conclusions and future directions 
 
In summary, INS CSC population can be enriched from both canine and human INS 
cell line. The data show that these cells not only express embryonic stem cell 
markers, but also have an invasive and tumourigenic phenotype and are more 
resistant to chemotherapy than the bulk of the tumour cells. Following a One Health 
approach, this study further contributes to the evidence that canine tumour model 
system can be used, alongside traditional rodent models, to study the equivalent 
human disease.  
Significantly, results suggest that it is possible to isolate canine INS CSCs using both 
isolation and enrichment methods. Whereas, for human INS CSCs the enriching 
method is the only one that in this study showed consistency. These results show that 
within INS reside different CSCs population unravelling heterogeneity within INS 
cancer cells. In the future, a combination of several enrichment methods coupling 
human and canine cell lines from different stages of the disease could be the key for 
isolating INS CSC different populations. Nonetheless, this study provide evidence 
that the carcinogenic behaviour of malignant INS could be driven by INS CSCs. We 
identified a set of genes involved in the INS CSC phenotype, thus opening new 








5 Targeting the Notch pathway to decrease 
chemoresistance of insulinoma cancer stem cell 
population 
 
5.1 Abstract  
5-Fluorouracil (5-FU) chemotherapy is used as adjuvant treatment for metastatic 
recurrent human insulinoma (INS), but drug resistance limits its efficacy. Emerging 
evidence suggests that the existence of cancer stem cells (CSCs) contributes to 
chemoresistance. The aim of the present study was to identify whether 5-FU 
treatment could generate residual cells with CSC-like properties in INS and target 
mechanisms that might contribute to chemoresistance of INS CSCs. Protein analysis 
showed that NOTCH2 and HES1 were activated in INS cancer cell lines, especially 
when treated with chemotherapy. Inhibition of the Notch pathway, using a gamma 
secretase inhibitor (GSI), significantly affected the viability of INS CSC. When used 
in combination GSI and cancer chemotherapy, the clonogenicity in vitro and the 
tumourigenicity in vivo of INS CSC were significantly reduced. 
These data provided molecular evidence that the Notch pathway plays an important 
role in INS CSC survival and chemoresistance. In particular, enhanced NOTCH2 and 
HES1 expression was correlated to an INS chemoresistant phenotype and thus might 




5.2  Introduction 
 
Cancer chemotherapeutic agents kill rapidly dividing cancer cells mainly inducing 
apoptosis by DNA damage and/or inhibited mitotic division (Abdullah and Chow, 
2013). Despite being one of the main anticancer treatments available at the moment, 
patients often develop resistance to chemotherapy and, thus, tumour relapse (Zhao, 
2017). Unfortunately, slowly dividing and non-dividing cancer cells are less sensitive 
to chemotherapy particularly when reduced doses are given to avoid side effects on 
rapidly dividing normal cells (Abdullah et al., 2013). The insensitivity of these 
cancer cells causes chemoresistance and plays a significant role in poor prognosis of 
cancer (Dean et al., 2005; Mitra et al., 2015). Some of the cancer cells possess an 
intrinsic resistance to chemotherapy. Whereas, other cancer cells are initially 
sensitive but acquire resistance during treatment (Dean et al., 2005). Regardless of 
the resistance mechanisms, the chemoresistant cancer cells are the major cause of 
tumour recurrence or relapse and have garnered the most attention clinically (Dean et 
al., 2005; Mitra et al., 2015). Despite the intensive studies, the processes by which 
tumours become chemoresistant and the causes of chemoresistance remain only 
partially understood (Wang et al., 2009; Acharyya et al., 2012; Abdullah and Chow, 
2013; Zhao, 2017). Growing evidence supports a critical role of CSCs in the 
chemoresistance mechanisms in many types of cancer including gliomas and 
glioblastoma (Irshad et al., 2015), breast (Pang et al., 2011), colorectal (Zhao et al., 
2016),  osteosarcoma (Pang et al., 2014), pancreatic (Wang et al., 2011) and ovarian 
cancer (Mao et al., 2014). Chemoresistance of CSCs can contribute to tumour 
initiation as well as continued tumour progression following treatment (Acharyya et 
al., 2012; Zhao, 2017). In particular, previous studies have shown an association 
between chemoresistance and acquisition of a CSC-like phenotype in some types of 
cancers (Wang et al., 2009; Xu et al., 2015; Zhao et al., 2016). For instance, in colon 
cancer and gastric cancer it has been previously reported that 5-FU treatment 
selectively enriches for a subset of CD133+ cancer cells with stem cell-like 
properties in vitro (Xu et al., 2015; Paschall et al., 2016). Consequently, CSCs 
investigation can be a powerful tool for the development of therapies for patients for 
whom traditional cancer chemotherapies and radiation treatments have poor clinical 
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outcomes (Lu et al., 2016). CSCs hold great promise for redefining cancer therapy in 
advanced-stage cases. However, the mechanisms behind the apparent inherent 
resistance to therapy harboured by CSCs are unknown but it is likely that CSCs use 
active mechanisms to evade cytotoxic drugs or radiation treatment (Mitra et al., 
2015). Because of their highly heterogeneous nature and the repeated refinement of 
the CSCs by new markers, it is difficult to categorise the specific or overlapping 
populations responsible for promoting the processes of dissemination, intravasation, 
dormancy, and relapse (Zhao et al., 2016). Therefore, the malignant behaviour of 
CSCs must be captured and characterised in different types of cancer, focusing 
particularly on drug-resistance and the identification of aberrant pathways in CSCs 
(Guo et al., 2006; Borah et al., 2015; Takebe et al., 2015). Evidence shows that 
many properties that are classically associated with stem cells are also characteristics 
of CSCs (Mitra et al., 2015). There are a number of signalling pathways functioning 
in normal stem cells, which have assigned roles in the early embryogenesis-like cell 
proliferation, cell differentiation, cell fate, and, particularly, self-renewal (Abetov et 
al., 2015). Although as genetic and epigenetic changes might have a role in the 
unrestrained growth, invasion and acquired resistance in cancer cells, deregulation of 
these pathways could be involved in maintaining the CSC phenotype (Borah et al., 
2015). Our increasing understanding of the molecular biology and aberrantly 
activated cellular pathways of CSCs has revealed some novel targets for therapeutic 
strategies that have successfully reduced CSCs both in vitro and in preclinical 
models (Wang et al., 2011; Lu et al., 2016). Of note, extensive experimental 
evidence has revealed Hedgehog, Wnt, Notch and TGF-beta pathways to be the key 
players in maintaining the proliferating capacity of CSCs and are activated in most of 
the solid tumors, including NET (Pannuti et al., 2011; Carter et al., 2013; Abetov et 
al., 2015; Borah et al., 2015). As discussed in the section 1.6.3, CSC-targeted 
therapies have been recently tested in clinical trials against the aforementioned 
pathways in a variety of tumours.  
In chapter 4 INS CSCs were successfully enriched from human and canine INS cell 
lines. Data demonstrated that the Notch pathway was associated with a stem cell-like 
phenotype in INS (Figure 4.2). The Notch signalling pathway is fundamental in 
pancreatic embryogenesis and plays an essential role in suppressing differentiation 
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and maintaining the pluripotency of embryonic stem cells (Edlund 2002; Wang et al., 
2011) (Figure 5.1). Briefly, Notch signalling is activated by the interaction of 
Jagged1&2 and Delta-like1,3&4 transmembrane ligands with Notch receptors (1–4) 
on adjacent cells. This leads to the endocytosis of ligands into the signal-sending cell 
and causes a conformational change of the extracellular domain of the Notch protein 
in the signal-receiving cell. This exposes a cleavage site in the signal-receiving cell 
for the ADAM proteins Kuzbanian (ADAM10) and TACE (ADAM17) and leads to 
the generation of a signalling intermediate known as NEXT (Notch extracellular 
truncation) in the signal-receiving cell. γ-secretase cleaves NEXT twice within the 
transmembrane domain to release the Notch intracellular domain (NICD) that 
translocate to the nucleus. Within the nucleus, NICD interacts with members of the 
CSL family of DNA-binding proteins, displacing transcriptional corepressors 
associated with the CSL proteins and recruiting members of the Mastermind-like 
(MAML) family of transcriptional co-activator. The genes transcribed differ 
significantly between tissues. However, members of the Hes/Hey family of 
transcriptional corepressors are commonly induced (Angelis et al., 1999; Roy, Pear 
and Aster, 2007; Brennan and Clarke, 2013) (Figure 5.1). 
Previous studies have analysed the key role of the Notch pathway in a number of 
processes including tumour initiation (Gao et al., 2014), self-renewal (Chiron et al., 
2012), and chemoresistance (Liu et al., 2013) of CSCs. The role of the Notch 
pathway has been previously described in various types of NETs (Grande et al., 
2011; Carter et al., 2013; Crabtree et al., 2016). However, to our knowledge, this is 
the first study to evaluate the role of the Notch pathway in INS tumourigenicity and 
in particular, its role in chemoresistance of INS CSCs. Our data showed that enriched 
INS CSCs did not only posess self-renewal and tumour-initiating capability but they 
were also resistant to therapeutic plasma dose range of 5-FU. Therefore, in this 
chapter the Notch pathway was investigated in vitro and in vivo to evaluate its role in 






Figure 5.1 Schematic representation of the Notch pathway signalling. The Notch pathway 
includes two families of ligands: the Jagged and Delta-like ligands. After binding there 
are four types of receptors that can be activated termed Notch1-4. These receptors undergo 
a two-step proteolytic cleavage, first by ADAM10, then by gamma-secretase. After 
proteolytic release, Notch intracellular domain translocates to the nucleus, interacts with 
CSL transcription factors (CBF1/RBP-Jκ, Su(H), Lag-1) which activate and promote 
transcription of downstream genes involved in various differentiation programmes (HES1, 




5.3  Materials and methods  
 
Basic methodological descriptions and brands not stated here are presented in 
Chapter 2. Specific materials and methods of the following chapter are described as 
follows. 
5.3.1  Sphere-formation assay 
 
The sphere forming ability of human and canine INS cells was determined following 
the protocol described in section 2.1.7. 
5.3.2  Drug treatment of cells 
 
Cells were treated with gamma-secretase inhibitor N-[N-(3,5-Difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester (DAPT) (Sigma-Aldrich)  diluted in DMSO 
over the indicated range of concentrations. Equal volumes of the vehicles were used 
as control. The sensitivity of the cells to DAPT was evaluated using cell proliferation 
assays as described in Chapter 2.1.8 and colony formation assays as described in 
Chapter 2.1.9. 
5.3.3  Flow cytometry 
 
CM and canINS were detached by trypsinisation, washed with PBS and stained with 
Zombie Violet Fixable Viability Kit (BioLegend Inc., USA) to detect dead cells. Next, 
cells were washed again with PBS and fixed in paraformaldehyde at 1% for 10 min at 
37°C and then chilled for one minute on ice. A batch of cells was also permeabilised by 
adding ice-cold 90% methanol slowly to pre-chilled cells, while gently vortexing. Cells 
were incubated for 30 min on ice, washed in incubation buffer (PBS 0.5% BSA) twice 
and resuspended in 100 L of the diluted primary antibody at 1:800 dilution. After 
incubation with the primary antibody, cells were washed and incubated with a 
fluorochrome-conjugated secondary antibody for 30 minutes. After washing with 
incubation buffer, cells were resuspended in PBS and analysed using BD Fortessa (BD 
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Biosciences, USA). The primary antibody used was monoclonal anti-rabbit Notch2 
(D76A6) XP® with anti-rabbit IgG (H+L) F(abI)2 Fragment Alexa Fluor® 647 
Conjugate (NewEnglandBio) as a secondary antibody. As a negative control Rabbit 
(DA1E) mAb IgG XP® Isotype control Alexa Fluor® 647 Conjugate has been used 
(NewEnglandBio) (Appendix 8.7: Figure 8.13 and Figure 8.14).  
5.3.4  Chorioallantoic membrane assay (CAM) 
 
The tumour forming and invasive ability in vivo of human and canine INS cells using 
CAM assay was determined following the protocol described in Chapter 2.1.10. 
5.3.5  Statistical analysis 
 
Statistical analysis was performed following the methodology described in Chapter 
2.6. 
 
5.4  Results 
 
5.4.1  The Notch pathway is overexpressed and active in 5-FU resistant 
INS cells  
 
Previous analysis of gene expression in human and canine INS CSCs had revealed that 
Notch pathway related receptor, NOTCH2, and its target gene, HES1 were significantly 
upregulated in both CM and canINS spheres (Figure 4.2). Using flow cytometry, 
evidence was provided that the NOTCH2 receptor is constitutively activated as present 
in both its inactive form (extracellular level) and active form (intracellular level) in INS 
cells (Figure 5.2 A-B). Protein analysis showed that both CM and canINS sphere cells 
demonstrated an intrinsic higher expression of NOTCH2 and HES1 compared to the 
adherent INS cells (Figure 5.2 C-D). After testing a set of chemotherapeutics commonly 
used in the treatment of human INS, 5-FU was identified as the most suitable drug to 
study INS cancer cells' chemoresistance (Table 4.1). Both CM and canINS 
 
 166 
tumourspheres were more resistant to 5-FU treatment compared to adherent cells in cell 
viability and clonogenicity assays as shown in Figure 4.3.  
To evaluate the role of the Notch pathway in INS chemoresistance, cells were treated 
with increasing doses of 5-FU. Results showed that 5-FU residual cells demonstrated an 
increased expression of both the inactive and active form of the NOTCH2 receptor in 
canINS (Figure 5.2 C) and CM cells (Figure 5.2 D). In response to an increase in active 
NOTCH2 expression, its downstream target gene HES1 was also overexpressed in cells 









Figure 5.2 Analysis of Notch pathway protein expression and activation in human and canine insulinoma (INS) cells.  A-B: Graph showing the 







NOTCH2 in its inactive transmembrane form (NOTCH2-TM) and in its active intracellular form (NOTCH2-IC), and HES1 with beta actin as a 





5.4.2  Inhibition of Notch signalling decreases viability and 5-FU 
resistance in INS CSC-enriched tumorspheres  
 
INS spheres were more resistant to 5-FU treatment compared to adherent cells 
(Figure 4.3) and 5-FU resistant INS cells demonstrated a higher expression of active 
NOTCH2 compared to the untreated adherent cells (Figure 5.2). Therefore, in the 
following section, the effect of Notch inhibition on INS cells was evaluated. A GSI, 
DAPT, was used to evaluate the response of INS cells to Notch blockade. Data 
showed that CM and canINS spheres were more sensitive to the Notch blockade 
compared to the adherent cells (Figure 5.4 A-B). Cell viability of canINS spheres 
was decreased at lower doses of DAPT (Figure 5.4 A) compared to CM spheres 
(Figure 5.4 B). Protein analysis was performed to show whether DAPT effectively 
blocked the Notch signalling pathway in INS cells (Figure 5.4 C-D). According to 
these data, treatment with DAPT effectively reduced NOTCH2 active form 
(NOTCH2-IC), and thus the transcription of HES1 in both canINS and CM spheres 
(Figure 5.4 C-D). Of note, in canINS spheres the blockade of the Notch signalling 
occured at lower doses of DAPT (Figure 5.4 C) compared to CM spheres (Figure 5.4 
D). Finally, when used in combination DAPT and 5-FU, the clonogenicity of CM 
and canINS spheres was significantly reduced, better than either drug alone (Figure 
5.4 A-B). The synergistic effect of the combination of 5-FU and DAPT was 











Figure 5.3 Function of the Notch pathway in canine and human insulinoma (INS) cancer stem cells (CSC). A-B: Cell viability assay of canine (A) 







blot analysis of NOTCH2 in its inactive transmembrane form (NOTCH2-TM) and in its active intracellular form (NOTCH2-IC), and HES1, with 
beta actin as a loading control in canine (C) and human (D) INS cell lines treated with increasing doses of gamma secretase inhibitor DAPT 









Figure 5.4 Combined treatment in vitro of canine (canINS) and human (CM) insulinoma cancer stem cells. A-B: Colony formation assay of canine 







values represent the comparison using 2 samples t-test within the adherent and the spheres. *P-value < 0.05. C-D: Calculation of the synergistic 
effect of the DAPT and 5-FU using e-bliss calculation in canINS (C) and CM (D). The method compares the observed combined response with the 





5.4.3  Notch inhibition enhances chemosensitivity to 5-FU treatment of 
INS CSC-enriched tumourspheres in vivo 
  
To validate the results obtained with the in vitro experiments, the in vivo CAM model 
was used to test the role of the Notch pathway in the tumour-initiation properties of 
enriched INS CSCs. Treatment with either 5-FU, DAPT, or their combination, in the 
CAM model demonstrated that the canine (Figure 5.5) and human (Figure 5.6) INS 
CSC populations were not able to proliferate when treated with a combination of 5-FU 
and DAPT. The amount of fluorescence in the triplicate CAMs for the different 
conditions was recorded. Results shown that the combination regimen of 5-FU and 
DAPT significantly decreased the INS CSC-like cells proliferation, while neither 












Figure 5.5 Representative photographs of the CAM 11 days after inoculation with canINS spheres following red membrane labelling. Cells have 
been treated with 5-FU (0.5 μM) and DAPT (20 μg/ml). Pictures on the top row show the merging of the brightfield channel; pictures on the bottom 








Figure 5.6 Representative photographs of the CAM 11 days after inoculation with CM spheres following red membrane labelling. Cells have been 
treated with 5-FU (5 μM) and DAPT (20 μg/ml). Pictures on the top row show the merging of the bright field channel; pictures on the bottom row 








Figure 5.7 Combined 5-Fluorouracil (5-FU) and DAPT treatment decreases human and canine insulinoma cancer stem cells tumourigenic 
potential in the in vivo chorioallantoic membrane (CAM) model. A-B: Graphs show the differences in fluorescence between the different conditions 













In chapter 4 it was demonstrated that CSCs could be enriched through tumorspheres 
culturing from both human and canine INS cell lines (Figure 4.1 A-B). INS CSCs 
were not only clonal in vitro and in vivo (Figure 4.5) but they were also resistant to 
cytotoxic chemotherapy (Figure 4.3). According to the CSC model, despite the 
sensitivity of bulk tumour cells to chemotherapy, CSCs are more resistant and lead 
ultimately to the failure of cytotoxic chemotherapy, increasing the need for new 
CSC-targeted therapies (Guo et al., 2006). Understanding the mechanisms by which 
CSCs can contribute to chemotherapy and tumour relapse is essential as it provides 
valuable clues to better addressing cancer therapy and more specifically, cancer 
therapy that accounts for the unique biology of CSCs (Abdullah et al., 2013). 
Therefore, potential targets involved in INS CSC chemoresistance have been 
investigated for targeted therapy. After isolating INS CSCs, the Notch pathway was 
identified as a potential target for INS CSC targeted therapy. Notch proteins are also 
oncoproteins, and deregulated Notch signalling has been demonstrated in many solid 
tumours, as well as NETs (Fan et al., 2006; Rasul et al., 2009; Dailey et al., 2013; 
Abel et al., 2014; Mao et al., 2014; Irshad et al., 2015).  Results in this study showed 
that NOTCH2 and its target gene HES1 were overexpressed in the enriched CSC 
population (Figure 4.2). NOTCH2 is the only Notch receptor that have demonstrated 
overexpression in both human and canine INS suggesting that NOTCH2 is a crucial 
Notch receptor through which signalling in INS CSCs is mediated. The relatively 
few studies published in NETs to date have focused primarily on the expression and 
function of Notch1. Previous studies have identified Notch1 as a tumour suppressor 
in the majority of NET (Grande et al., 2011; Carter et al., 2013; Crabtree, Singleton 
and Miele, 2016). Although it was demonstrated that depending on the activated 
Notch receptors, Notch signalling can play tumour suppressive roles in some cancer 
types and oncogenic functions in others (Xu et al., 2013; Liu et al., 2017). Of note, 
different responses to Notch1 and Notch2 activation have been also seen within 
NETs. For instance, in small cell lung carcinoma, Notch1 activation inhibits tumor 
growth, whereas Notch2 signalling is involved in tumour promotion in small cell 
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lung carcinoma xenograft mice. These findings suggest that different receptor could 
have various functions during tumourigenesis of NET (Carter et al., 2013; Crabtree 
et al., 2016). According to our results, NOTCH2 was constitutively active in human 
and canine INS cells, both adherent and enriched spheres. This data showed that the 
Notch pathway is not only present but also active in the whole bulk of the INS cells, 
demonstrating the importance of cell-cell communication during tumorigenesis. Of 
note, the Notch pathway was upregulated in 5-FU chemoresistant INS cells. The 
enhanced Notch signalling may reflect selective enrichment of the INS 5-FU 
resistant cells; thus strengthening the hypothesis of a Notch-mediated INS 
chemoresistant phenotype. Previous studies have already shown the involvement of 
the Notch pathway in chemoresistance of a variety of tumours (Meng et al., 2009; 
Candy et al., 2013; Liu et al., 2013; Mei et al., 2015). For instance, overexpression 
of HES1 has been related to an increased resistance to 5-FU in colon cancer (Candy 
et al., 2013) and oesophageal squamous cell carcinoma (Liu et al., 2013).  
Additionally, the rationale of considering the Notch pathway as a pathway triggering 
CSC has been already shown in various types of cancer (Fan et al., 2006, 2010; 
Dailey et al., 2013; Mao et al., 2014; Irshad et al., 2015). For instance, recent 
reviews have shown that the Hes-1/achaete–scute complex-like 1 network impacts on 
the tumourigenesis of NETs via Notch signalling (Crabtree et al., 2016). Therefore, 
the effects of Notch blockade were tested in human and canine INS cells. A major 
class of agents targeting the Notch pathway is the γ-secretase inhibitors (GSIs). GSIs 
are the first class of pan-Notch inhibitors to reach clinical development in oncology 
(Ran et al., 2017). GSIs prevent the final proteolytic cleavage of Notch receptors that 
releases the active intracellular fragment (Figure 5.1). In particular, we chose DAPT 
as it has been widely tested for its efficacy as a pan Notch inhibitor in a plethora of in 
vitro studies (Wu et al., 2010; Mao et al., 2014; Wang et al., 2014; Lee et al., 2015). 
Recently, it was also described its efficacy on inhibiting NOTCH2 receptor amongst 
all the Notch receptors (Ran et al., 2017). Our results showed that DAPT, 
significantly decreased the survival of INS CSCs. Several studies have underlined 
the value of Notch targeting to reduce tumorsphere formation, prevent in vivo tumour 
formation and decrease chemoresistance in CSCs (Rizzo et al., 2008; Pannuti et al., 
2011; Abel et al., 2014). Nonetheless, due to their lack of specificity, pan-Notch 
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inhibitors can be more effective when used in combination with current therapies 
(Brennan and Clarke, 2013; Ran et al., 2017). Therefore, a combined regimen of 
DAPT and 5-FU was used to deplete the INS CSC population both in vitro and in 
vivo. Data showed that treatment with DAPT alone did not inhibit CSC clonogenicity 
in vitro. However, when used in combination, DAPT and 5-FU significantly 
inhibited the colony-forming ability of enriched INS CSCs to a higher degree than 
either therapy alone. These findings were confirmed in the in vivo CAM assay 
highlighting a significant decrease in tumour formation after treatment with DAPT 
and 5-FU. According to our results, 5-FU-chemoresistant cells highly express 
NOTCH2 receptor and HES1 target gene, thus the Notch pathway is used as a 
mechanism of chemoresistance from INS cells. In particular, in enriched INS CSC 
the NOTCH pathway through NOTCH2/HES1 cascade is correlated to INS cells’ 
stemness. Therefore, we can speculate that inhibiting the Notch pathway might cause 
a change in the INS CSC from quiescence to differentiation, making them sensitive 
to the effect of the 5-FU. The mechanism of synergy of these two drugs needs further 
investigations. Nonetheless, preclinical studies have already shown that inhibition of 
Notch using DAPT enhances the cytotoxic effects of chemotherapy in various type 
of cancers (Meng et al., 2009; Lee et al., 2015; Li et al., 2015). For example, in 
metastatic colon cancer, oxaliplatin-induced activation of Notch1 signalling is 
reduced by simultaneous GSI treatment, increasing tumour sensitivity to oxaliplatin 
(Meng et al., 2009). In breast cancer, combined GSI and doxorubicin treatment 
results in synergistic cytotoxicity in triple negative breast cancer cell lines and 
decreased tumourigenicity in mouse xenograft models (Li et al., 2015). In gastric 
cancer and ovarian cancer, Notch blockade increments cytotoxic effects of 5-FU and 
cisplatin, respectively (Wang et al., 2014; Lee et al., 2015).  
 
5.6 Conclusions and future directions 
 
In summary, the Notch pathway plays an important role in INS CSC survival and 
chemoresistance. In particular, treatment with 5-FU directly activates the Notch 
signalling pathway, through a Notch2/Hes1 cascade. The increased activation of 
Notch in response to chemotherapy may be clinically significant because it will 
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identify INS patients who would benefit from GSI treatment based on these 
molecular changes. Targeting the Notch pathway has shown a significant increment 
in the cytotoxic effects of 5-FU on the INS CSC population; although, the underlying 
mechanism of this process requires further studies. However, based on these results, 
GSI treatment could be a useful method to sensitise INS cancer cells to 
chemotherapy as previously reported for advances stages of solid tumours in phase I 
clinical trials (Richter et al., 2014). Demonstrating that inhibition of the Notch 
pathway has functional consequences thus provides further evidence that this 
pathway is not only differentially expressed but it is also involved in INS tumour 
growth. Translationally, modulatory or inhibitory drugs targeting the Notch pathway 
may be applied in the treatment of INS, but its role needs to be more clearly 
elucidated. Since GSIs, including DAPT, inhibit cleavage of all Notch receptor 
families, these results may not be due to exclusive Notch2 signalling effects. 
Therefore, future studies will clarify the significance of specifically targeting either 
NOTCH2 or HES1 to develop novel therapies. Nonetheless, in the following study 
the Notch pathway demonstrated to be an attractive target for innovative treatment 




6 General discussion 
 
6.1 Summary of findings 
 
PNETs are neuroendocrine tumours of the duodenal-pancreatic region that often 
present many challenging problems in diagnosis and treatment (Ito et al., 2012; Reid 
et al., 2014; Rossi et al., 2014; Giuroiu and Reidy-Lagunes, 2015). The behaviours 
of these tumours are highly variable and range from nearly benign to extremely 
aggressive. It has been recently appreciated that they are frequently more malignant 
than previously thought and can be a source of considerable morbidity as many 
patients have a protracted course (Rossi et al., 2014). They also require treatment 
approaches that differ from those used for most common pancreatic adenocarcinoma 
(Ito et al., 2012; Rossi et al., 2014; Giuroiu & Reidy-Lagunes 2015). 
In the last decade, thanks to improvements in diagnosis and case finding, PNETs 
have gained increased attention due to the rise of their incidence (Ro et al., 2013). 
For instance, the development of standardised classification systems for pathological 
reporting and novel target medical treatments, such as everolimus and sunitinib, have 
increased our understanding of PNETs. Since then, numerous consensus guidelines 
for PNET management/ treatment of locally invasive and metastatic disease, have 
been developed by the European Neuroendocrine Tumour Society and the North 
American Neuroendocrine Tumour Society (Ito et al., 2012; Baudin et al., 2014; 
Reid et al., 2014; Rossi et al., 2014). Due to high heterogeneity of these tumours, so 
far, very few studies have specifically addressed the behaviour of the different PNET 
subtypes.  INS are the most commonly diagnosed functioning PNETs in humans 
(around 30% of total PNETs) (Jonkers et al., 2007). Although the optimal clinical 
management of INS involves a multidisciplinary approach, surgery remains the only 
curative treatment for early-stage disease. In advanced stages, alternative therapeutic 
approaches, including chemotherapy, antiangiogenic therapy, and selective internal 





The overall aim of this project was to improve our understanding of the complex 
functional biology of INS to develop novel therapeutic options for patients diagnosed 
with this disease. Considering the similar clinicopathologic features, canine INS was 
studied as a model of human INS carcinogenesis.  
 
The first objective was to identify the mechanisms responsible for canine INS 
carcinogenesis using integrative computational approaches. The strategy of RNA 
sequencing for establishing gene expression profiles has been widely accepted in 
human research (Soneson et al., 2013), and thanks to the recently whole canine 
genome characterisation (Hoeppner et al., 2014), novel studies are developing to 
study this fascinating natural model of carcinogenesis for a variety of cancers (Davis 
and Ostrander, 2014).  
According to the global gene expression analysis, different gene profiles 
characterised early and late stage of canine INS (Figure 6.1). Of interest, the majority 
of changes in gene expression occurred in the early stages of canine INS 
tumourigenesis and were majorly related to activation of beta cell differentiation 
mechanisms and increased insulin secretion (Figure 6.1). For instance, a large cluster 
of genes involved in the insulin secretory pathway such as PDX1, NESTIN, IGF2 
were overexpressed in canine INS tissues compared with the control pancreatic 
tissues. Considering that hyperinsulinism is characteristic of INS, the predominance 
of the genes participating in the insulin secretory pathway suggested that an altered 
secretion might be a significant mechanism to increase insulin production in canine 
INS patients. Also, genes related with pancreatic beta cell differentiation such as 
PAX4, NKX2, INSM1, SOX17 were upregulated in primary canine INS lesions. For 
instance, INSM1 has been previously related to human INS carcinogenesis (Wang et 
al., 2004) and studied as a negative prognosticator in human PNETs (Fujino et al., 
2015, 2017). Thus, we could speculate that an unbalanced pancreatic beta cell 
differentiation might cause an abnormal islet development and represent an early set 
of mutations and lead to formation of primary canine INS lesions.  
In contrast, primary INS lesions and metastatic lymph nodes had a similar genetic 
profile, consistently with data previously published (Buishand et al., 2013). 
According to our data, tight-junctions related genes, such as claudins, were 
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downregulated, and chemokine signalling-related genes were upregulated in 
metastatic tissues. According to the literature, downregulation of claudins-related 
genes causes loss of cell adhesion, which in cancer is an essential step towards 
metastatic spread (Zeng et al., 2014). Of interest, loss of claudins expression, it has 
been related to EMT in the generation of stem cells from human islets (Gershengorn 
et al., 2004). These findings highlighted that inflammation and loss of cell adhesion 
could be critical mechanisms during metastatic spread of canine INS (Figure 6.1). 
Through functional analysis we investigated the altered hubs in malignant canine 
INS progression. Extracellular matrix and ribosome activity were significant 
functions altered during early and late stage of canine INS (Figure 6.1). Ribosome 
activity plays a pivotal role during translation and protein synthesis. Although it is 
known that ribosome activity is often altered in cancer and affects the protein 
synthesis machinery (Goudarzi and Lindström, 2016), the role of RPs as tumour 
suppressors, or in certain cases, as tumour-causing or promoting genes is unknown. 
As discussed in section 3.5, an unbalanced ribosome assembly pathway leads to 
impaired protein synthesis, and as such, the level of critical tumour suppressors may 
be decreased below a threshold level (Goudarzi and Lindström, 2016; Wang et al., 
2016). This mechanism may lead to the INS cell to compensate a ribosome deficit by 
activation of pathways that boost ribosome production, e.g. the mTOR pathway. 
Considering that the mTOR signalling plays a key role in INS carcinogenesis (Zhan 
et al., 2012), we could speculate that a loss or downregulation of RPs might alter the 
protein machinery in canine INS causing an uncontrolled cell growth through the 
mTOR pathway. This situation may create pressure to mutate components in the cell 
that restrains the mTOR pathway, such as PTEN and p53, which can ultimately 
cause uncontrolled cell growth and malignant transformation (Wang et al., 2016).  
In conclusion, in this project, preliminary data were collected over the global 
molecular biology of canine INS opening new insights on the carcinogenesis of this 
poorly studied tumours.  
 
After obtaining a broad vision of the altered gene expression patterns during canine 
INS carcinogenesis, the second objective was to analyse functional and mechanistic 
behaviours of canine INS compared with the human malignant form. For this scope, 
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cell lines remain an invaluable source for developing techniques and assays, 
especially when trying to analyse behaviours that could not be tested on patients or 
on primary tissues, which may be available on a limited basis. Nevertheless, one key 
difficulty in investigating the mechanisms of INS tumourigenesis is the limited 
number of appropriate INS models. In this study, we characterised and compared in 
vitro and in vivo a primary canine INS cell line and a metastatic human INS cell line 
to identify mechanisms involved in resistance to conventional therapy and metastatic 
spread of this disease. Extensive cancer research in the past few decades has 
recognised the existence of a rare subpopulation of stem cells in the niche of cancer 
cells, the CSC. Current treatment strategies are often unspecific, and CSCs' inherent 
resistance to conventional chemotherapy results in many cases in tumour recurrence 
(Mitra et al., 2015). Despite the growing evidence to support the existence of CSCs 
in a wide array of solid tumours, a comprehensive characterisation of a PNET CSCs 
has not yet been reported. In the last few years, there is an increasing interest in the 
isolation of CSCs from a range of human and canine solid tumours (Stoica et al., 
2009; Pang et al., 2012, 2014; Rybicka et al., 2016). Thus, suggesting that CSCs are 
essential in a variety of cancers and supports the use of canines as an appropriate 
comparative model for studying the involvement of CSCs in oncogenesis. However, 
little is known about the molecular mechanism of pathogenesis of INS due to lack of 
research materials and the high heterogeneity within the PNETs. Therefore, more 
studies are needed to define the presence of a subpopulation of INS CSC. 
In this thesis, a subset of highly invasive cells has been isolated and characterised by 
human and canine INS cancer cell lines. These subpopulations of cancer cells result 
positive for stem cell markers and resistant to chemotherapy, similar to CSCs 
isolated in previous studies (Stoica et al., 2009; Pang et al., 2012, 2014; Rybicka et 
al., 2016). In this PhD project, it was shown that tumorsphere culture represents a 
potential mean of enriching putative INS CSC. Many studies in our lab have reported 
the use of this assay to successfully isolate candidate CSC populations from cancer 
cell lines (Pang et al., 2011, 2013, 2014; Pang et al., 2017).  
Based on selection using stem-cell surface markers, INS CSC populations were 
isolated in both human and canine cell lines. Thanks to gene and protein analysis, a 
few markers representative of human and canine INS CSC were identified such as 
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CD24, CD34, CD133 and CD90. Even though, CD133 and CD34 were valuable 
surface markers for isolating chemoresistant canine INS CSCs, these stem cell-
associated surface markers were not efficient to isolate human INS CSCs. 
Considering the extensive heterogeneity even in a single tumour, it is it is possible 
that different CSCs may coexist within the human INS CSC subpopulation. It should 
be noted that so far no universal marker for CSCs has been identified. All of the 
currently described CSC markers can be detected not only on CSCs but also, to a 
certain extent, on normal stem cells or normal cancer cells or even normal tissues 
(Blacking et al., 2007). Nonetheless, the lack of CSC surface marker candidate 
commonly expressed in both human and canine INS showed that while CSC markers 
might be informative to understand the cancer cell population, they alone cannot 
define CSCs.  
Given the current lack of specificity and instability of the CSC population, the 
reliability of any system of CSC isolation and enrichment has to be tested 
experimentally through the in vivo tumour-initiating assay, as self-renewal capacity 
is one of the principal cellular characteristics of CSCs (Guo et al., 2006).  The in vivo 
CAM assay was used for this purpose demonstrating that tumorsphere-enriched 
CSCs are clonal and able to form tumours in vivo.  
In summary, this part of the study revealed that, even though the existence of CSC 
remains a controversial topic, human and canine INS present such a cellular 
hierarchy, as previously shown in a variety of cancers (Gaur et al., 2011; Wang et 
al., 2011; Pang et al., 2013; Hou et al., 2014). 
 
After isolating INS CSCs, the third objective of this study was to identify potential 
targets for novel INS CSC targeted therapy. CSCs are best characterized by 
enhanced drug-resistance, which could be derived either directly from their previous 
generations or through accumulation of the constant genomic and epigenetic 
mutations (Mitra et al., 2015). The mechanisms behind CSCs chemoresistance have 
not been fully elucidated yet thus, in this study, molecules or pathways directly 
related to drug resistance and active survival pathways of CSCs in INS have been 
explored. Our results show that the expression of the Notch related-genes is 
increased in the enriched CSC population. In particular, NOTCH2 and its target gene 
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HES1 are overexpressed in both human and canine enriched INS CSC populations. 
Following protein analysis, we confirmed that the Notch pathway, through 
Notch2/Hes1 cascade, is constitutively activated in human and canine INS CSCs. 
The role of Notch pathway has been previously studied in various types of NET 
(Grande et al., 2011; Carter et al., 2013; Crabtree et al., 2016). Although, to our 
knowledge, this is the first study that evaluated the importance of the Notch pathway 
in INS tumourigenicity and its function in INS CSC survival and chemoresistance. 
Given a large number of disease settings in which aberrant Notch signalling is 
involved, improved understanding of this pathway as a rational target is a pressing 
need.  Results showed that Notch blockade significantly decreased cell viability of 
both human and canine enriched INS CSC (Figure 5.4). Moreover, treatment with 5-
FU chemotherapy selected a chemoresistant Notch-active cancer cell population 
providing a rationale to study the Notch pathway as a mechanism of chemoresistance 
in INS CSCs. Furthermore, it was demonstrated that the lack of the Notch pathway 
sensitised INS CSCs to the effects of chemotherapeutics; thus this pathway could not 
only disrupt the maintenance of CSCs but also reduce their chemoresistance. These 
results were validated in vivo using the CAM model. The efficacy of the CAM assay 
was demonstrated as an in vivo model for screening of potential novel therapeutics in 
INS and evidence was provided that modulating Notch signalling pathway may be of 
great potential to eliminate CSC populations in INS.  
 
In summary, this section of the study showed that treatment with 5-FU activated the 
Notch signalling pathway, through a Notch2/Hes1 cascade, and that combined 
treatment with Notch inhibitors and chemotherapy synergistically attenuated 
chemotherapy-enriched CSC population. Previous studies showed that the Notch 
pathway through HES1 cascade functions as an upstream regulator of the mTOR 
pathway, activating Akt signalling pathway, silencing PTEN (Gutierrez and Look, 
2007) and controlling p53 activity through cMyc signalling (Wong et al., 2012) 
(Figure 6.2). As discussed in section 1.5.1, mTOR and p53 collaborate during INS 
carcinogenesis (Pelengaris and Khan, 2001). Targeting the PI3K/mTOR signal 
transduction using everolimus (section 1.5.2) has shown to delay progression-free 
and overall survival in INS (Zhan et al., 2012). Therefore, we could speculate that 
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the Notch pathway through a Notch2/Hes1 cascade acts as an oncogene in INS 
tumorigenesis promoting CSC survival and chemoresistance via mTOR activation 
and p53 aberration (Figure 6.2). In future studies, specifically targeting either 
NOTCH2 and/or HES1 could validate this hypothesis unravelling the downstream 
mechanisms involved in a putative Notch-driven INS carcinogenesis. Nonetheless, in 
this study we provided evidence that blockade of the Notch pathway decreased 
survival and chemoresistance of highly malignant INS cells thus providing a 
rationale for further investigation of this therapeutic strategy that might prevent the 





Figure 6.1 A two-stage model of canine insulinomas' carcinogenesis. Early stage: 
upregulation of beta cell differentiation and downregulation of apoptosis increase cell 
proliferation in the normal islets. Increased numbers of islet cells can elevate insulin 
secretion and induce a stressful microenvironment where cells mutate their ribosome 
activity, and the protein machinery is altered. In this condition, cell-cell interactions 
diminish and cells acquire invasive capability. Late stage: cell growth in the absence of 
cell-cell interaction causes loss of their cell adhesion and cells start to migrate towards the 
lymph vessel. An increased cell survival mechanism (PI3K signalling) and an increased 
inflammation (chemokine signalling) push the cells to disrupt the lymph vessel and 
metastasise to the adjacent lymph nodes. These mechanisms together might be responsible 








   
Figure 6.2 Diagram showing the model of molecular mechanisms involved in insulinoma (INS) carcinogenesis. The downregulation of the activity 
of ribosome proteins contributes to an increase of the mTOR signalling and thus, increasing cell proliferation. Notch activation, through a 
Notch2/Hes1cascade, upregulates Akt signalling and downregulates p53 pathway. HES1, via repression of PTEN and c-Myc, acts as a critical 
mediator of the Notch function increasing proliferation and decreasing apoptosis in INS cells. Solid line: active. Dotted line: inactive. Red: 










6.2  Limitations, controversies and recommendations for future 
research 
 
One of the main shortcomings of this study was the shortage of tumour samples for 
the RNA-seq analysis. Due to the rarity of these tumours and the difficulties on 
isolating samples with high-quality RNA, significant challenges were faced during 
sample selection for this study. Furthermore, considering the control tissues were not 
matched to the tumour samples additional bias might have been introduced within 
this study. Therefore, despite the efforts made in selecting the samples and in the 
experimental design, the high inter- and intra- samples variability might have 
affected the validity of the data on differential gene patterns, including bias caused 
by the selection of normal pancreas as control tissues rather than isolated beta cells. 
Nevertheless, great quality of the controls was demonstrated thanks to the high 
homogeneity of their gene expression profiles. These observations represented an 
excellent starting-point for our comparisons. Moreover, RNA-Seq data analysis and 
functional analysis of tumour samples and metastases showed a set of altered gene 
patterns consistent with previously published data (Buishand et al., 2013). To 
improve the power of the study, we recommend, in the future, increasing the number 
of samples and adding purified beta cells to the control tissues. Nonetheless, the 
overall consistency of the results obtained in this project gave some useful guidelines 
for the development of future RNA analysis of canine INS on a large scale.  
 
The second part of the study was predominantly focused on the characterisation and 
functional analysis of a canine and human immortalised INS cell lines. Even though 
the use of cell lines have proven to be very useful for studying changes during 
carcinogenesis, limitations arise from continuous in vitro passaging related to 
mutations in the genome. This approach might lead to underestimating the scale of 
both mutations and differential responses within tumours and immortalised cell lines. 
Considering the paucity of INS models and difficulties in immortalising INS cell 
lines, experiments were performed on a canine primary INS cell line and a human 
metastatic INS cell line. Thus, some inconsistency might have been recorded due to 
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the different origin and species of the two cell lines used. In the future, the use of 
human and canine INS cell lines derived from both primary and metastatic lesions 
would clarify the efficacy of the present findings. Still, data comparing human and 
canine INS cell lines were overall consistent and confirmed our hypothesis that 
canine INS could represent a good model for studying human INS carcinogenesis. 
 
Finally, the CSC hypothesis is possibly the most controversial topic in current 
biomedical research. Although CSCs have been well characterised in numerous 
malignancies, controversies have arisen on the CSC nature mainly related to the 
origin and frequency of CSCs and their phenotypic and functional properties (Wang 
et al., 2015). It is reasonable considering that our knowledge of CSCs is still not 
complete and based on the understanding of normal stem cells. For these reasons, in 
the last decade, various names such as CSC, stem cell-like cancer cell, tumour-
initiating cell and tumour-propagating cell have been suggested by different research 
groups (Fan et al., 2006; Yang et al., 2007; Pang et al., 2012; Mei et al., 2015).  
Recent studies suggest that the state of CSCs is plastic and that CSCs can have 
different origins, including progenitor or normal cancer cell with acquired self-
renewal capabilities through mutation and/or epigenetic change (Mitra et al., 2015). 
A foundation of the CSC theory is that the CSC and non-CSC populations are 
biologically distinct, with different inherent properties. Thus, this observed plasticity 
of CSCs has majorly challenged another primary hypothesis of CSC theory over the 
unidirectional development. This opens a new debate line about the existence of a 
clear separation within CSCs and non-CSCs (Guo et al., 2006). 
Another fundamental paradox regarding CSC theory is that CSCs have to be dormant 
to be resistant to therapy and yet have to proliferate together with normal cancer cells 
to maintain a certain proportion size in tumours. To elucidate this contradiction the 
concept of “cancer stemloids” has been introduced (Wang et al., 2015). According to 
this theory, a part of CSCs are dormant and shielded from selective pressure thus 
unable to drive tumour progression, whereas cancer stemloids are proliferating self-
renewing cells that during clonal evolution accumulate mutations and eventually 
drive tumour progression. This explanation is theoretically important as it provides a 
basis to design therapies to selectively kill CSCs and spare normal resting stem cells. 
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For instance, a combination of stem-cell specific antibodies and anticancer drugs that 
are toxic only to cycling cells could allow targeting proliferating self-renewing CSCs 
(Wang et al., 2015). 
In summary, the current CSC hypothesis is contentious and the controversies may 
remain in the next few years. However, increasing understanding of the fundamental 
biology of CSCs could provide us with a promising opportunity to target tumour 
cells resistant to conventional therapies, as it has been already evidenced in recent 
CSC-related clinical trials (Pannuti et al., 2011; Borah et al., 2015; Takebe et al., 
2015). Nonetheless, in this study, we demonstrated that a CSC population with 
malignant features can be enriched in canine and human INS providing a rationale 
for future targeted INS CSC therapy.  
 
 
6.3    Conclusions and future perspectives 
 
Human and canine malignant INS have similar clinical and pathological features, 
therefore, canine INS was successfully used in this project as a model to study in-
depth human INS carcinogenesis. Using integrative computational approaches, we 
have identified gene signatures characteristic of early and late tumourigenesis of 
malignant canine INS. As a result, novel markers have been investigated for future 
INS target therapy.  
Following a comparative approach, a subpopulation of highly malignant cells has 
been enriched and characterised as CSCs in both human and canine INS.  In vitro 
and in vivo data demonstrated that the Notch pathway could be fundamental for 
maintaining the survival and increasing chemoresistance of the CSC pool in 
malignant human and canine INS. In particular, NOTCH2 and HES1 were 
investigated as markers of INS CSC populations. These markers may have a clinical 
significance and help identify INS patients who would benefit from treatment with 
Notch inhibitors based on the change of these molecular levels. However, 
considering the lack of specificity of the Notch inhibitor currently tested, future 
studies should focus on defining the significance of explicitly targeting either 
NOTCH2 or HES1. Nevertheless, targeting the Notch pathway has exhibited great 
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potential to be an improved treatment for INS and reduce tumour relapse in what is 
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8.1 Canine cell line validation 
 




Figure 8.1 Canine cell line validation using Short-tandem repeat (STR) analysis to 




8.2 Canine cell line characterisation 
 
Figure 8.2 canINS characterisation through RT-PCR. RT-PCR of neuroendocrine transcription 
factor (PDX1) and insulin related genes (INS and IGF2) using GADPH as a loading control 
comparing the primary insulinoma (PI) from which canINS was derived and the adherent canINS 
cell line. 
 
Figure 8.3 Representative pictures of different passages of canINS in adherent (A) and sphere (B) 





8.3 RNA-sequencing data quality analysis 
Figure 8.4 RNA quality check of canine samples using RNA integrity number 
 
Well RIN 28S/18S (Area) Conc(ng/ μl) Sample name 
A0 - - 97.5 Ladder 
A4 6.7 0.9 217 BEN 
B4 6.7 0.3 100 N17 
C4 6.7 1.1 445 D35 
D4 7.0 1.2 258 B13 
F4 6.5 1.2 275 H30 
A1 7.3 1.0 100 W36 
E1 7.9 1.5 130 P3B 
F1 7.5 1.0 168 SmM 
A2 6.6 1.1 144 SnM 
B2 7.0 1.5 490 NP4 
C2 7.8 1.7 185 NP1 
D2 7.7 1.6 225 NP2 
E2 7.9 1.5 240 NP3 
F2 7.5 1.8 386 LN1 
G2 9.2 2.3 354 LN3 




8.4 Differential gene expression of RNA-sequencing data 
 
Figure 8.5 Genes networks interactions and functions of the top differentially expressed 









Table 8.1 Annotated differentially expressed genes in primary canine insulinomas compared to normal canine pancreatic tissues. FC, fold change; 
CPM, count per millions; FDR, false discovery rate4 
GeneID logFC logCPM P-Value FDR Description 
ENSCAFG00000018810 -3.26059 2.710309 5.43E-11 5.95E-07 MKL/myocardin-like 2 [Source:HGNC Symbol;Acc:HGNC:29819] 
ENSCAFG00000032335 5.987148 4.299956 7.38E-11 5.95E-07 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:J9P9F2] 
ENSCAFG00000020276 4.103535 4.414725 1.64E-10 8.84E-07 cysteine-rich, angiogenic inducer, 61 [Source:HGNC Symbol;Acc:HGNC:2654] 
ENSCAFG00000025237 -7.63504 -0.86988 3.54E-10 1.30E-06 carbonic anhydrase III [Source:HGNC Symbol;Acc:HGNC:1374] 
ENSCAFG00000018875 -3.33822 2.475732 4.58E-10 1.30E-06 hook microtubule-tethering protein 1 [Source:HGNC Symbol;Acc:HGNC:19884] 
ENSCAFG00000015657 5.896898 6.408434 4.85E-10 1.30E-06 proprotein convertase subtilisin/kexin type 1 inhibitor [Source:HGNC 
Symbol;Acc:HGNC:17301] 
ENSCAFG00000013945 6.615357 4.825368 7.22E-10 1.66E-06 complement component 1, q subcomponent-like 1 [Source:HGNC 
Symbol;Acc:HGNC:24182] 
ENSCAFG00000006909 5.320692 3.164192 1.21E-09 2.44E-06 LIM domain only 1 [Source:HGNC Symbol;Acc:HGNC:6641] 
ENSCAFG00000031298 -2.92763 2.631921 2.37E-09 3.92E-06 zinc finger with KRAB and SCAN domains 1 [Source:HGNC 
Symbol;Acc:HGNC:13101] 
ENSCAFG00000029490 3.98087 3.425515 2.54E-09 3.92E-06 transmembrane p24 trafficking protein 9 [Source:HGNC 
Symbol;Acc:HGNC:24878] 
ENSCAFG00000015244 4.954428 5.47062 2.77E-09 3.92E-06 protein tyrosine phosphatase, receptor type, N [Source:HGNC 
Symbol;Acc:HGNC:9676] 
ENSCAFG00000001719 6.235457 3.750041 3.32E-09 3.92E-06 paired box 4 [Source:HGNC Symbol;Acc:HGNC:8618] 
                                                 







GeneID logFC logCPM P-Value FDR Description 
ENSCAFG00000013222 4.767875 3.970888 3.39E-09 3.92E-06 myelin transcription factor 1 [Source:HGNC Symbol;Acc:HGNC:7622] 
ENSCAFG00000005173 5.324881 4.467571 3.40E-09 3.92E-06 NK2 homeobox 2 [Source:HGNC Symbol;Acc:HGNC:7835] 
ENSCAFG00000016052 5.504503 4.125219 5.11E-09 5.47E-06 solute carrier family 29 (equilibrative nucleoside transporter), member 4 
[Source:HGNC Symbol;Acc:HGNC:23097] 
ENSCAFG00000001254 4.676927 6.419811 5.43E-09 5.47E-06 early growth response 1 [Source:HGNC Symbol;Acc:HGNC:3238] 
ENSCAFG00000025255 -3.09757 2.802967 6.10E-09 5.78E-06 pseudopodium-enriched atypical kinase 1 [Source:HGNC 
Symbol;Acc:HGNC:29431] 
ENSCAFG00000025442 5.47718 4.802894 7.40E-09 6.63E-06 potassium voltage-gated channel subfamily H member 2  [Source:RefSeq 
peptide;Acc:NP_001003145] 
ENSCAFG00000015146 5.590355 3.787805 7.87E-09 6.68E-06 synapsin I [Source:HGNC Symbol;Acc:HGNC:11494] 
ENSCAFG00000028506 -7.63283 -0.61407 8.93E-09 6.88E-06 Alpha-amylase  [Source:UniProtKB/TrEMBL;Acc:J9P0G7] 
ENSCAFG00000015750 5.153271 3.302478 9.03E-09 6.88E-06 IQ motif and Sec7 domain 3 [Source:HGNC Symbol;Acc:HGNC:29193] 
ENSCAFG00000002964 5.397304 2.443603 9.67E-09 6.88E-06 leucine rich repeat containing 4B [Source:HGNC Symbol;Acc:HGNC:25042] 
ENSCAFG00000001423 5.387739 5.357894 9.90E-09 6.88E-06 copine V [Source:HGNC Symbol;Acc:HGNC:2318] 
ENSCAFG00000001244 5.782502 4.936136 1.02E-08 6.88E-06 receptor accessory protein 2 [Source:HGNC Symbol;Acc:HGNC:17975] 
ENSCAFG00000013663 5.324924 4.432561 1.10E-08 7.07E-06 guanine nucleotide binding protein (G protein), alpha z polypeptide [Source:HGNC 
Symbol;Acc:HGNC:4395] 
ENSCAFG00000032227 4.428743 3.788197 1.14E-08 7.07E-06 olfactomedin 1 [Source:HGNC Symbol;Acc:HGNC:17187] 
ENSCAFG00000008318 5.283127 4.616507 1.28E-08 7.67E-06 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:J9P8N2] 
ENSCAFG00000013851 -2.52668 4.246097 1.42E-08 8.15E-06 FYVE and coiled-coil domain containing 1 [Source:HGNC 
Symbol;Acc:HGNC:14673] 







GeneID logFC logCPM P-Value FDR Description 
ENSCAFG00000030624 -3.40891 2.040184 1.71E-08 8.82E-06 CKLF-like MARVEL transmembrane domain containing 4 [Source:HGNC  
ENSCAFG00000015455 -3.14754 3.283921 1.73E-08 8.82E-06 epithelial cell transforming 2 [Source:HGNC Symbol;Acc:HGNC:3155] 
ENSCAFG00000016991 5.113856 5.226188 1.75E-08 8.82E-06 seizure related 6 homolog (mouse)-like 2 [Source:HGNC 
Symbol;Acc:HGNC:30844] 
ENSCAFG00000011986 -5.28289 0.60902 1.89E-08 9.22E-06 perilipin 1 [Source:HGNC Symbol;Acc:HGNC:9076] 
ENSCAFG00000001292 6.06448 3.739476 2.12E-08 1.01E-05 lymphocyte antigen 6 complex, locus H [Source:HGNC Symbol;Acc:HGNC:6728] 
ENSCAFG00000019290 6.361058 3.855673 2.21E-08 1.02E-05 PDZ domain containing 4 [Source:HGNC Symbol;Acc:HGNC:21167] 
ENSCAFG00000014197 5.402228 4.034561 2.64E-08 1.17E-05 RUN domain containing 3A [Source:HGNC Symbol;Acc:HGNC:16984] 
ENSCAFG00000000272 -2.83921 3.614884 2.70E-08 1.17E-05 ARFGEF family member 3 [Source:HGNC Symbol;Acc:HGNC:21213] 
ENSCAFG00000018423 -3.45153 0.899278 2.76E-08 1.17E-05 integrin subunit alpha 2 [Source:HGNC Symbol;Acc:HGNC:6137] 
ENSCAFG00000012831 5.282994 2.857633 3.04E-08 1.23E-05 cornichon family AMPA receptor auxiliary protein 2 [Source:HGNC 
Symbol;Acc:HGNC:28744] 
ENSCAFG00000028878 5.538705 4.185949 3.12E-08 1.23E-05 - 
ENSCAFG00000002944 5.376577 3.584511 3.13E-08 1.23E-05 glucokinase (hexokinase 4) [Source:HGNC Symbol;Acc:HGNC:4195] 
ENSCAFG00000007115 -2.6593 2.746762 3.63E-08 1.39E-05 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1PKQ8] 
ENSCAFG00000015328 5.467506 5.933879 3.76E-08 1.41E-05 transmembrane protein 130 [Source:HGNC Symbol;Acc:HGNC:25429] 
ENSCAFG00000031922 4.734678 8.743398 3.91E-08 1.42E-05 glutathione peroxidase 3 [Source:HGNC Symbol;Acc:HGNC:4555] 
ENSCAFG00000004315 5.738158 3.266964 3.97E-08 1.42E-05 synapse differentiation inducing 1 [Source:HGNC Symbol;Acc:HGNC:15885] 
ENSCAFG00000000930 -2.77524 3.644007 4.10E-08 1.44E-05 AF4/FMR2 family member 4 [Source:HGNC Symbol;Acc:HGNC:17869] 
ENSCAFG00000016657 5.351262 5.003235 5.25E-08 1.80E-05 cadherin related family member 2 [Source:HGNC Symbol;Acc:HGNC:18231] 
ENSCAFG00000004321 5.468252 5.17912 5.95E-08 1.97E-05 tetraspanin 1 [Source:HGNC Symbol;Acc:HGNC:20657] 







GeneID logFC logCPM P-Value FDR Description 
[Source:HGNC Symbol;Acc:HGNC:946] 
ENSCAFG00000009739 5.829201 2.380679 6.24E-08 1.97E-05 nerve growth factor (beta polypeptide) [Source:HGNC Symbol;Acc:HGNC:7808] 
ENSCAFG00000006915 3.120668 3.693428 6.39E-08 1.98E-05 myotubularin related protein 7 [Source:HGNC Symbol;Acc:HGNC:7454] 
ENSCAFG00000002613 5.927436 4.717845 6.68E-08 2.00E-05 synaptotagmin 5 [Source:HGNC Symbol;Acc:HGNC:11513] 
ENSCAFG00000009428 5.112308 3.627949 6.71E-08 2.00E-05 cyclin and CBS domain divalent metal cation transport mediator 1 [Source:HGNC 
Symbol;Acc:HGNC:102] 
ENSCAFG00000014687 4.890872 5.262421 6.88E-08 2.02E-05 transmembrane protein 59 like [Source:HGNC Symbol;Acc:HGNC:13237] 
ENSCAFG00000004583 7.926904 1.858479 7.11E-08 2.05E-05 RAB37, member RAS oncogene family [Source:HGNC Symbol;Acc:HGNC:30268] 
ENSCAFG00000012005 5.949764 1.216195 7.49E-08 2.12E-05 prolactin releasing hormone receptor [Source:HGNC Symbol;Acc:HGNC:4464] 
ENSCAFG00000006660 -3.24531 4.226864 7.80E-08 2.16E-05 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 
[Source:HGNC Symbol;Acc:HGNC:11057] 
ENSCAFG00000028604 5.777008 5.1772 7.89E-08 2.16E-05 V-set and transmembrane domain containing 2 like [Source:HGNC 
Symbol;Acc:HGNC:16096] 
ENSCAFG00000014996 6.002361 1.261288 8.11E-08 2.16E-05 cyclin-dependent kinase 5, regulatory subunit 2 (p39) [Source:HGNC 
Symbol;Acc:HGNC:1776] 
ENSCAFG00000012987 5.255455 4.836488 8.19E-08 2.16E-05 potassium channel, voltage gated eag related subfamily H, member 6 
[Source:HGNC Symbol;Acc:HGNC:18862] 
ENSCAFG00000009820 -4.61177 0.611095 8.51E-08 2.21E-05 nitric oxide synthase 1 [Source:HGNC Symbol;Acc:HGNC:7872] 
ENSCAFG00000004385 5.569835 4.287522 9.07E-08 2.32E-05 otoferlin [Source:HGNC Symbol;Acc:HGNC:8515] 
ENSCAFG00000010382 4.679916 3.484436 9.45E-08 2.35E-05 amyloid beta (A4) precursor protein-binding, family A, member 2 [Source:HGNC 
Symbol;Acc:HGNC:579] 







GeneID logFC logCPM P-Value FDR Description 
ENSCAFG00000014627 -6.55084 3.236627 9.71E-08 2.35E-05 Elongation factor 1-alpha  [Source:UniProtKB/TrEMBL;Acc:F2Z4P4] 
ENSCAFG00000016186 4.596511 9.513824 9.97E-08 2.35E-05 secretogranin II [Source:HGNC Symbol;Acc:HGNC:10575] 
ENSCAFG00000032120 5.404698 3.694562 1.00E-07 2.35E-05 C1q and tumor necrosis factor related protein 6 [Source:HGNC 
Symbol;Acc:HGNC:14343] 
ENSCAFG00000018170 -2.62326 4.362235 1.00E-07 2.35E-05 insulin receptor [Source:HGNC Symbol;Acc:HGNC:6091] 
ENSCAFG00000017133 5.303563 1.927711 1.08E-07 2.49E-05 - 
ENSCAFG00000010559 4.973056 6.819662 1.11E-07 2.49E-05 secretagogin, EF-hand calcium binding protein [Source:HGNC 
Symbol;Acc:HGNC:16941] 
ENSCAFG00000010175 4.644821 3.690634 1.11E-07 2.49E-05 cadherin 22, type 2 [Source:HGNC Symbol;Acc:HGNC:13251] 
ENSCAFG00000004865 3.891504 3.299405 1.14E-07 2.52E-05 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily d, member 3 [Source:HGNC Symbol;Acc:HGNC:11108] 
ENSCAFG00000012810 5.620443 1.269393 1.15E-07 2.52E-05 transmembrane protein 151A [Source:HGNC Symbol;Acc:HGNC:28497] 
ENSCAFG00000010872 4.84071 1.941841 1.18E-07 2.55E-05 adhesion G protein-coupled receptor B2 [Source:HGNC Symbol;Acc:HGNC:944] 
ENSCAFG00000012794 5.095502 5.58296 1.22E-07 2.59E-05 CUGBP, Elav-like family member 3 [Source:HGNC Symbol;Acc:HGNC:11967] 
ENSCAFG00000005988 4.582952 8.188557 1.33E-07 2.79E-05 chromogranin B [Source:HGNC Symbol;Acc:HGNC:1930] 
ENSCAFG00000019362 4.636094 5.659348 1.40E-07 2.89E-05 L1 cell adhesion molecule [Source:HGNC Symbol;Acc:HGNC:6470] 
ENSCAFG00000009873 -3.02732 3.605554 1.47E-07 3.00E-05 mannosidase, alpha, class 1A, member 2 [Source:HGNC Symbol;Acc:HGNC:6822] 
ENSCAFG00000015290 -2.95776 0.931148 1.53E-07 3.09E-05 SFT2 domain containing 2 [Source:HGNC Symbol;Acc:HGNC:25140] 
ENSCAFG00000004443 4.9168 3.414682 1.56E-07 3.12E-05 FBJ murine osteosarcoma viral oncogene homolog B [Source:HGNC 
Symbol;Acc:HGNC:3797] 
ENSCAFG00000019956 4.391637 3.34165 1.70E-07 3.34E-05 WAP four-disulfide core domain 1 [Source:HGNC Symbol;Acc:HGNC:15466] 







GeneID logFC logCPM P-Value FDR Description 
ENSCAFG00000018827 -2.62718 2.782322 1.94E-07 3.72E-05 excision repair cross-complementation group 4 [Source:HGNC  
ENSCAFG00000005605 3.930913 3.111339 2.08E-07 3.87E-05 RELT tumor necrosis factor receptor [Source:HGNC Symbol;Acc:HGNC:13764] 
ENSCAFG00000014882 4.528802 0.524189 2.08E-07 3.87E-05 growth differentiation factor 15 [Source:HGNC Symbol;Acc:HGNC:30142] 
ENSCAFG00000014822 -2.52339 3.317045 2.09E-07 3.87E-05 SECIS binding protein 2-like [Source:HGNC Symbol;Acc:HGNC:28997] 
ENSCAFG00000016405 3.797384 4.46976 2.13E-07 3.91E-05 transmembrane protein 132A [Source:HGNC Symbol;Acc:HGNC:31092] 
ENSCAFG00000013694 -5.16554 0.693649 2.28E-07 4.12E-05 adiponectin, C1Q and collagen domain containing [Source:HGNC 
Symbol;Acc:HGNC:13633] 
ENSCAFG00000020033 -4.18796 -1.11328 2.32E-07 4.12E-05 C-type lectin domain family 3 member A [Source:HGNC 
Symbol;Acc:HGNC:2052] 
ENSCAFG00000000915 5.265739 4.704253 2.32E-07 4.12E-05 regulatory factor X6 [Source:HGNC Symbol;Acc:HGNC:21478] 
ENSCAFG00000006944 -3.03063 2.83843 2.37E-07 4.13E-05 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 
[Source:HGNC Symbol;Acc:HGNC:11060] 
ENSCAFG00000029607 3.604868 3.690097 2.38E-07 4.13E-05 syntaxin binding protein 6 (amisyn) [Source:HGNC Symbol;Acc:HGNC:19666] 
ENSCAFG00000028566 4.620689 3.217499 2.41E-07 4.14E-05 neurensin 1 [Source:HGNC Symbol;Acc:HGNC:17881] 
ENSCAFG00000020398 -2.89941 1.948053 2.48E-07 4.20E-05 pyruvate dehyrogenase phosphatase catalytic subunit 2 [Source:HGNC 
Symbol;Acc:HGNC:30263] 
ENSCAFG00000007029 4.855321 4.662147 2.54E-07 4.26E-05 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E2RC57] 
ENSCAFG00000014603 4.684328 2.734413 2.59E-07 4.31E-05 tripartite motif containing 9 [Source:HGNC Symbol;Acc:HGNC:16288] 
ENSCAFG00000019623 4.811981 4.120328 2.66E-07 4.38E-05 F-box and leucine-rich repeat protein 16 [Source:HGNC 
Symbol;Acc:HGNC:14150] 
ENSCAFG00000016019 3.020809 4.03316 2.75E-07 4.47E-05 fatty acid desaturase 2 [Source:HGNC Symbol;Acc:HGNC:3575] 







GeneID logFC logCPM P-Value FDR Description 
ENSCAFG00000019574 5.181725 3.329141 3.05E-07 4.83E-05 acyl-CoA thioesterase 7 [Source:HGNC Symbol;Acc:HGNC:24157] 
ENSCAFG00000010548 4.410438 5.522616 3.05E-07 4.83E-05 delta/notch like EGF repeat containing [Source:HGNC Symbol;Acc:HGNC:24456] 
ENSCAFG00000031669 3.905592 2.513455 3.09E-07 4.84E-05 cannabinoid receptor interacting protein 1 [Source:HGNC 
Symbol;Acc:HGNC:24546] 
ENSCAFG00000013037 4.684318 4.895024 3.20E-07 4.96E-05 guanylate cyclase 2C [Source:HGNC Symbol;Acc:HGNC:4688] 
ENSCAFG00000014257 4.663591 3.574601 3.26E-07 5.01E-05 protein phosphatase 2 regulatory subunit B, gamma [Source:HGNC 
Symbol;Acc:HGNC:9306] 
ENSCAFG00000005264 5.021629 2.616905 3.40E-07 5.17E-05 insulinoma associated 1 [Source:HGNC Symbol;Acc:HGNC:6090] 
ENSCAFG00000001815 -4.47388 1.121664 3.88E-07 5.80E-05 guanine deaminase [Source:HGNC Symbol;Acc:HGNC:4212] 
ENSCAFG00000014302 5.121032 2.394708 3.88E-07 5.80E-05 actin like 6B [Source:HGNC Symbol;Acc:HGNC:160] 
ENSCAFG00000029950 5.168064 2.468404 4.07E-07 6.03E-05 protein kinase (cAMP-dependent, catalytic) inhibitor beta [Source:HGNC 
Symbol;Acc:HGNC:9018] 
ENSCAFG00000002951 4.559632 3.189683 4.12E-07 6.04E-05 synaptosome associated protein 91kDa [Source:HGNC Symbol;Acc:HGNC:14986] 
ENSCAFG00000014243 3.511697 3.267092 4.46E-07 6.48E-05 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:H9GWE1] 
ENSCAFG00000014639 3.338963 4.475065 4.54E-07 6.53E-05 complement component 1, q subcomponent, C chain [Source:HGNC 
Symbol;Acc:HGNC:1245] 
ENSCAFG00000011742 3.770207 2.910382 4.70E-07 6.66E-05 pleckstrin homology domain containing O1 [Source:HGNC 
Symbol;Acc:HGNC:24310] 
ENSCAFG00000014583 5.032874 2.428702 4.71E-07 6.66E-05 carboxypeptidase Z [Source:HGNC Symbol;Acc:HGNC:2333] 
ENSCAFG00000018854 4.82356 2.686925 4.91E-07 6.87E-05 seizure related 6 homolog (mouse) [Source:HGNC Symbol;Acc:HGNC:15955] 








GeneID logFC logCPM P-Value FDR Description 
ENSCAFG00000010476 -3.19988 3.995097 5.17E-07 6.94E-05 notch 2 [Source:HGNC Symbol;Acc:HGNC:7882] 
ENSCAFG00000005250 6.605866 3.784714 5.20E-07 6.94E-05 urocortin 3 [Source:HGNC Symbol;Acc:HGNC:17781] 





Figure 8.6 Genes networks interactions and functions of the top differentially expressed 









Table 8.2 Annotated differentially expressed genes in primary insulinoma against metastatic lymph nodes. FC, fold change; CPM, count per 
millions; FDR, false discovery rate.5 
GeneID logFC logCPM PValue FDR Description 
ENSCAFG00000000090 5.413538 4.136216 4.47E-08 0.00074 melanocortin 4 receptor [Source:HGNC Symbol;Acc:HGNC:6932] 
ENSCAFG00000002118 3.278324 5.750329 1.52E-07 0.001253 paraoxonase 3 [Source:HGNC Symbol;Acc:HGNC:9206] 
ENSCAFG00000005293 6.312874 3.071982 5.10E-07 0.002811 SLIT and NTRK like family member 5 [Source:HGNC Symbol;Acc:HGNC:20295] 
ENSCAFG00000008768 6.851048 0.794369 9.94E-07 0.004109 glutamate receptor, ionotropic, kainate 1 [Source:HGNC Symbol;Acc:HGNC:4579] 
ENSCAFG00000014225 4.685339 8.663584 1.46E-06 0.004835 pappalysin 2 [Source:HGNC Symbol;Acc:HGNC:14615] 
ENSCAFG00000013123 5.741419 0.096028 2.33E-06 0.005117 family with sequence similarity 196 member A [Source:HGNC 
Symbol;Acc:HGNC:33859] 
ENSCAFG00000020380 4.127214 3.642315 2.69E-06 0.005117 adenylate kinase 5 [Source:HGNC Symbol;Acc:HGNC:365] 
ENSCAFG00000018593 3.34194 2.521036 2.69E-06 0.005117 phosphatidylinositol-specific phospholipase C, X domain containing 3 
[Source:HGNC Symbol;Acc:HGNC:31822] 
ENSCAFG00000011356 3.302773 8.007952 3.41E-06 0.005117 von Willebrand factor A domain containing 5A [Source:HGNC 
Symbol;Acc:HGNC:6658] 
ENSCAFG00000007775 2.963817 3.807721 3.64E-06 0.005117 nuclear receptor coactivator 2 [Source:HGNC Symbol;Acc:HGNC:7669] 
ENSCAFG00000008867 -5.97914 4.005739 3.68E-06 0.005117 inter-alpha-trypsin inhibitor heavy chain 1 [Source:HGNC Symbol;Acc:HGNC:6166] 
ENSCAFG00000003494 4.978143 1.432672 4.00E-06 0.005117 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 [Source:HGNC 
Symbol;Acc:HGNC:22195] 
ENSCAFG00000023437 -8.40857 4.737752 4.02E-06 0.005117 SEC14-like lipid binding 4 [Source:HGNC Symbol;Acc:HGNC:20627] 
                                                 







GeneID logFC logCPM PValue FDR Description 
ENSCAFG00000005689 3.366323 3.815815 4.59E-06 0.005424 neuronal pentraxin I [Source:HGNC Symbol;Acc:HGNC:7952] 
ENSCAFG00000000834 3.551235 5.440746 5.59E-06 0.005778 tumor necrosis factor receptor superfamily member 11b [Source:HGNC 
Symbol;Acc:HGNC:11909] 
ENSCAFG00000018448 7.275648 4.189348 8.60E-06 0.008368 immunoglobulin heavy constant epsilon [Source:HGNC Symbol;Acc:HGNC:5522] 
ENSCAFG00000009984 8.821599 0.795789 9.71E-06 0.008524 T-box, brain 1 [Source:HGNC Symbol;Acc:HGNC:11590] 
ENSCAFG00000019160 8.024146 3.719553 9.88E-06 0.008524 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:L7N0I5] 
ENSCAFG00000010339 -8.31121 8.304282 1.08E-05 0.008524 transcobalamin 1 [Source:HGNC Symbol;Acc:HGNC:11652] 
ENSCAFG00000010014 8.132274 0.155571 1.12E-05 0.008524 zona pellucida glycoprotein 4 [Source:HGNC Symbol;Acc:HGNC:15770] 
ENSCAFG00000023580 5.618274 0.18747 1.16E-05 0.008524 - 
ENSCAFG00000009850 5.187896 3.02403 1.19E-05 0.008524 dynein, axonemal, heavy chain 5 [Source:HGNC Symbol;Acc:HGNC:2950] 
ENSCAFG00000004299 2.637691 4.71848 1.41E-05 0.009741 glutamate decarboxylase 2 [Source:HGNC Symbol;Acc:HGNC:4093] 
ENSCAFG00000011587 -6.45235 3.783893 1.63E-05 0.010777 neuronal guanine nucleotide exchange factor [Source:HGNC 
Symbol;Acc:HGNC:7807] 
ENSCAFG00000008126 -11.4968 9.152697 1.82E-05 0.011555 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1PZN8] 
ENSCAFG00000013221 5.94448 -0.22337 2.10E-05 0.012843 - 
ENSCAFG00000002342 2.787659 4.981553 2.39E-05 0.012854 ets variant 1 [Source:HGNC Symbol;Acc:HGNC:3490] 
ENSCAFG00000002540 -7.69326 5.71575 2.40E-05 0.012854 claudin 19 [Source:HGNC Symbol;Acc:HGNC:2040] 
ENSCAFG00000009975 3.869341 2.941773 2.40E-05 0.012854 solute carrier family 2 (facilitated glucose transporter), member 13 [Source:HGNC 
Symbol;Acc:HGNC:15956] 
ENSCAFG00000009258 4.222116 2.142936 2.50E-05 0.012854 cytohesin 1 interacting protein [Source:HGNC Symbol;Acc:HGNC:9506] 
ENSCAFG00000005603 3.445453 3.535069 2.60E-05 0.012854 isthmin 1, angiogenesis inhibitor [Source:HGNC Symbol;Acc:HGNC:16213] 







GeneID logFC logCPM PValue FDR Description 
ENSCAFG00000008164 3.598028 0.685451 2.64E-05 0.012854 transmembrane protein 154 [Source:HGNC Symbol;Acc:HGNC:26489] 
ENSCAFG00000009941 -6.09444 1.85253 4.03E-05 0.018493 stathmin domain containing 1 [Source:HGNC Symbol;Acc:HGNC:44668] 
ENSCAFG00000000487 2.76762 9.685715 4.29E-05 0.019178 MHC class I DLA-88 precursor  [Source:RefSeq peptide;Acc:NP_001014767] 
ENSCAFG00000007008 3.069456 1.762053 4.50E-05 0.0196 RAB3C, member RAS oncogene family [Source:HGNC Symbol;Acc:HGNC:30269] 
ENSCAFG00000016479 -3.59055 4.969102 4.88E-05 0.020668 transmembrane protein 184A [Source:HGNC Symbol;Acc:HGNC:28797] 
ENSCAFG00000029145 6.409748 5.569631 5.17E-05 0.020668 prokineticin receptor 1 [Source:HGNC Symbol;Acc:HGNC:4524] 
ENSCAFG00000009232 4.371116 6.030789 5.25E-05 0.020668 adhesion molecule with Ig-like domain 2 [Source:HGNC Symbol;Acc:HGNC:24073] 
ENSCAFG00000016056 7.371578 0.001948 5.25E-05 0.020668 chromosome X open reading frame 67 [Source:HGNC Symbol;Acc:HGNC:33738] 
ENSCAFG00000023899 7.285858 1.596778 5.40E-05 0.020703 carcinoembryonic antigen-related cell adhesion molecule 20 [Source:HGNC 
Symbol;Acc:HGNC:24879] 
ENSCAFG00000018785 6.821707 3.162634 5.52E-05 0.020703 Rho GTPase activating protein 36 [Source:HGNC Symbol;Acc:HGNC:26388] 
ENSCAFG00000011716 2.985608 1.788362 5.78E-05 0.020703 ubiquitin associated and SH3 domain containing B 
[Source:HGNCSymbol;Acc:HGNC:29884] 
ENSCAFG00000014154 -3.04355 4.453639 5.94E-05 0.020703 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1PRT9] 
ENSCAFG00000001727 4.703709 1.120523 5.99E-05 0.020703 leucine rich repeat and Ig domain containing 2 [Source:HGNC 
Symbol;Acc:HGNC:21207] 
ENSCAFG00000000681 4.015662 4.133856 6.01E-05 0.020703 fibrillin 2 [Source:HGNC Symbol;Acc:HGNC:3604] 
ENSCAFG00000010858 3.265506 5.144436 6.41E-05 0.021508 limbic system-associated membrane protein [Source:HGNC 
Symbol;Acc:HGNC:6705] 
ENSCAFG00000031149 3.298262 4.766274 6.50E-05 0.021508 lymphocyte transmembrane adaptor 1 [Source:HGNC Symbol;Acc:HGNC:26005] 
ENSCAFG00000008130 -10.6671 7.837529 7.04E-05 0.02283 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1PZN8] 







GeneID logFC logCPM PValue FDR Description 
ENSCAFG00000000473 6.14522 -0.25471 7.49E-05 0.023385 thyrotropin-releasing hormone degrading enzyme [Source:HGNC  
ENSCAFG00000008692 4.853102 3.465914 8.30E-05 0.02421 chemokine (C-X-C motif) ligand 13 [Source:HGNC Symbol;Acc:HGNC:10639] 
ENSCAFG00000025531 5.298697 2.67068 8.31E-05 0.02421 contactin associated protein-like 2 [Source:HGNC Symbol;Acc:HGNC:13830] 
ENSCAFG00000005583 5.754361 1.142792 8.39E-05 0.02421 glutamate receptor, metabotropic 7 [Source:HGNC Symbol;Acc:HGNC:4599] 
ENSCAFG00000007728 2.449113 6.030118 8.49E-05 0.02421 solute carrier family 4, sodium bicarbonate cotransporter, member 8 [Source:HGNC 
Symbol;Acc:HGNC:11034] 
ENSCAFG00000000492 4.627745 3.663675 8.65E-05 0.024258 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1PE31] 
ENSCAFG00000013988 6.096607 -1.52843 8.83E-05 0.024319 KIAA1024 [Source:HGNC Symbol;Acc:HGNC:29172] 
ENSCAFG00000008467 3.155912 5.325941 8.97E-05 0.024319 EGF-like repeats and discoidin I-like domains 3 [Source:HGNC 
Symbol;Acc:HGNC:3173] 
ENSCAFG00000029100 -9.6037 4.478581 9.44E-05 0.025188 ripply transcriptional repressor 1 [Source:HGNC Symbol;Acc:HGNC:25117] 
ENSCAFG00000017080 -11.1816 2.825372 0.000101 0.026348 epsin 3 [Source:HGNC Symbol;Acc:HGNC:18235] 
ENSCAFG00000017480 -9.34709 9.167655 0.000102 0.026348 aquaporin 8 [Source:HGNC Symbol;Acc:HGNC:642] 
ENSCAFG00000002028 2.619021 5.140393 0.00011 0.027179 very low density lipoprotein receptor [Source:HGNC Symbol;Acc:HGNC:12698] 
ENSCAFG00000002498 2.632324 2.811878 0.000112 0.027179 histone deacetylase 9 [Source:HGNC Symbol;Acc:HGNC:14065] 
ENSCAFG00000010414 -8.39131 4.716021 0.000112 0.027179 glucagon [Source:HGNC Symbol;Acc:HGNC:4191] 
ENSCAFG00000001927 6.496054 -2.10774 0.000112 0.027179 transmembrane protein 252 [Source:HGNC Symbol;Acc:HGNC:28537] 
ENSCAFG00000023647 -8.38703 5.131435 0.000115 0.027504 keratin 19, type I [Source:HGNC Symbol;Acc:HGNC:6436] 
ENSCAFG00000002095 7.871758 -1.12118 0.000116 0.027504 adhesion G protein-coupled receptor F4 [Source:HGNC Symbol;Acc:HGNC:19011] 
ENSCAFG00000015429 -8.5549 10.44299 0.000124 0.028987 protein disulfide isomerase family A member 2 [Source:HGNC 
Symbol;Acc:HGNC:14180] 







GeneID logFC logCPM PValue FDR Description 
ENSCAFG00000000131 -6.09334 5.804107 0.000135 0.030577 glutaminase 2 [Source:HGNC Symbol;Acc:HGNC:29570] 
ENSCAFG00000003703 2.412112 2.746102 0.000145 0.032055 SET domain containing (lysine methyltransferase) 7 [Source:HGNC 
Symbol;Acc:HGNC:30412] 
ENSCAFG00000030890 4.990546 -0.19279 0.000148 0.032207 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:J9P455] 
ENSCAFG00000002402 3.94871 -0.35047 0.000154 0.032988 diacylglycerol kinase beta [Source:HGNC Symbol;Acc:HGNC:2850] 
ENSCAFG00000018877 -7.26956 4.011299 0.00016 0.033077 natriuretic peptide receptor 3 [Source:HGNC Symbol;Acc:HGNC:7945] 
ENSCAFG00000005057 -7.30316 5.274069 0.000162 0.033077 inter-alpha-trypsin inhibitor heavy chain 2 [Source:HGNC Symbol;Acc:HGNC:6167] 
ENSCAFG00000012609 -9.12612 12.37093 0.000165 0.033077 CUB and zona pellucida-like domains 1 [Source:HGNC Symbol;Acc:HGNC:17937] 
ENSCAFG00000007124 -9.12834 7.118399 0.000165 0.033077 FXYD domain containing ion transport regulator 3 [Source:HGNC 
Symbol;Acc:HGNC:4027] 
ENSCAFG00000008874 2.196825 5.330629 0.000167 0.033077 hormonally up-regulated Neu-associated kinase [Source:HGNC 
Symbol;Acc:HGNC:13326] 
ENSCAFG00000002914 -9.0375 11.92677 0.000168 0.033077 kallikrein-1 precursor  [Source:RefSeq peptide;Acc:NP_001003262] 
ENSCAFG00000010901 3.735649 2.441554 0.000172 0.033077 fatty acyl-CoA reductase 2 [Source:HGNC Symbol;Acc:HGNC:25531] 
ENSCAFG00000016373 -8.00219 3.969844 0.000173 0.033077 arylacetamide deacetylase-like 4 [Source:HGNC Symbol;Acc:HGNC:32038] 
ENSCAFG00000016301 -8.88686 16.30217 0.000174 0.033077 chymotrypsin C [Source:HGNC Symbol;Acc:HGNC:2523] 
ENSCAFG00000029087 -7.49504 5.156802 0.000175 0.033077 GATA binding protein 4 [Source:HGNC Symbol;Acc:HGNC:4173] 
ENSCAFG00000004446 2.102584 5.044488 0.000177 0.033077 transmembrane protein 43 [Source:HGNC Symbol;Acc:HGNC:28472] 
ENSCAFG00000020084 -8.72137 16.10934 0.000178 0.033077 Chymotrypsinogen 2 Chymotrypsin 2 chain A Chymotrypsin 2 chain B Chymotrypsin 
2 chain C [Source:UniProtKB/Swiss-Prot;Acc:P04813] 
ENSCAFG00000019267 -9.32712 12.71248 0.000182 0.033444 deoxyribonuclease I [Source:HGNC Symbol;Acc:HGNC:2956] 







GeneID logFC logCPM PValue FDR Description 
ENSCAFG00000014733 -8.84092 15.94977 0.000189 0.034024 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1PI75] 
ENSCAFG00000010348 -8.86952 4.227818 0.000195 0.034024 trefoil factor 3 [Source:HGNC Symbol;Acc:HGNC:11757] 
ENSCAFG00000005458 -7.19894 5.754844 0.000195 0.034024 claudin 10 [Source:HGNC Symbol;Acc:HGNC:2033] 
ENSCAFG00000014481 -8.7263 16.38149 0.000202 0.03415 Anionic trypsin  [Source:UniProtKB/Swiss-Prot;Acc:P06872] 
ENSCAFG00000012561 -9.85081 7.170177 0.000203 0.03415 deleted in malignant brain tumors 1 [Source:HGNC Symbol;Acc:HGNC:2926] 
ENSCAFG00000020083 -9.5441 14.46867 0.000205 0.03415 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E2RSM7] 
ENSCAFG00000025016 3.178023 0.657592 0.000205 0.03415 C-X-C motif chemokine  [Source:UniProtKB/TrEMBL;Acc:F1PMC0] 
ENSCAFG00000007893 -4.8334 4.213767 0.000206 0.03415 retinol binding protein 4 [Source:HGNC Symbol;Acc:HGNC:9922] 
ENSCAFG00000003429 -8.94569 4.988933 0.000213 0.034841 cystic fibrosis transmembrane conductance regulator [Source:HGNC 
Symbol;Acc:HGNC:1884] 
ENSCAFG00000016065 -4.43835 7.516535 0.000226 0.036621 60S ribosomal protein L6  [Source:UniProtKB/TrEMBL;Acc:F1Q424] 
ENSCAFG00000015753 -10.3318 1.981585 0.000229 0.036759 surfactant protein D [Source:HGNC Symbol;Acc:HGNC:10803] 
ENSCAFG00000011175 -5.71392 3.737615 0.000232 0.036836 Na+/K+ transporting ATPase interacting 1 [Source:HGNC 
Symbol;Acc:HGNC:25743] 
ENSCAFG00000007686 3.765447 -0.12012 0.00024 0.03778 solute carrier organic anion transporter family member 5A1 [Source:HGNC 
Symbol;Acc:HGNC:19046] 
ENSCAFG00000009670 -7.78503 5.876514 0.000245 0.038148 recombination signal binding protein for immunoglobulin kappa J region-like 
[Source:HGNC Symbol;Acc:HGNC:13761] 
ENSCAFG00000024968 -8.64783 15.03396 0.00025 0.038414 carboxypeptidase A1 [Source:HGNC Symbol;Acc:HGNC:2296] 
ENSCAFG00000000868 -3.58541 6.199531 0.000251 0.038414 SPARC related modular calcium binding 2 [Source:HGNC 
Symbol;Acc:HGNC:20323] 







GeneID logFC logCPM PValue FDR Description 
ENSCAFG00000008893 -6.77198 0.808194 0.00026 0.038875 ventricular zone expressed PH domain containing 1 [Source:HGNC  
ENSCAFG00000025473 -8.45197 15.23339 0.000263 0.038875 carboxypeptidase A4 [Source:HGNC Symbol;Acc:HGNC:15740] 
ENSCAFG00000017615 2.631327 2.328871 0.000273 0.038875 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 [Source:HGNC 
Symbol;Acc:HGNC:17827] 
ENSCAFG00000013291 -5.18413 6.23609 0.000274 0.038875 -  
ENSCAFG00000019801 -5.68514 7.369966 0.000274 0.038875 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:E2R5E9] 
ENSCAFG00000003075 6.611216 2.93008 0.000278 0.038875 amphiregulin [Source:HGNC Symbol;Acc:HGNC:651] 
ENSCAFG00000009696 -5.5737 6.616194 0.000278 0.038875 WAP four-disulfide core domain 2 [Source:HGNC Symbol;Acc:HGNC:15939] 
ENSCAFG00000024988 -3.31959 3.184731 0.000279 0.038875 frizzled-related protein [Source:HGNC Symbol;Acc:HGNC:3959] 
ENSCAFG00000017191 2.909902 2.014403 0.00028 0.038875 transmembrane p24 trafficking protein family member 8 [Source:HGNC 
Symbol;Acc:HGNC:18633] 
ENSCAFG00000029139 5.060855 -0.73334 0.000285 0.038997 sodium channel, voltage gated, type XI alpha subunit [Source:HGNC 
Symbol;Acc:HGNC:10583] 
ENSCAFG00000010325 -8.53467 9.712077 0.000285 0.038997 gastric intrinsic factor [Source:HGNC Symbol;Acc:HGNC:4268] 
ENSCAFG00000015860 -8.53321 3.623894 0.000289 0.039138 secretoglobin, family 1A, member 1 (uteroglobin) [Source:HGNC 
Symbol;Acc:HGNC:12523] 
ENSCAFG00000008226 -8.86108 15.05102 0.000291 0.039138 carboxypeptidase B precursor  [Source:RefSeq peptide;Acc:NP_001003005] 
ENSCAFG00000012892 -8.50389 8.42447 0.000295 0.039281 endoplasmic reticulum protein 27 [Source:HGNC Symbol;Acc:HGNC:26495] 
ENSCAFG00000008319 3.333094 -0.32058 0.000301 0.039495 chondrolectin [Source:HGNC Symbol;Acc:HGNC:17807] 
ENSCAFG00000031298 2.296518 3.02524 0.000305 0.039495 zinc finger with KRAB and SCAN domains 1 [Source:HGNC 
Symbol;Acc:HGNC:13101] 







GeneID logFC logCPM PValue FDR Description 
peptide;Acc:NP_001010954] 
ENSCAFG00000008670 2.212305 5.555275 0.000309 0.03965 protein tyrosine kinase 2 beta [Source:HGNC Symbol;Acc:HGNC:9612] 
ENSCAFG00000009330 2.685463 2.939346 0.000323 0.041094 synaptic vesicle glycoprotein 2C [Source:HGNC Symbol;Acc:HGNC:30670] 
ENSCAFG00000000587 -6.63255 3.095562 0.000331 0.041735 grainyhead-like transcription factor 2 [Source:HGNC Symbol;Acc:HGNC:2799] 
ENSCAFG00000011852 -8.54384 15.71782 0.000343 0.04279 pancreatic lipase-related protein 1 [Source:HGNC Symbol;Acc:HGNC:9156] 
ENSCAFG00000006647 -8.55149 11.03874 0.000344 0.04279 serine peptidase inhibitor, Kazal type 1 [Source:HGNC Symbol;Acc:HGNC:11244] 
ENSCAFG00000014536 -8.809 9.225646 0.00035 0.043207 serpin peptidase inhibitor, clade I (pancpin), member 2 [Source:HGNC 
Symbol;Acc:HGNC:8945] 
ENSCAFG00000010349 -8.1587 9.84284 0.000358 0.043816 trefoil factor 2 [Source:HGNC Symbol;Acc:HGNC:11756] 
ENSCAFG00000003818 -8.8074 16.51734 0.000367 0.044113 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1PCE8] 
ENSCAFG00000019238 -4.53596 6.730212 0.000367 0.044113 matrix metallopeptidase 23B [Source:HGNC Symbol;Acc:HGNC:7171] 
ENSCAFG00000023682 2.447999 1.860781 0.000368 0.044113 protocadherin gamma subfamily A, 1 [Source:HGNC Symbol;Acc:HGNC:8696] 
ENSCAFG00000017061 7.040803 -1.71466 0.000385 0.045169 outer dense fiber of sperm tails 4 [Source:HGNC Symbol;Acc:HGNC:19056] 
ENSCAFG00000028653 -10.1301 7.801111 0.000385 0.045169 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:J9NST6] 
ENSCAFG00000010375 -5.14177 1.117658 0.000386 0.045169 alpha 1,3-galactosyltransferase 2 [Source:HGNC Symbol;Acc:HGNC:30005] 
ENSCAFG00000024895 5.662521 -1.66278 0.000392 0.045169 Olfactory receptor  [Source:UniProtKB/TrEMBL;Acc:F1PTA0] 
ENSCAFG00000018023 -8.53712 14.30157 0.000392 0.045169 glycoprotein 2 (zymogen granule membrane) [Source:HGNC 
Symbol;Acc:HGNC:4441] 
ENSCAFG00000011446 2.319016 3.119531 0.000395 0.045169 ubiquitin specific peptidase 13 (isopeptidase T-3) [Source:HGNC 
Symbol;Acc:HGNC:12611] 
ENSCAFG00000024062 -8.40878 9.066328 0.000396 0.045169 Uncharacterized protein  [Source:UniProtKB/TrEMBL;Acc:F1PAB0] 







GeneID logFC logCPM PValue FDR Description 
ENSCAFG00000005426 3.645683 5.652025 0.000402 0.04524 ribonuclease, RNase A family, 4 [Source:HGNC Symbol;Acc:HGNC:10047] 
ENSCAFG00000002064 4.63158 1.203302 0.000408 0.045301 solute carrier family 5 (sodium/choline cotransporter), member 7 [Source:HGNC 
Symbol;Acc:HGNC:14025] 
ENSCAFG00000008093 -5.41801 4.39659 0.000414 0.045334 4-hydroxyphenylpyruvate dioxygenase [Source:HGNC Symbol;Acc:HGNC:5147] 
ENSCAFG00000023446 -6.36399 3.745458 0.000414 0.045334 fructose-bisphosphatase 2 [Source:HGNC Symbol;Acc:HGNC:3607] 
ENSCAFG00000011815 -8.40678 15.69088 0.000424 0.046114 pancreatic lipase [Source:HGNC Symbol;Acc:HGNC:9155] 
ENSCAFG00000020334 -8.86682 13.97005 0.000427 0.046186 chymotrypsin-like [Source:HGNC Symbol;Acc:HGNC:2524] 
ENSCAFG00000015984 6.230282 -0.5904 0.000432 0.04639 A-kinase anchoring protein 4 [Source:HGNC Symbol;Acc:HGNC:374] 
ENSCAFG00000003833 -2.64966 4.687933 0.000444 0.047369 syndecan 1 [Source:HGNC Symbol;Acc:HGNC:10658] 
ENSCAFG00000017147 2.221196 4.250376 0.000448 0.047458 angel homolog 1 (Drosophila) [Source:HGNC Symbol;Acc:HGNC:19961] 
ENSCAFG00000007862 -4.79146 6.154264 0.000451 0.047458 solute carrier family 43 (amino acid system L transporter), member 1 [Source:HGNC 
Symbol;Acc:HGNC:9225] 
ENSCAFG00000018597 -5.46868 2.662824 0.000459 0.048028 laminin subunit alpha 1 [Source:HGNC Symbol;Acc:HGNC:6481] 
ENSCAFG00000028559 -8.45186 4.229013 0.000464 0.048256 solute carrier family 25 member 45 [Source:HGNC Symbol;Acc:HGNC:27442] 
ENSCAFG00000012675 -3.61044 4.566662 0.000477 0.049275 selenium binding protein 1 [Source:HGNC Symbol;Acc:HGNC:10719] 
ENSCAFG00000009859 3.304718 -0.39781 0.000482 0.049389 GPRIN family member 3 [Source:HGNC Symbol;Acc:HGNC:27733] 
ENSCAFG00000019872 -8.00404 15.55308 0.000484 0.049389 carboxyl ester lipase [Source:HGNC Symbol;Acc:HGNC:1848] 








Table 8.3 Differentially expressed genes common within the three dataset. logFC, fold change6 




















VWA5A von Willebrand factor A 
domain containing 5A  
Glycoprotein involved in cell 
adhesion and migration often altered 
in a variety of cancers 
3.13235 2.808187 8.007952 
ENSCAFG00000002118 
 
PON3 paraoxonase 3  Enzyme controlling cell death 
through apoptosis in response to 
DNA damage 
3.057447 9.857268 5.750329 
ENSCAFG00000000487 
 
TAP2 MHC class I DLA-88 
precursor   
Involved in the presentation of 
foreign antigen to the immune 
system. Loss or mutation contributes 
to the evasion of cancer cell from the 
host immune system 
2.662129 2.539064 9.685715 
ENSCAFG00000004299 
 
GAD3 glutamate decarboxylase 2  Enzyme that acts as major 
autoantigen in insulin-dependent 
2.20579 10.10222 4.71848 
                                                 











TNFRS11B tumour necrosis factor 
receptor superfamily 
member 11b  
Regulates osteoclast development 
and it has been related with poor 
prognosis factor in a variety of 
cancers 
2.39948 5.312691 5.440746 
ENSCAFG00000008692 
 
CCL13 chemokine (C-X-C motif) 
ligand 13 
Overexpressed and related to poor 
prognosis in breast and lung cancer 
3.690534 -3.41308 3.465914 
ENSCAFG00000007728 
 
SCL4A8 solute carrier family 4, 
sodium bicarbonate 
cotransporter, member 8  
Carrier protein involved in transport 
of glucose 
1.602634 4.79368 6.030118 
ENSCAFG00000000681 
 
FB2 fibrillin 2  Extracellular matrix protein involved 
in tumour invasion. Involved in 
hypermethilation in pancreatic cancer 
3.204135 3.92762 4.133856 
ENSCAFG00000017147 
 
ANGEL1 angel homolog 1 
(Drosophila) 
Highly expressed in normal pancreas -1.29944 4.355296 4.250376 
ENSCAFG00000010858 
 
LSAMP limbic system-associated 
membrane protein  
It mediates neuronal growth and acts 
as a tumour suppressor. Deletion 
associated with more malignant 
prostate cancer and osteosarcoma 
2.371685 5.308851 5.144436 
ENSCAFG00000009232 
 
AMIGO2 adhesion molecule with Ig-
like domain 2  
Leuchine-rich repeat containing cell 
adhesion molecule implicated 
overexpressed in gastric, thyroid and 







GENE ID GENE SYMBOL GENE ROLE LOGFC 
pancreatic cancer 
ENSCAFG00000014225 PAPPA2 pappalysin 2  Inhibitory factor of insulin growth 
factor. Mutation in this gene cause 
insulin resistance particularly in 
pregnancy derived diabetes 









8.5 Functional analysis of RNA-sequencing data 
Table 8.4 Gene ontology terms upregulated in primary insulinomas vs normal pancreas using gene set enrichment analysis7 
NAME DESCRIPTION SIZE FDR 
GO:0031012 extracellular_matrix 158 0 
GO:0005578 proteinaceous_extracellular_matrix 155 0 
GO:0005581 collagen_trimer 44 2.91E-04 
GO:0001558 regulation_of_cell_growth 30 2.18E-04 
GO:0008201 heparin_binding 72 6.97E-04 
GO:0005576 extracellular_region 424 5.81E-04 
GO:0045597 positive_regulation_of_cell_differentiation 27 1.00E-03 
GO:0005520 insulin-like_growth_factor_binding 17 0.001643 
GO:0007601 visual_perception 49 0.00165 
GO:0005125 cytokine_activity 93 0.002006 
GO:0042102 positive_regulation_of_T_cell_proliferation 37 0.001903 
GO:0005249 voltage-gated_potassium_channel_activity 51 0.001961 
GO:0050840 extracellular_matrix_binding 21 0.001878 
GO:0006813 potassium_ion_transport 79 0.002053 
GO:0045595 regulation_of_cell_differentiation 25 0.002437 
                                                 







NAME DESCRIPTION SIZE FDR 
GO:0034765 regulation_of_ion_transmembrane_transport 64 0.002989 
GO:0031018 endocrine_pancreas_development 18 0.004143 
GO:0071805 potassium_ion_transmembrane_transport 78 0.004637 
GO:0005201 extracellular_matrix_structural_constituent 26 0.004895 
GO:0006955 immune_response 157 0.005 
GO:0043197 dendritic_spine 35 0.005135 
GO:0043025 neuronal_cell_body 116 0.006244 
GO:0042391 regulation_of_membrane_potential 55 0.00703 
GO:0006816 calcium_ion_transport 75 0.008151 
GO:0005244 voltage-gated_ion_channel_activity 62 0.007895 
GO:0007269 neurotransmitter_secretion 18 0.008763 
GO:0072562 blood_microparticle 64 0.009048 
GO:0086091 regulation_of_heart_rate_by_cardiac_conduction 22 0.011053 
GO:0035987 endodermal_cell_differentiation 25 0.010792 
GO:0005267 potassium_channel_activity 39 0.010636 
GO:0001540 beta-amyloid_binding 23 0.010601 
GO:0005245 voltage-gated_calcium_channel_activity 29 0.010892 
GO:0032024 positive_regulation_of_insulin_secretion 17 0.01088 
GO:0050853 B_cell_receptor_signaling_pathway 26 0.011608 







NAME DESCRIPTION SIZE FDR 
GO:0030199 collagen_fibril_organization 30 0.01215 
GO:0005216 ion_channel_activity 141 0.015884 
GO:0008076 voltage-gated_potassium_channel_complex 54 0.015603 
GO:0002376 immune_system_process 27 0.016381 
GO:0030507 spectrin_binding 16 0.019292 
GO:0030073 insulin_secretion 25 0.019713 
GO:0008009 chemokine_activity 28 0.019595 
GO:0005251 delayed_rectifier_potassium_channel_activity 24 0.020797 
GO:0005178 integrin_binding 66 0.021452 
GO:0051965 positive_regulation_of_synapse_assembly 47 0.022655 
GO:0007268 synaptic_transmission 75 0.024499 
GO:1903561 extracellular_vesicle 42 0.025033 
GO:0003341 cilium_movement 15 0.024529 
GO:0007612 learning 32 0.027483 
GO:0007267 cell-cell_signaling 47 0.027073 
GO:0010951 negative_regulation_of_endopeptidase_activity 80 0.032177 
GO:2000352 negative_regulation_of_endothelial_cell_apoptotic_process 19 0.033195 
GO:0034220 ion_transmembrane_transport 125 0.032847 
GO:0035235 ionotropic_glutamate_receptor_signaling_pathway 17 0.041853 







NAME DESCRIPTION SIZE FDR 
GO:0048786 presynaptic_active_zone 15 0.041007 
GO:1902042 negative_regulation_of_extrinsic_apoptotic_signaling_pathway_via_death_domain_receptors 19 0.047548 
GO:0071310 cellular_response_to_organic_substance 18 0.046743 
GO:0042056 chemoattractant_activity 19 0.048779 









Table 8.5 Gene ontology terms downregulated in primary insulinomas vs normal pancreas using gene set enrichment analysis8 
NAME    DESCRIPTION 
SIZE         FDR   
       
GO:0022627    cytosolic_small_ribosomal_subunit 29               0.0        
GO:0022625    cytosolic_large_ribosomal_subunit 26               0.0021156834         
GO:0006412    translation 247             0.0018979316        
GO:0003735    structural_constituent_of_ribosome 194             0.0017787857        
GO:0018024    histone-lysine_N-methyltransferase_activity 24               0.0019956175         
GO:0005840    ribosome 197             0.0016630146        
GO:0006414    translational_elongation 34               0.0049810847        
GO:0006606    protein_import_into_nucleus 28               0.009734071         
GO:0034968    histone_lysine_methylation 21               0.008965263        
GO:0047485    protein_N-terminus_binding 60               0.009387202        
GO:0006888    ER_to_Golgi_vesicle-mediated_transport 45               0.009992128        
GO:0030433    ER-associated_ubiquitin-dependent_protein_catabolic_process 48               0.012185925         
GO:0003746    translation_elongation_factor_activity 32               0.011248546       
GO:0010494    cytoplasmic_stress_granule 25               0.014950822         
GO:0030529    intracellular_ribonucleoprotein_complex 174             0.01601557         
GO:0051568    histone_H3-K4_methylation 16               0.030657513         
GO:0008536    Ran_GTPase_binding 19               0.02910957        
                                                 







NAME    DESCRIPTION 
SIZE         FDR   
       
GO:0032922    circadian_regulation_of_gene_expression 39               0.03574508         
GO:0006730    one-carbon_metabolic_process 25               0.03484931        
GO:0005801    cis-Golgi_network 29               0.03317578         
GO:0017148    negative_regulation_of_translation 33               0.041525565         
GO:0045727    positive_regulation_of_translation 28               0.040887456        
GO:0016627    oxidoreductase_activity,_acting_on_the_CH-CH_group_of_donors 25               0.03947905         
GO:0016573    histone_acetylation 27               0.04306576         
GO:0006446    regulation_of_translational_initiation 22               0.042669903         
GO:0070301    cellular_response_to_hydrogen_peroxide 25               0.049455997         









Table 8.6 Pathways upregulated in primary insulinomas vs normal pancreas using Reactome tool9 
NAME DESCRIPTION SIZE FDR 
R-CFA-1442490 Collagen degradation 45 0 
R-CFA-1650814 Collagen biosynthesis and modifying enzymes 59 0 
R-CFA-1474228 Degradation of the extracellular matrix 83 0 
R-CFA-1296071 Potassium Channels 77 0 
R-CFA-1474290 Collagen formation 71 0 
R-CFA-112316 Neuronal System 231 2.81E-04 
R-CFA-166658 Complement cascade 42 7.13E-04 
R-CFA-2022090 Assembly of collagen fibrils and other multimeric structures 38 7.31E-04 
R-CFA-1474244 Extracellular matrix organization 216 8.34E-04 
R-CFA-419037 NCAM1 interactions 20 8.30E-04 
R-CFA-1296072 Voltage gated Potassium channels 32 0.001128 
R-CFA-166663 Initial triggering of complement 23 0.001101 
R-CFA-198933 Regulation of gene expression in neuroendocrine committed (NEUROG3+) progenitor cells 65 0.001272 
R-CFA-216083 Integrin cell surface interactions 77 0.00283 
R-CFA-375276 Peptide ligand-binding receptors 105 0.003519 
R-CFA-3000178 ECM proteoglycans 40 0.00871 
R-CFA-194223 Regulation of beta cell development 16 0.012661 
R-CFA-373076 Class A/1 (Rhodopsin-like receptors) 170 0.013647 
                                                 







NAME DESCRIPTION SIZE FDR 
R-CFA-500792 GPCR ligand binding 216 0.023978 
R-CFA-112315 Transmission across Chemical Synapses 161 0.026287 
R-CFA-2129379 Molecules associated with elastic fibres 29 0.026925 
R-CFA-70171 Glycolysis 22 0.028065 
R-CFA-166786 Creation of C4 and C2 activators 16 0.027523 
R-CFA-1566948 Elastic fibre formation 33 0.028165 
R-CFA-418594 G alpha signalling events 91 0.038687 
R-CFA-5576892 Phase_0 rapid depolarisation 26 0.039231 
R-CFA-5576894 Phase_1 inactivation of fast Na+ channels 20 0.040212 
R-CFA-112314 Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell 108 0.042135 
R-CFA-975634 Retinoid metabolism and transport 31 0.043184 
R-CFA-6806667 Metabolism of fat-soluble vitamins 39 0.042293 









Table 8.7 Pathways downregulated in primary insulinoma compared to normal pancreatic tissues using Reactome tool 
NAME DESCRIPTION SIZE FDR 
R-CFA-72766 Translation 62 0 
R-CFA-72702 Ribosomal scanning and start codon recognition 47 0 
R-CFA-72649 Translation initiation complex formation 46 0 
R-CFA-72662 Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 47 0 
R-CFA-156827 L13a-mediated translational silencing of Ceruloplasmin expression 46 3.77E-04 
R-CFA-532668 N-glycan trimming in the ER and Calnexin/Calreticulin cycle 17 6.35E-04 
R-CFA-70895 Branched-chain amino acid catabolism 22 0.001809 
R-CFA-72695 Formation of the ternary complex, and subsequently, the 43S complex 39 0.001975 
R-CFA-72737 Cap-dependent Translation Initiation 53 0.002719 
R-CFA-72613 Eukaryotic Translation Initiation 53 0.002447 
R-CFA-901042 Calnexin/calreticulin cycle 15 0.003483 
R-CFA-6811440 Retrograde transport at the Trans-Golgi-Network 41 0.006645 
R-CFA-204174 Regulation of pyruvate dehydrogenase (PDH) complex 16 0.0243 
R-CFA-1227986 Signaling by ERBB2 37 0.024519 
R-CFA-2173793 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer 40 0.031826 









Table 8.8 Gene ontology terms downregulated in metastatic lymph nodes vs primary insulinomas using gene set enrichment analysis 
NAME    DESCRIPTION SIZE          FDR         
GO:0003735    structural_constituent_of_ribosome 200             0.0        
GO:0005840    ribosome 203             0.0         
GO:0006412    translation 253             0.0        
GO:0072562    blood_microparticle 64               0.0017276717        
GO:0004252    serine-type_endopeptidase_activity 100             0.0013821374         
GO:0008236    serine-type_peptidase_activity 88               0.0025729418        
GO:0030529    intracellular_ribonucleoprotein_complex 177             0.0027126358        
GO:0006414    translational_elongation 34               0.032809116         
 
 
Table 8.9 Pathways upregulated in metastatic lymph nodes compared to primary insulinomas using Reactome tool 
NAME DESCRIPTION SIZE FDR 








Table 8.10 Pathways downregulated in metastatic lymph nodes compared to primary insulinomas using Reactome tool 
NAME DESCRIPTION SIZE FDR 
R-CFA-156590 Glutathione conjugation 25 0.013401 
R-CFA-196741 Cobalamin (Cbl, vitamin B12) transport and metabolism 20 0.031193 
R-CFA-72766 Translation 63 0.027515 
R-CFA-5368287 Mitochondrial translation 79 0.027888 
R-CFA-72695 Formation of the ternary complex and the 43S complex 40 0.033168 
R-CFA-5419276 Mitochondrial translation termination 78 0.028773 
R-CFA-72613 Eukaryotic Translation Initiation 54 0.034266 
R-CFA-70614 Amino acid synthesis and interconversion (transamination) 24 0.034897 
R-CFA-72737 Cap-dependent Translation Initiation 54 0.038949 
R-CFA-5389840 Mitochondrial translation elongation 76 0.035154 
R-CFA-156827 L13a-mediated  translational silencing of Ceruloplasmin expression 47 0.036565 
R-CFA-72662 Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 48 0.038595 
R-CFA-71291 Metabolism of amino acids and derivatives 207 0.041431 







8.6 Human and canine primers for qRTPCR 
Table 8.11 Human primers sequences for qRTPCR (Chiron et al., 2012; Gao et al., 2014; Deng et al., 2015; Eskandani, Abdolalizadeh and 
Hamishehkar, 2015; Irshad et al., 2015; Seyedi et al., 2015; Sukowati et al., 2015) 10 
Gene Forward sequence Reverse sequence Product 
size (bp) 
OCT4 GAGAACCGAGTGAGAGGCAACC CATAGTCGCTGCTTGATCGCTTG 186 
INS TTCTTCTACACACCCAAGAC CTAGTTGCAGTAGTTCTCCA 192 
SOX2 AACCCCAAGATGCACAACTC GCTTAGCCTCGTCGATGAAC 158 
SOX9 CCCTTCGTGGAGGAGGCGGA CCGGAGGAGGAGTGTGGCGA 198 
NANOG GCCTGTGA TTTGTGGGCCTGA  GTGGAAGAA TCAGGGCTGTCCTG  135 
PDX1 CAGCACTCCACCTTGGGACC  TCCCCGCTGTGTGTGTTAGGG  101 
ISL1 GA TCAAA TGCGCCAAGTGCAG  CAGCGGAAACACTCGA TGTGA  93 
PA CTTTGTGGATAACCATGACAATCAA CAACTGCCATTTTATACAGCCTAG 95 
PNLIP TTGCGTGTGGAACCTGACG TCTTTTCCTGCTACTGCTCCCAGC 83 
GHR CCATTGCCCTCAACTGGACTT  AATATCTGCATTGCGTGGTGC  95 
                                                 







Gene Forward sequence Reverse sequence Product 
size (bp) 




















HEY1 GCCGAGATCCTGCAGATGA  GCTGGGAAGCGTAGTTGTTG  223 
JAG1 CGGCCTCTGAAGAACAGAAC TCACCAAGCAACAGA TCCAA  82 
JAG2 AGGTGGAGACGGTTGTTAC TTGCACTGGTAGAGCACGTC  231 
HES1 ACGTGCGAGGGCGTTAATAC ATTGATCTGGGTCATGCAGTTG 75 
CD90 CGCTCTCCTGCTAACAGTCTTGC CCCCCACAGTGCCAAAGAGC 185 
CD24 AAACAACAACTGGAACTTCAAGTAACT  GGTGGTGGCATTAGTTGGATTT  83 







Gene Forward sequence Reverse sequence Product 
size (bp) 
CD133 TGGATGCAGAACTTGACAACGT ATACCTGCTACGACAGTCGTGGT 350 
VIMENTIN AACTTCTCAGCA TCACGA TGAC  TTGTAGGAGTGTCGGTTGTTAAG  62 
SNAIL1 TCTGAGTGGGTCTGGAGGTG  CTCTAGGCCCTGGCTGCTAC  109 
GADPH CAAGATCATCAGCAATGCCT CAGGGATGATGTTCTGGAGAG 194 










Table 8.12 Canine primers sequences for qRTPCR (Michishita et al., 2011; Hodgkiss-Geere et al., 2012; Boerkamp et al., 2013; Buishand et al., 
2013; Dailey et al., 2013; Kruitwagen et al., 2014; Schotanus et al., 2014; van Rijn et al., 2014; Lu et al., 2015)11 
Gene Forward sequence Reverse sequence Product 
size (bp) 
OCT4 CTCTGCAGCCAATCAACCACAA GGAGAGGGGGATGAGAAGTACAAT 237 
INS TCAAGCAGATCACTGTCC GGTGTTGGTTCACAAAGG 89 
IGF2 CTTCTGGAGACCTACTGTGC CTGCTTCCAGGTGTCGTATTG 128 
SOX2 AACCCCAAGATGCACAACTC CGGGGCCGGTATTTATAATC 289 
SOX9 CCAACGCCATCTTCAAGG GGAGTGCACCTCGCTCAT 71 
NANOG CTATAGAGGAGAGCACAGTGAAG  GTTCGGATCTACTTTAGAGTGAGG  160 





ISL1 GGTTTCTCCGGATTTGGAAT  CACGAAGTCGTTCTTGCTGA  164 






GHR GCGCATCCCAGAGTCTACA  ACCATGACGAACCCCATCT  115 
                                                 







Gene Forward sequence Reverse sequence Product 
size (bp) 
LIFR ACTGGAGTTGGACCTCAGAC  CTGAGAATCAGGTGACCAAG 129 


































HES1  CATCCAAGCCTATCATGGAGA GTTCCGGAGGTGCTTCACT  163 












Gene Forward sequence Reverse sequence Product 
size (bp) 
CD34 TGACACCCCAAGTACCATCA GGCTCCTTCTCACACAGCAC 162 
CD133 CTGGGGCTGCTCTTTGTGAT AGGCCCCATTTTTCTTCTGTC 115 
VIMENTIN GGAGCAGCAGAACAAGATCC AGACGTGCCAAAGAAGCATT  282 
SNAIL1 CCCAAGCCCAGCCGATGAG  CTTGGCCACGGAGAGCCC  200 
GADPH TGTCCCCACCCCCAATGTATC 
 












8.7 Flow Cytometry 
 
Figure 8.7 Flow cytometry for CD34 in the canine adherent insulinoma cell line. The relation between side scatter (SSC) and forward scatter (FSC) 
is used to identify the proportion of alive single cells (A).  This experiment has been performed using two negative controls: cells + dead cell 








Figure 8.8 Flow cytometry for CD24 in the canine adherent insulinoma cell line. The relation between side scatter (SSC) and forward scatter (FSC) 
is used to identify the proportion of alive single cells (A).  This experiment has been performed using two negative controls: cells + dead cell 








Figure 8.9 Flow cytometry for CD90 in the canine adherent insulinoma cell line. The relation between side scatter (SSC) and forward scatter (FSC) 
is used to identify the proportion of alive single cells (A).  This experiment has been performed using two negative controls: cells + dead cell 








Figure 8.10 Flow cytometry for CD34 in the human adherent insulinoma cell line. The relation between side scatter (SSC) and forward scatter 
(FSC) is used to identify the proportion of alive single cells (A).  This experiment has been performed using two negative controls: cells + dead cell 








Figure 8.11 Flow cytometry for CD24 in the human adherent insulinoma cell line. The relation between side scatter (SSC) and forward scatter 
(FSC) is used to identify the proportion of alive single cells (A).  This experiment has been performed using two negative controls: cells + dead cell 








Figure 8.12 Flow cytometry for CD90 in the human adherent insulinoma cell line. The relation between side scatter (SSC) and forward scatter 
(FSC) is used to identify the proportion of alive single cells (A).  This experiment has been performed using two negative controls: cells + dead cell 














Figure 8.13 Flow cytometry for NOTCH2 in the canine adherent insulinoma cell line at the extracellular (A) and intracellular (B) level. The 
relation between side scatter (SSC) and forward scatter (FSC) is used to identify the proportion of alive single cells.  This experiment has been 







Violet; and cells + Zombie violet + isotype +secondary antibody. canINS shows about 77% of NOTCH2+ population at extracellular level (A) and 














Figure 8.14 Flow cytometry for NOTCH2 in the human adherent insulinoma cell line at the extracellular (A) and intracellular (B) level. The 
relation between side scatter (SSC) and forward scatter (FSC) is used to identify the proportion of alive single cells (A).  This experiment has been 







Violet; and cells + Zombie violet + isotype +secondary antibody. CM shows about 67% of NOTCH2+ population at extracellular level (A) and 96% 








8.8 Fluorescent-activated cell sorting 
 
Figure 8.15 Fluorescence-activated cell sorting (FACS) of canine adherent insulinoma cell line. Tables show settings for CD24 PE labelled 








Figure 8.16 Fluorescence-activated cell sorting (FACS) of human adherent insulinoma cell line. Tables show settings for CD24 PE labelled 








Figure 8.17 Fluorescence-activated cell sorting (FACS) of canine adherent insulinoma cell line. Tables show settings for CD90 PE-Cy5 labelled 








Figure 8.18 Fluorescence-activated cell sorting (FACS) of human adherent insulinoma cell line. Tables show settings for CD90 PE-Cy5 labelled 





8.9 qRTPCR data 
 
Figure 8.19 qRT-PCR of self-renewal pathway (A), stem cell (B), pancreatic markers and 
growth factor and growth factor receptor (D) related genes comparing CM and canINS in 
both adherent and sphere culturing conditions. The P-values represent the comparison 
with a stated hypothesis (values >1) using one samples t-test. *P-values <0.05 were 
considered statistically significant. 
  
